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Abstract 
The research on hepatitis C virus protein NS5A has developed rapidly over the decades, 
primarily with the advent of the JFH1 cell culture infectious clone which allowed the study of 
all aspects of the virus lifecycle from entry to exit. As the important target of DAAs, the NS5A 
protein of hepatitis C virus (HCV) plays roles in both virus genome replication and assembly. 
NS5A comprises three domains, of these domain I is believed to be involved exclusively in 
genome replication. In contrast, domains II and III are required for the production of infectious 
virus particles and are largely dispensable for genome replication. Domain I is highly conserved 
between HCV and related hepaciviruses, and is highly structured, exhibiting different dimeric 
conformations.   
To investigate the functions of domain I in more detail, a mutagenic study of 12 absolutely 
conserved and surface-exposed residues were conducted within the context of a JFH1-derived 
sub-genomic replicon and infectious virus. Whilst most of these abrogated genome replication, 
three mutants (P35A, V67A and P145A) retained the ability to replicate but showed defects in 
virus assembly. Whilst P35A exhibited a modest reduction in infectivity, V67A and P145A 
produced no infectious virus.  
Using a combination of density gradient fractionation, biochemical analysis and high-
resolution confocal microscopy, it was demonstrated that V67A and P145A disrupted the 
recruitment of NS5A to lipid droplets.  In addition, the localisation and size of lipid droplets in 
cells infected with these two mutants were perturbed. Biophysical analysis revealed that V67A 
and P145A abrogated the ability of purified domain I to dimerize and resulted in an increased 
affinity of binding to HCV 3’UTR RNA. Taken collectively, we propose that domain I of NS5A 
plays multiple roles in assembly, binding nascent genomic RNA and transporting it to lipid 
droplets where it is transferred to Core. In parallel, this study also set out to investigate the 
interactions of NS5A domain I with cellular proteins by the approach of quantitative proteomic 
analysis.  
This study reveals novel functions of NS5A domain I in assembly of infectious HCV and provides 
new perspectives on the virus lifecycle. 
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SEC Size Exclusion Chromatography 
SEC-MALLS 
Size Exclusion Chromatography - Multi-Angle Laser 
Light Scattering 
SEM Standard error of the mean 
SGR Sub-Genomic Replicon 
siRNA Small interfering RNA 
SP Signal peptidase  
SPP  Signal peptide peptidase 
SOAT1 Sterol O-acyltransferase 1 
SOC Standard of care 
SPgV simian Pegivirus 
SRBI scavenger receptor b1 
SREBP Sterol regulatory element–binding protein  
SUMO Small Ubiquitin-like Modifier 
SVR sustained virological response 
T Thr, threonine 
TAE Tris-Acetate-EDTA buffer 
TAG Triglyceride 
TC Tissue culture 
TFR1 Transferrin receptor 1  
TGN Trans-Golgi network 
TIP47 Tail-interacting protein of 47 kDa 
TJ Tight junction 
TLR Toll-like receptors 
TMD Transmembrane domain 
TMR Tetramethylrhodamine  
TMT Tandem Mass Tagging 
TRAM Translocation associated membrane protein 
TRAPD Translocon-associated protein subunit delta 
TRIF TIR-domain-containing adapter-inducing interferon-β 
U Uracil 
UTR Untranslated Region 
V Val, valine 
xxii 
 
v/v Volume by Volume 
VAMP Vesicle-associated membrane protein 
VAP VAMP-associated protein 
VLDL Very-Low Density Lipoprotein 
VLDL Very-Low Density Lipoprotein 
W Trp, tryptophan 
w/v weight by volume 
WHO World Health Organisation 
WT Wildtype 
Y Tyr, tyrosine 
YFV Yellow Fever Virus 
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1.1 Hepatitis C Virus 
1.1.1 Identification of Hepatitis C virus (HCV) 
Hepatitis refers to the inflammation of the liver and is most commonly attributed to viral 
hepatitis. Infectious viral hepatitis is an important challenge to health worldwide (Stanaway et 
al., 2016). The causative agents are mainly hepatitis A-E viruses. Hepatitis A virus (HAV) and 
hepatitis E virus (HEV) are endemic in many low-income countries (Rein et al., 2012, Jacobsen 
and Wiersma, 2010). Hepatitis B virus (HBV) and hepatitis C virus (HCV) can also cause acute 
illness but more commonly lead to progressive liver fibrosis, cirrhosis, and an increased risk of 
liver cancer (specifically hepatocellular carcinoma)(Ott et al., 2012, Mohd Hanafiah et al., 
2013).  
The hepatitis C virus (HCV) was first identified in 1989 as the causative agent of non-A non-B 
hepatitis (NANBH) (Bradley et al., 1983, van der Poel et al., 1989, Bradley et al., 1985). It is a 
blood-borne pathogen and is typically transmitted from exposure to blood products of an 
infected individual (Chen and Morgan, 2006). Prior to the identification of HCV, the major route 
of infection was through medical transfusion of unscreened infected blood products. After the 
implementation of screening the incidence of transfusion acquired HCV dramatically reduced 
to around 1:2,000,000 (Schreiber et al., 1996). As a result in the US there was a decline in new 
cases of HCV from an estimated 180,000 in 1988 to around 30,000 by 1995 (Alter et al., 1999). 
However, increased awareness of disease transmission on the back the HIV epidemic is likely 
also a factor in this reduction. Despite these dramatic reductions in transmission, due to the 
asymptomatic nature and long duration until clinical presentation of symptoms, it is difficult 
to identify acute HCV infection (Patel et al., 2016). Major routes of transmission are now mostly 
confined to intravenous drug use (IDU), sexual contact and parenteral transmission (Chan et 
al., 2016). 
1.1.2 Pathology of HCV 
HCV infection is a main cause of chronic liver diseases worldwide (Calvaruso et al., 2018). After 
infection with hepatitis C virus, most of acute infection are asymptomatic and undiagnosed, 
but where symptoms are observed they tend to present after 3-12 weeks, shortly after the 
typical peak in HCV RNA detected in the serum. More specific symptoms of viral hepatitis can 
be encountered in a minority of individuals including malaise, loss of appetite, nausea, 
vomiting, abdominal pain, joint pain and jaundice (Westbrook and Dusheiko, 2014). The level 
of aminotransferase and HCV RNA in serum is the routine screening indicator for HCV infection.  
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Following the peak of RNA (105-107 IU/ml) in serum, only 15%-25% of patients could clear the 
virus as the RNA becomes undetectable (Chen and Morgan, 2006). Rare percentage of acute 
infection will process into fulminant hepatic failure (Younis et al., 2015, Chen and Morgan, 
2006). 
If HCV RNA could be detected beyond 6-month infection, these patients are considered to be 
chronically infected. Approximately 80% of infected individuals will progress into this stage 
(Chen and Morgan, 2006). Chronic HCV infection induces end-stage liver diseases such as liver 
cirrhosis and hepatocellular carcinoma, presenting a public health problem of high 
socioeconomic impact with 71 million people persistently infected and more than 400 000 
deaths per year (Calvaruso et al., 2018). 1–4% per year of infected individuals will develop 
hepatocellular carcinoma (HCC). The risk factors associated with disease progression are 
varied, including age at time of infection, gender, coinfection with HIV or HBV, and excessive 
consumption of alcohol (Chen and Morgan, 2006). In addition, progression of disease is 
different between genotypes. Genotype 3 infections are often self-cleared during acute 
infection but have a faster progression to liver fibrosis and steatosis in chronic infections, 
whereas individuals infected with genotype 4 are more likely to develop chronic infection 
(Lehmann et al., 2004, Nunez and Soriano, 2005). Liver failure and HCC caused by HCV infection 
is a leading cause of liver transplantation in many countries, with the added complication of 
graft re-infection in most cases (Rubín et al., 2011). 
There is no protective vaccine against HCV yet. However, the development of direct-acting 
antivirals targeting different proteins and functions in HCV life cycle has dramatically changed 
the treatment options for chronic hepatitis C, leading to new hopes to cure HCV (Boson et al., 
2017). 
1.1.3 Classification of HCV and Epidemiology 
HCV belongs to the Hepacivirus genus in the Flaviviridae family, which also comprises the 
genera Flavivirus, Pestivirus and Pegivirus (Figure 1.1A) (Simmonds et al., 2017). Members of 
the Hepacivirus genus are distinct genetically but somewhat similar in genome organisation to 
members of the Flavivirus genus and the recently assigned Pegivirus genus (Stapleton et al., 
2011). Within Hepacivirus genus, HCV is currently the sole human pathogen. GB virus -B (GBV-
B) and non-primate hepacivirus (NPHV) are non-human viruses, also in Hepacivirus genus, 
identified in tamarin monkeys, dogs, rodents and horses (Stapleton et al., 2011, Kapoor et al., 
2013, Kapoor et al., 2011, Burbelo et al., 2012), which are more closely related to HCV. 
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Flaviviridae family contains many well-known pathogens, the Flavivirus genus is the host to 
yellow fever virus (YFV), dengue virus (DENV) and Japanese encephalitis virus (JEV); border 
disease virus (BDV) and bovine viral diarrhea virus (BVDV) belong to the Pestivirus genus; 
simian Pegivirus (SPgV/ GBV-A), human Pegivirus (HPgV/GBV-C) and bat Pegivirus (BPgV /GBV-
D) were classified into the Pegivirus genus (Stapleton et al., 2011, Simmonds et al., 2017). 
The classification of HCV genotypes and subtypes is mainly based on differences of nucleotide 
and amino acid sequence (Simmonds, 2012, Simmonds et al., 2005).  Using consensus criteria,  
HCV isolates can be classified into 7 genotypes (1-7) and 67 subtypes (a-z) (Smith et al., 2014) 
(Figure 1.1B). Between genotypes, the genetic variability is approximately 30-35 %, whereas 
genome sequence between subtypes differs by 20-25% on the average of complete genome, 
in which regions in E1 and E2 glycoproteins are more variable while nucleotide sequences in 
core and non-structural proteins are more conserved. 5′ UTR shared the highest conservation 
as its specific sequences and RNA secondary structures are indispensable for genome 
replication and translation (Simmonds, 2004).  
The distribution of HCV genotypes throughout the world varies globally, showing specific 
geographical ranges in the human population and associations with particular risk groups for 
infection (Messina et al., 2015). Genotype 1 infections are mostly attributed to subtypes 1a 
and 1b and widely distributed globally, whereas genotype 3 is prevalent in South Asia (Figure 
1.1C). Genotype 1 and 3 infections are more prevalent than all other genotypes globally (Figure 
1.1C), accounting for around 83.4 million and 54.3 million infected cases, respectively. The 
other genotypes 2, 4-7 are responsible for the remaining cases (~25%) of HCV worldwide 
(Figure 1.1C). Of these, genotype 2 dominates in West Africa, genotype 4 in Central and North 
Africa, genotype 5 in South Africa, and genotype 6 in South East Asia, with only one  genotype 
7  isolate in Canada from a Central African immigrant (Figure 1.1C) (Messina et al., 2015). 
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Figure 1.1 Phylogenetic analysis of the Flaviviridae family and HCV genotypes and the 
worldwide distribution. 
A. Phylogenetic tree of members of the family Flaviviridae showing its primary division into 
four genera. The tree was based on comparison of conserved regions of the RNA polymerase 
sequences, adapted from (Kapoor et al., 2011). B.  Evolutionary tree of 7 genotypes of HCV  
from 129 representative complete HCV coding sequences, adapted from (Smith et al., 2014). 
C. Global distribution of HCV by genotype and prevalence, size of pie charts is proportional to 
the number of seroprevalent cases, adapted from (Messina et al., 2015). 
 
HCV is a blood borne pathogen. Acute and chronic HCV patients and chronic HCV carriers are 
the main source of infection.  Transmission of HCV requires contact with contaminated blood 
products. Medical blood transfusion was the leading cause of HCV transmission (Lauer and 
Walker, 2001). Incidence rate caused by blood transfusion was dramatically reduced by 
introduction of routine screening for liver disease, increased serum alanine aminotransferase 
(ALT) levels and HCV antibodies (Donahue et al., 1992, Schreiber et al., 1996). Currently the 
majority of the new infections are through intravenous drug-use, which is estimated to account 
for around 80% of infections in the developed world (Sy and Jamal, 2006). In some developing 
countries, blood transfusion is still a route of transmission because of continued use of unsafe 
healthcare related practises. Other routes of transmission are much less common, such as the 
health care workers, from religious or cultural practices including tattooing, body piercing and 
acupuncture, sexual contact and perinatal transmission (Alter, 2007).  
1.1.4 Therapies for HCV 
With approximately 80% of acute infections processing into chronic infections, following that 
10-50% of patients will progress to cirrhosis in next 20 years and develop hepatocellular 
C 
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carcinoma (HCC). HCV plays an important role throughout the evolution of this progress. Hence, 
in order to prevent or delay the progression of hepatitis, effective antiviral therapy is of 
paramount importance. The aim of antiviral therapy is to maximize the inhibition of virus 
replication or even clear the virus, reduce liver necrosis and fibrosis to prevent the progress of 
cirrhosis, thereby improving the quality of lives of patients and reducing the occurrence of 
hepatocellular carcinoma. 
Prior to the advent of direct acting antivirals (DAAs), the standard of care (SOC) for HCV 
infection was pegylated interferon-alpha (PEG-IFNα) and ribavirin (RBV). The efficiency of 
treatment for HCV was classified by a sustained virological response (SVR), defined as 
undetectable RNA 12-24 weeks after completing treatment. Combination of PEG-IFNα and RBV 
has been reported to achieve SVR in 54-63% of cases depending on the genotype treated, 
genotype 2 and 3 respond well to this therapy while genotype 1 is harder to treat. Typically 
treatment of PEG-IFNα and RBV lasts 24 weeks, which can be reduced to 12 weeks for infection 
of genotype 2 and 3, but extended to 48 weeks or longer for infection of genotype 1 
(Hadziyannis et al., 2004, Manns et al., 2001). However, the major problem for this treatment  
is that patients frequently discontinue this therapy before SVR is achieved because of the side 
effects which include headaches, fever, arthralgia, myalgia, haemolytic anaemia, fatigue, 
dermatitis and depression  or weight loss (Manns et al., 2001).  
Patients requiring antiviral treatment are heterogeneous and include inexperienced as well as 
experienced patients such as relapsers, partial-responders or non-responders to combination 
therapy with PEG-IFNα and RBV. Relapsers initially achieve an undetectable level of HCV RNA 
by the end of treatment but serum HCV RNA levels become detectable sometime thereafter 
(Pearlman and Sjogren, 2010). A large number of patients are non-responders who do not 
achieve viral clearance at the end of therapy (Pearlman and Traub, 2011). There are patients 
who can respond and achieve a decline of  HCV RNA by more than 2log10  but still detectable 
at week 12 and 24, they are partial responders (Rau et al., 2012). Patients who present with 
acute HCV infections have 90% chance of preventing the development of chronic infection 
treated with PEG-IFNα alone for 24 weeks (Wiegand et al., 2006).  
Treatment related side effects remains a challenge to take treatment decisions in a clinical 
setting with cost restrictions. Therefore predicting the patient response to therapy is a major 
consideration. Thus, an individualized therapy concept in clinical practice is mandatory. 
Together with HCV genotypes, different genetic variants have been identified with a strong 
association with therapy response, fibrosis and treatment-related side effects. Polymorphisms 
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of the interleukin 28B (IL28B) gene were identified as a baseline predictors for fibrosis 
progression and therapy response (Fischer et al., 2012, Rau et al., 2012, Thompson et al., 2010).  
With a number of direct acting antivirals (DAA) being approved for use by the Food and Drug 
Administration (FDA), the treatment of HCV has been dramatically improved for HCV infected 
patients. The DAAs to date are mainly targeted towards the HCV non-structural proteins 
NS3/4A protease, NS5A or NS5B polymerase.  
The first two DAAs licenced by the FDA were NS3/4A protease inhibitors boceprevir (Merk) and 
telaprevir (Janssen-Vertex). Both of these drugs are linear peptidomimetic structures that can 
reversibly form a covalent bond with the catalytic serine of NS3/4A to directly block the viral 
life cycle (Salam and Akimitsu, 2013, Hazuda et al., 2013, Kwong et al., 2011). To date, the 
single DAA in combination with RBV and PEG-IFNα are only licenced for the treatment of 
genotype 1 infection, which improved SVR rates from 45% to 75% (Manns and von Hahn, 2013). 
Despite the increased SVR rate, both boceprevir and telaprevir have a number of drawbacks 
such as a narrow genotype specificity and emergence of resistance-associated variants (RAVs) 
(for example R155K) (Sarrazin and Zeuzem, 2010, McCown et al., 2009), which calls for 
generation of more efficient drugs. Still targeting NS3/NS4 protease, the second generation of 
DAA-grazoprevir retains NS3/4A binding properties even in absence of R155K and was recently 
licensed in a combination therapy with the NS5A inhibitor elbasvir and RBV (Keating, 2016, 
Lahser et al., 2016). 
The RNA-dependent RNA polymerase (NS5B) from hepatitis C virus (HCV) is a key enzyme in 
HCV replication. Thus, NS5B is a major target for the development of antiviral compounds 
directed against HCV. Hence, the second group of DAAs are targeting the viral polymerase NS5B 
with drugs classified into nucleotide or non-nucleotide inhibitors (Sofia et al., 2012). The non-
nucleotide inhibitors inhibit the NS5B polymerase through an allosteric mechanism via binding 
to thumb domain site I and II or palm sites of NS5B (Kukolj et al., 2005). The representative of 
non-nucleotide inhibitors are beclabuvir (BMS-791325) (Rigat et al., 2014) and dasabuvir 
(Gentile et al., 2014). Currently, dasabuvir (Viekira Pak) was licenced in the multi DAA therapy 
(Mantry and Pathak, 2016). Nucleoside-based DAAs became the backbone of HCV therapeutic 
regimens as they show pan-genotype activity and a high barrier to resistance (Feld, 2014). 
Sofosbuvir,  a nucleoside analogue inhibitor, is the first approved DAA with potent activity and 
high genetic barrier against all HCV genotypes (Marino et al., 2014). 
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Another effective HCV inhibitor is Daclatasvir (Bristol-Myers Squibb), targeting the NS5A 
protein and active at pM concentrations (Belema and Meanwell, 2014). Clinical trials to date 
showed that combination of Daclatasvir and Sofosbuvir with or without RBV once daily for 12 
or 24 weeks achieved SVR rates >90% for genotype 1 including difficult -to -treat patients (Pol 
et al., 2016). Ledipasvir, velpatasvir, pibrentasvir, ombitasvir and elbasvir are all currently 
licenced in combination with either NS5B, NS3/NS4 protease or Cytochrome P450-3A4 
inhibitors and achieved high SVR rates (Afdhal et al., 2014, Hezode et al., 2017, Poordad et al., 
2017, Lawitz et al., 2015, Sulkowski et al., 2015, Kwo et al., 2017).  The effectiveness of NS5A 
inhibitors in combination with the nucleotide inhibitor sofosbuvir indicate that this 
combination will become common components of many if not all therapies in the future. 
Even the development of DAAs has resulted in dramatic improvement in the tolerability and 
efficacy of treatment of HCV, with profound potential to prevent liver disease, high price of 
DAAs remains the major obstacle to popularize use of DAAs. Therefore, it is necessary to find 
a balanced way for both patients and pharmaceutical companies to increase access to hepatitis 
C virus treatment (Rosenthal and Graham, 2016). 
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Manufacturer          
(Brand ) 
DAA (Target ) 
Combination 
therapy 
Genotype 
 
Bristol-Myers 
Squibb Company                   
(Daklinza) 
daclatasvir(NS5A)             
N/A 1 or 3 
 
sofosbuvir (NS5B polymerase)  
Gilead Sciences     
(Epclusa) 
sofosbuvir(NS5B polymerase) 
N/Aa 
1, 2, 3, 4, 5, or 
6 
 
velpatasvir(NS5A)  
Gilead Sciences    
(Harvoni) 
ledipasvir (NS5A) 
b 1, 4, 5or 6 
 
sofosbuvir(NS5B polymerase)  
Vertex 
Pharmaceuticals 
(Incivek) 
telaprevir (NS3/4A protease) RBV / Peg-IFNα 1 
 
AbbieVie               
(Mavyret) 
glecaprevir  (NS3/4A protease) 
N/A c 
 1, 2, 3, 4, 5 or 
6  
 
pibrentasvir (NS5A )  
Janssen Pharma  
(Olysio) 
simeprevir (NS3/4A protease)) RBV / PEG-IFNαc 1 
 
Gilead Sciences    
(Sovaldi) 
sofosbuvir (NS5B polymerase) 
RBV / PEG-IFNα 1 or 4  
RBV 2 or 3  
AbbVie Inc.       
(Technivie) 
ombitasvir (NS5A) 
RBV 4 
 
paritaprevir(NS3/4A protease )  
ritonavir(Cytochrome P450-
3A4) 
 
Merck & Co.         
(Victrelis) 
boceprevir (NS3) RBV / PEG-IFNα 1 
 
AbbVie Inc.                 
(Viekira Pak) 
ombitasvir (NS5A) 
RBVc 1 
 
paritaprevir(NS3/4A protease )  
ritonavir(Cytochrome P450-
3A4) 
 
dasabuvir (NS5B polymerase)  
Merck Sharp 
Dohme (Zepatier) 
elbasvir (NS5A) 
RBV 1 or 4 
 
grazoprevir (NS3/4A protease )  
 
Table 1.1: Current FDA approved therapies for HCV.  
a-with compensated cirrhosis or with decompensated cirrhosis for use in combination with 
ribavirin; b-In those with genotype 1 and advanced cirrhosis (decompensated) or with 
genotype 1 or 4 with or without cirrhosis (compensated) who have had a liver transplant, 
Harvoni is used with ribavirin; c-without cirrhosis or with compensated cirrhosis. 
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1.2 Molecular virology of HCV 
1.2.1 Genomic organisation 
HCV is a positive-sense single-strand RNA virus, prototype member of the Hepacivirus genus 
of  the family Flaviviridae (Simmonds, 2013). The HCV genome consists of a single- stranded 
RNA of about 9,600 nucleotides comprising a single large open reading frame (ORF) and 
flanked by 5’ and 3’ untranslated regions (UTRs) (Figure 1.2). The 5’ UTR is highly structured 
and consists of the internal ribosome entry site (IRES), which is important for the initiation of 
cap-independent translation of the polyprotein (Hashem et al., 2013). The 3’UTR consists of a 
short genotype-specific variable region, a tract of variable length comprising solely pyrimidine 
residues (predominantly U), and a conserved 98-nucleotide sequence, known as the X region, 
containing three stem-loops (Blight and Rice, 1997, Kolykhalov et al., 1996). The 3’ UTR is the 
initiation site for the synthesis of the negative-strand RNA during viral replication and is 
involved in translational regulation (Song et al., 2006). The ORF encodes a polypeptide 
precursor of about 3,000 amino acids, which is cleaved co- or post translationally by cellular 
and viral proteases into ten mature products (Figure 1.2). The first three proteins cleaved from 
amino-terminal region of the polyprotein are structural proteins core (C), envelope proteins E1 
and E2, which are the components of virus particles. Following them,  p7 and NS2 support 
particle assembly while not being incorporated into the particles, denoted as non-structural 
(NS) proteins (Bartenschlager et al., 2011); the remaining polyprotein cleavage products are 
NS3, NS4A, NS4B, NS5A and NS5B, which are required for membrane-associated RNA 
replication (Lohmann et al., 1999a) (Figure 1.2). There is the other small ORF overlapping with 
the core protein ORF, encoding a single protein, alternative reading frame protein (ARFP) or 
frame protein (F) (Walewski et al., 2001, Varaklioti et al., 2002).  
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Figure 1.2 Organization of the HCV genome.  
The genome of HCV consists of a single open reading frame encoding a polyprotein of 
approximately 3000 aa, flanked by UTRs (5’UTR and 3’UTR). Post translation, the polyprotein 
is cleaved by signal peptide peptidase (SPP), signal peptidase (SP), NS2- NS3 protease (NS2), 
and NS3 protease and NS4A complex (NS3-4A), leading to the production of functional HCV 
protein. Numbers refer to position of amino acids of genotype 2a JFH1 isolate (Genbank 
accession: AB047639). Picture is adapted from (Paul et al., 2014). 
 
1.2.2 Structural proteins  
1.2.2.1 Core protein - nucleocapsid protein 
Core protein of HCV is a dimeric protein with multiple functions. The  main function is to form 
the viral capsid to surround and protect the genomic RNA, while the virus passes from a cell to 
another (Polyak et al., 2006). The monomeric core containing 191 aa can be separated into two 
domains by different amino acid compositions and hydrophobicity profiles. Domain I, N-
terminal domain, is hydrophilic and rich in basic amino acid residues, which are highly 
conserved. Domain I plays important roles in RNA binding and oligomerization during 
nucleocapsid formation, 1-82 amino acids as the intrinsically disordered region are  sufficient 
to package genomic RNA into the virus particle (Ivanyi-Nagy et al., 2006, Fromentin et al., 
2007). By contrast, domain II is hydrophobic and is responsible for coordinating core 
localisation to the ER and lipid droplet (LD) membranes, and is considered as the LDs binding 
domain (Boulant et al., 2006). Domain II contains two amphipathic helices separated by a short 
hydrophobic loop and interacts in-plane with the phospholipid monolayer of lipid droplets 
(cLDs) (McLauchlan et al., 2002). The association of core with LD is critical for assembly of viral 
particles (Shavinskaya et al., 2007). Apart from a function in virus assembly, core has been 
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shown to be involved in a number of host processes including cell apoptosis, gene 
transcription, cell signalling and immune regulation (McLauchlan, 2000).  
1.2.2.2 E1 and E2- envelope glycoproteins  
HCV E1 and E2 envelope glycoproteins are the major viral structural proteins expressed on the 
surface of virus particles, which are essential for viral entry and release via mediating receptor 
binding at the cell surface. E1 and E2 are type 1 transmembrane glycoproteins, which are 
translocated into the endoplasmic reticulum (ER), where they interact to form noncovalent 
heterodimers between their transmembrane domains and ectodomains (Duvet et al., 1998, 
Dubuisson et al., 2002). In the mature virions, they can form large complexes stabilised by 
disulphide bridges (Vieyres et al., 2010). E1 and E2 show in complicated folding patterns 
mediated by a range of host chaperons and are post-translationally modified by N-
glycosylation in different sites (Goffard et al., 2005, Vieyres et al., 2014). X-ray crystallography 
revealed the structures of N-terminal domain E1 and core ectodomain of E2 (El Omari et al., 
2014, Khan et al., 2014a). The E2 ectodomain consists of a compact, globular domain structure, 
consisting mostly of β-strands and random coil with two small α-helices. The β-strands mainly 
are formed by an immunoglobulin-like fold and an additional novel domain (Khan et al., 
2014a). E1 N-terminal domain exhibits in homodimers  and  is also rich in β-sheets like E2 but 
with a single long α-helix sandwiched between antiparallel β strands (El Omari et al., 2014). 
Structural data also showed that E1 of HCV does not resemble the class II fusion protein fold, 
whereas other members of family Flaviviridae encode class II fusion proteins which mediate 
virion envelope fusion with the host cell membrane (Kielian, 2006). Therefore, it indicates that 
HCV membrane fusion mediated by E1 and E2 might proceed by another mechanism that is 
still unclear (Khan et al., 2015, Li and Modis, 2014).   
1.2.3 Non-structural proteins 
1.2.3.1 p7  
Following the structural proteins is p7, a viroporin of only 63 amino acids, which is essential 
for virus assembly, maturation and release (Jones et al., 2007a, Steinmann et al., 2007, 
Wozniak et al., 2010). First, p7 is required for an early stage of virus assembly through 
interaction with NS2 recruiting core from LD to the proposed site of virus assembly on ER-
derived membraned (Boson et al., 2011, Tedbury et al., 2011). The second major role of p7 is 
that it oligomerizes to form hexameric and heptameric cation-specific ion channels (Griffin et 
al., 2003, Premkumar et al., 2004, Montserret et al., 2010). The formation of oligomeric p7 ion 
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channels equilibrates pH gradients within the secretory and endolysosomal vesicles in the 
egress and release pathways that would otherwise increase acidic conditions and damage 
maturation of virions (Wozniak et al., 2010, Gentzsch et al., 2013). p7 protein is considered to 
be a nonstructural (NS) protein as it is not incorporated into HCV virions (Vieyres et al., 2013). 
1.2.3.2 NS2 
Non-structural protein 2 (NS2) is a membrane protein of 23 kDa containing three N-terminal 
transmembrane domains and a C-terminal cysteine protease domain. The N-terminal domain 
is composed of three transmembrane α-helices, which are important for anchoring NS2 to ER 
membranes (Jirasko et al., 2010, Jirasko et al., 2008). The C-terminal domain I is a catalytic 
cysteine protease which is responsible for the cleavage on the NS2-3 boundary of the HCV 
polyprotein by autoprotease activity (Grakoui et al., 1993). However, optimisation of HCV sub-
genomic replicons demonstrated that NS2 is not required for genome replication (Lohmann et 
al., 1999a), NS2 protease activity is required for polyprotein processing and RNA replication of 
full-length HCV genomes (Kolykhalov et al., 2000, Welbourn et al., 2005). Whereas, NS2 is 
involved in  early stage of virus assembly, bringing together E1-E2 glycoprotein complex, p7, 
and the NS3-4A enzyme complex within the plane of the ER membrane via N-terminal TM 
domains of NS2 (Phan et al., 2009, Jirasko et al., 2010, Boson et al., 2011, Ma et al., 2011, 
Popescu et al., 2011, Stapleford and Lindenbach, 2011). These protein-protein interactions are 
required to recruit core protein from LDs into sites of virus assembly (Counihan et al., 2011). 
1.2.3.3 NS3/4A complex 
The NS3-4A enzyme complex is essential for HCV polyprotein processing and genome 
replication. NS3 of 70 kDa is a multifunctional protein divided into two domains that encodes 
two enzymatic activities. The first N-terminal 180 residues of NS3 forms a serine protease while 
181-631aa of the C-terminal domain function as NTPase/RNA helicase (Morikawa et al., 2011). 
The small NS4A protein (6 kDa) works as a cofactor for both NS3 serine protease and RNA 
helicase activities (Bartenschlager et al., 1995). NS4A contains an N-terminal TM domain, a 
central peptide assisting the NS3 serine protease domain, and a C-terminal acidic peptide 
involved in RNA replication and virus assembly, perhaps through its ability to modulate NS3 
RNA helicase activity (Beran et al., 2009, Phan et al., 2011). 
The N-terminal serine protease of NS3 is responsible for cleavage of both itself and the 
remaining of polyprotein. Post NS3 cleavage, N -terminal transmembrane domain of NS3A will 
anchor into ER membranes. Efficient protease processing of NS3 requires the NS4A cofactor 
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which both contributes to the protease fold of NS3 and anchors the NS3/4A protein to 
membranes. For the processing of remaining polyprotein (NS4A-NS5B), NS3/4A protease first 
cleaves the NS5A-NS5B boundary to release mature NS5B. The resulting NS4A-NS5A is next 
processed between NS4A and NS4B followed by the final cleavage at the junction of NS4B and 
NS5A to achieve every separate NS proteins (Morikawa et al., 2011).  
The C-terminal helicase domain of NS3 is a DExH/D-box protein belonging to the RNA helicases 
superfamily 2 (Huang et al., 2010).  The helicase activity of NS3/NS4A is shown to unwind 
dsRNA and highly structured RNA in a 3’–5’ direction (Tai et al., 1996). High-resolution  crystal 
structures of three conformations allowed us to unambiguously track the positional changes 
of RNA bound to full-length HCV NS3 during helicase activity (Appleby et al., 2011, Gu and Rice, 
2010). A “ratchet” mechanism of NS3 helicase is identified in the unidirectional translocation 
along RNA with a step size of one base per nucleotide hydrolysis cycle, which provides the 
opportunities to develop specific inhibitors to block this action (Gu and Rice, 2010). 
Post polyprotein processing, NS3-4A is involved in other stages of the virus lifecycle including 
virus assembly (de Chassey et al., 2008, Ma et al., 2008). Interestingly, mutations in NS3 that 
enhance RNA replication cause defects in virus assembly, suggesting that NS3 may contribute 
to the switch between RNA replication and virus assembly (Pietschmann et al., 2009). 
Furthermore, the interaction between NS2 and NS3-4A is involved in recruiting LD-associated 
core protein into virus assembly (Counihan et al., 2011). Moreover, HCV NS3/NS4A protease 
works to evade the innate immune response as MAVS, TRIF, and Riplet are the targets of 
NS3/NS4A protease and the cleavage by NS3/4A will inactivate both RIG-I/MDA5 and TLR3-
independent antiviral innate immunity pathways (Morikawa et al., 2011, Schoggins and Rice, 
2013, Li et al., 2005, Gokhale et al., 2014). 
1.2.3.4 NS4B 
NS4B is a highly hydrophobic protein (27 kDa), which is membrane protein that plays an 
essential role in the formation of HCV RNA replication complexes. It consists of two α-helices 
at its N-terminus, four central transmembrane domains and a C-terminal helices (Gouttenoire 
et al., 2010a). The second N-terminal α-helix functions as a transmembrane helix identified as 
a major determinant for the oligomerization of NS4B formation of the membranous web, 
representing sites of HCV RNA replication (Lundin et al., 2006, Gouttenoire et al., 2010b, Egger 
et al., 2002, Paul et al., 2011). Therefore, NS4B is important for  RNA replication through 
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involvement in multiple interactions with other viral proteins (Jones et al., 2009, Paredes and 
Blight, 2008, David et al., 2015), and production of infectious HCV particles (Han et al., 2013). 
1.2.3.5 NS5A 
NS5A is a highly phosphorylated and multifunctional protein that play essential roles 
throughout HCV life cycles from genome replication to production of virus. RNA of NS5A 
encodes approximately 448 amino acids of 49 kDa theoretically, but actually presents in 56kDa 
and 58kDa forms, termed basal- and hyper-phosphorylated NS5A respectively, resolvable by 
SDS-PAGE analysis (Kaneko et al., 1994). It consists of three domains linked by low complexity 
sequences (LCS) and an N-terminal α-helix associated with phospholipid membranes (Figure 
1.3A) (Tellinghuisen et al., 2004). A detailed consideration of NS5A protein will be presented in 
Section 1.3. 
1.2.3.6 NS5B 
NS5B (62 kDa) is the RNA-dependent RNA polymerase (RdRp) that replicates the viral genome 
by synthesis of both intermediary negative sense and positive sense RNA. It is composed of an 
N-terminal catalytic domain, a linker, and a hydrophobic transmembrane domain (TMD) 
comprising the C-terminal 21aa, anchoring the protein to intracellular membranes. Three 
dimensional crystal structures of HCV NS5B  showed in  a typical right-hand shape with fingers, 
thumb, and palm subdomains, which is shared by most other polymerases (Ago et al., 1999, 
Bressanelli et al., 1999, Lesburg et al., 1999). Fingers and thumb subdomains provide important 
contacts for the nucleic acid substrate, while the palm contains the catalytic active site. These 
subdomains form the so-called ‘‘closed’’ conformation of the polymerase for initiation of RNA 
synthesis.  De novo priming by NS5B at the 3’ UTR requires two nucleotide binding sites in the 
catalytic pocket to synthesize a dinucleotide stimulated by high concentrations of GTP (Ferrari 
et al., 2008, Lohmann et al., 1999b). Binding of GTP to NS5B is likely to trigger the 
conformational changes of NS5B  from closed formation to RNA elongation state which open 
the catalytic pocket to accommodate dsRNA (Harrus et al., 2010, Ranjith-Kumar et al., 2003, 
Mosley et al., 2012, Scrima et al., 2012). Compared with genotype 1, JFH1 from genotype 2a 
exhibited a much-closed conformation of NS5B that is more suited to hold a single-stranded 
template required for de novo initiation of RNA synthesis.  This structural property of JFH1 
contributes to the higher replication efficiency than genotype 1 isolates (Simister et al., 2009). 
The catalytic palm pocket contains a GDD motif of NS5B polymerase active site responsible for 
coordinating two magnesium ions (Jablonski and Morrow, 1995). GDD motif is typically 
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mutated into GND to inactivate NS5B polymerase by disrupting its coordination, and this 
mutation (GND) is usually used as a non-replicating (polymerase-defective) negative control in 
our research. 
1.3 NS5A 
1.3.1 Structure of NS5A 
The Non-Structural 5A protein (NS5A) is a 49 kDa protein, however 56 and 58 kDa forms, 
termed basal- and hyper-phosphorylated respectively, are resolvable by SDS-PAGE 
(Neddermann et al., 1999), which has an essential role throughout the virus life cycle (Ross-
Thriepland and Harris, 2014b, Ross-Thriepland and Harris, 2015). It is comprised composed of 
three major domains (I, II and III) linked by low complexity sequences (Tellinghuisen et al., 
2004) (Figure 1.3A). The protein is anchored to phospholipid membranes by an N-terminal 
amphipathic helix (residues 1-33) in a manner essential for replication (Brass et al., 2002, Penin 
et al., 2004).  
NS5A N-terminal membrane anchor domain (1-33aa) is highly conserved (Brass et al., 2007) 
and its helical structure is the determinant for ER membrane targeting and binding, which 
provides a platform for the stabilization of NS5A in the HCV replication complex (Penin et al., 
2004, Brass et al., 2002, Sapay et al., 2006). N-terminal amphipathic helix domain is embedded 
in-plane in the cytosolic leaflet of the ER membrane, with a hydrophobic side buried in the 
membrane and a polar/charged side accessible from the cytosol. The Trp rich, N-terminal 
amino acids 5 to 12 of the helix, seem to be located more closely to the membrane interface, 
whereas the Lys-rich, C-terminal amino acids 19 to 26 appears to be buried slightly more 
deeply into the hydrophobic core of the membrane (Penin et al., 2004, Brass et al., 2002). N-
terminal membrane anchor is functionally conserved among HCV and related viruses, which is 
essential for the assembly of a functional viral replication complex (Brass et al., 2002, Penin et 
al., 2004, Sapay et al., 2006, Brass et al., 2007). 
Following the α-helix, is a both conserved and highly structured domain I which folds into an 
unusual structure and mediates homodimerization. Domain I is the only domain of NS5A with 
a crystal structure (Lambert et al., 2014, Love et al., 2009, Tellinghuisen et al., 2005). The 
structures revealed that domain I coordinates a zinc atom within a tetracysteine motif, has a 
disulphide bond at the C terminus, and the presence of a basic RNA-binding groove between 
the NS5A dimer interfaces (Figure 1.3B). Both structure and function of domain I are 
introduced in detail in section 5.1. 
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Although dimeric in the crystal structure, limited evidence exists to support a dimeric structure 
in vivo (Lim et al., 2012). Models for NS5A dimers associated with the membrane have been 
proposed, however these lack experimental evidence (Ross-Thriepland and Harris, 2015). Both 
the tetracysteine motif and disulphide bond are required for maintaining the structure of 
domain I (Tellinghuisen et al., 2005). 
A number of HCV related hepaciviruses have been identified which share a high degree of 
sequence homology with domain I but not domains II and III (Burbelo et al., 2012, Kapoor et 
al., 2011, Kapoor et al., 2013). Secondary structure prediction programs indicate that the 
organisation of NS5A into three domains separated by LCS are shared among the hepaciviruses 
(Lauck et al., 2013). 
Unlike domain I, domain II and domain III are natively unfolded (Liang et al., 2007, Hanoulle et 
al., 2009b, Verdegem et al., 2011). Structural analysis of domain II by nuclear magnetic 
resonance(NMR) identified α-helical structures within domain II containing  a classical poly-
proline Src homology 3 (SH3) binding motif (Feuerstein et al., 2012). Domain III of NS5A  is less 
conserved and apparently possesses a great deal of inherent flexibility (Remenyi et al., 2014, 
Tellinghuisen et al., 2008b, Arumugaswami et al., 2008), as it tolerates large heterologous 
insertions, such as green fluorescent protein (GFP), and still retains its activity during RNA 
replication (McCormick et al., 2006, Moradpour et al., 2004). 
The first low complexity sequence (LCS I), a region rich in serine, is composed of 36 amino acids 
and links domain I and domain  II. LCS I is absolutely conserved across all genotypes of HCV, 
implying an essential role in the virus life cycle.  It is documented that  LCS I is the predominant 
location for phosphorylation of NS5A (Ross-Thriepland and Harris, 2014b, Katze et al., 2000, 
Lemay et al., 2013, Appel et al., 2005b, Hsu et al., 2017). More recent research point out that 
phosphorylation of NS5A is by regulatory mechanisms via sequential phosphorylation cascade 
such that phosphorylation of S235 is a prerequisite to S238 phosphorylation (Hsu et al., 2017). 
However, the exact mechanism remains to be further elucidated.  
The low complexity sequence II (LCSII) is a short (13aa), proline rich region of NS5A linking 
domain II and III.  Within this region, there are two closely spaced polyproline motifs that are 
able to bind to the SH3 domains of Src-family tyrosine kinases, which are involved in RNA 
replication and viral assembly (Macdonald et al., 2004, Ross-Thriepland and Harris, 2014a). 
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Figure 1.3 Schematic representation of NS5A protein. 
A. NS5A is composed of three domains divided by two low complexity sequences (LCS I and 
LCS II) and is linked with an N-terminal (1-33aa) amphipathic helix (AH). Domain I coordinates 
a zinc ion in a highly ordered manner. Number of positions is based on genotype 2a JFH1 
isolate. B. Model of structure of N5SA. AH anchors to the membrane and two domain I 
monomers form into the dimeric conformation revealed by (Tellinghuisen et al., 2005). The 
unstructured domain II and III are illustrated.  
 
 
 
A 
 
B 
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1.3.2 Functions of NS5A in HCV lifecycle 
NS5A plays multifunctional roles in different stages of the virus lifecycle from genome 
replication to virus assembly, the separation of which is regulated by different domains of 
NS5A. As a membrane-bound protein, the N-terminal α-helix plays a critical role in membrane 
association (Palomares-Jerez et al., 2010, Brass et al., 2002) and also is required for RNA 
replication (Elazar et al., 2003). Domains I and II are mostly required for genome replication 
(Tellinghuisen et al., 2005, Ross-Thriepland et al., 2013). In comparison, although domain III 
contributes to genome replication it is dispensable and is instead required for HCV assembly 
(Tellinghuisen et al., 2008b, Tellinghuisen et al., 2008a, Hughes, 2010, Hughes et al., 2009b, 
Hughes et al., 2009a, Appel et al., 2008, Zayas et al., 2016). 
Within the membrane anchoring N-terminal fragment of NS5A, introduction of three helix- 
disrupting mutations completely abrogated the ability of the replicon to establish G418-
resistant colonies, implying that NS5A membrane association is an indispensable event during 
HCV RNA replication (Elazar et al., 2003, Penin et al., 2004). 
The detailed functions of domain I throughout the HCV life cycle will be described in Section 
5.1. 
The serine-rich cluster LCS I linking domain I and domain II is highly phosphorylated, and is 
involved in genome replication and virus assembly. It was proposed that  
hyperphosphorylation inhibits genome replication as it was identified that mutations that 
significantly reduce hyperphosphorylation yet have no effect on either genome replication or 
virus assembly and release (e.g., S146D and S225D) (Ross-Thriepland and Harris, 2014b). 
In contrast to domain I, domain II has been more extensively studied and is well known to be 
involved in replication and virus assembly via interactions with viral and host proteins. Apart 
from the N-terminal 30 residues of this domain, residues spanning the remainder were shown 
to be essential for genome replication with different genotypes (Tellinghuisen et al., 2008b, 
Appel et al., 2008, Ross-Thriepland et al., 2013). Intriguingly, there were a number of residues 
towards the C terminus of domain II that were conserved between the two genotypes (1b and 
2a) yet when mutated exhibited different phenotypes, for example Y317A in JFH1 had a null 
phenotype (Ross-Thriepland et al., 2013) but was lethal in the corresponding residue in Con1 
(Y321A) (Tellinghuisen et al., 2008b) and mutations of residues W312, A313, Y330 and V336 in 
JFH1 were lethal, but in Con1 the corresponding mutations have either a null or partial 
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phenotype. This observation suggests that it is not possible to extrapolate between the 
different genotypes and may perhaps reflect differences in protein - protein interactions. 
Between domain II and III, there are two closely spaced polyproline motifs (termed PP2.1 and 
PP2.2), with the consensus sequence Pro-X-X-Pro-X-Lys/Arg in LCS II shared by both genotypes 
1b and 2a, which have been characterized to mediate interactions with cellular SH3 domains. 
Mutagenesis analysis proved that LCS II is required for both RNA replication and virus assembly 
(Hughes et al., 2009a). PP2.1 has been shown to be only required for genotype 1b RNA 
replication. It’s worth mentioning that P346A within PP2.1 dramatically attenuated genotype 
1b replication, but corresponding P342A in genotype 2a showed a reduction in virus 
production without any effect on RNA replication (Hughes et al., 2009a). PP2.2 is not required 
for RNA replication of all subgenomic replicons, while it may play roles in virus persistence 
through ion channel modulation and inhibition of apoptosis (Mankouri et al., 2009, Amako et 
al., 2013). 
NS5A domain III is mostly involved in virus assembly. In particular, the C-terminal 38 amino 
acids are required for virus assembly. Deletions in domain III perturb co-localisation between 
NS5A with core on LDs, suggesting that it might be linked with production of infectious virus. 
Based on this evidence, a model is put forward in which core recruits either NS5A or the NS5A-
containing replication complex (RC) via direct interaction with domain III to the assembly site 
(Appel et al., 2008). Additionally , a 19-residue insertion near the C terminus of domain III 
found exclusively in genotype 2 HCV isolates is dispensable for assembly, with deletion only 
modestly effecting genome replication (Hughes et al., 2009b). A C-terminal serine cluster in 
domain III, a determinant of the NS5A-core interaction via phosphorylation, is important for 
virion production (Masaki et al., 2008). Mutations of serine 452,454 and 457 disrupt the 
interaction with core and reduce the amount of RNA co-immunoprecipitated with core. Of 
note, these mutations shift the localisation of NS5A from fractions enriched in LD proteins 
towards ER fractions, indicating that domain III is important to regulate RNA replication and 
HCV particle formation.  Additional evidence shows that mutations in NS5A that enhance RNA 
replication cause decreases in virus assembly, suggesting that NS5A may contribute to the 
switch between replication and assembly (Pietschmann et al., 2009). 
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1.3.3 NS5A-interacting partners  
1.3.3.1 RNA  
As one important component of the replication complex essential for RNA replication, NS5A 
has been shown to bind RNA in vitro (Foster et al., 2010, Huang et al., 2005). It is also 
demonstrated that each of the three domains possess the ability to bind the HCV 3’UTR.  For 
the binding determinant in 3’UTR, full-length NS5A lacking the N-terminal amphipathic helix 
exhibited a higher affinity for the poly(U/UC) region than for the X-region (Foster et al., 2010). 
Peptidyl-prolyl isomerase cyclophilin A (CypA) can bind to domain II and stimulate the RNA-
binding activity of domain II but not of domains I and III (Foster et al., 2011). Detailed 
biochemical characterization of NS5A-RNA binding revealed that it was inhibited by a high 
concentration of EDTA, implying a requirement for Zn2+ or other divalent cations. Cysteines 
(Cys-39, Cys-57, Cys-59, and Cys-80) of NS5A domain I critical for dimerization are also 
important for RNA-binding and replication (Lim et al., 2012). It is proposed that dimerization 
of domain I is correlational with RNA binding activity of NS5A domain I. Based on the nature 
of revealed structures of domain I, there is a large groove in dimers providing an attractive 
RNA-binding pocket (Tellinghuisen et al., 2005). However, the mechanism of how NS5A is 
involved during RNA synthesis remains to be determined.  These experiments might ultimately 
provide clues as to how the replicase machinery works to replicate HCV RNA.  
RNA binding of NS5A plays an essential role in the switch from RNA replication to virus 
assembly. It was reported that mutation blocks the NS5A-core protein interaction, resulting in 
perturbation of association between the core protein and HCV RNA. It is thus tempting to 
consider that NS5A can transport the viral genome RNA synthesized by the replication complex 
to the surface of LDs or LD-associated membranes, where the core protein localizes, leading to 
facilitation of nucleocapsid formation (Masaki et al., 2008). 
1.3.3.2 Viral proteins 
Apart from RNA binding activity, when NS5A is involved in the replication complex it can 
interact with various cellular factors and viral proteins, which are required for HCV replication 
(Paul et al., 2014). In the replication complex, the phosphorylation of NS5B RdRp was activated 
by NS5A, at least in vitro. This activation might be mediated by the RNA-binding ability of NS5A 
or by direct interaction with NS5B (Shirota et al., 2002, Quezada and Kane, 2013). It was also 
shown that deletions within NS5A that abrogated the interaction with NS5B also rendered the 
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subgenomic replicon non-functional, whereas a deletion that had no effect on NS5B binding 
was replication-competent (Shimakami et al., 2004).  
Interestingly, NS4B, together with NS3 and NS4A, seem to be directly involved in modulation 
of NS5A hyperphosphorylation (Koch and Bartenschlager, 1999, Neddermann et al., 1999). 
NS4B direct association with NS5A might thus play a role in the regulation of NS5A 
hyperphosphorylation. Recent research demonstrated that domain I of NS5A was sufficient to 
mediate its interaction with NS4B, and then affect viral genome replication (David et al., 2015). 
A combination of standard biochemical and genetic protein-protein interaction assays, 
demonstrated that NS5A was able to interact independently with all the non-structural 
proteins, including itself (Dimitrova et al., 2003). Taken together with these observations, it is 
clear that NS5A does indeed participate in a multi-protein replication complex. However, the 
molecular details of the structure and function of this complex remain major challenges. 
NS5A participation in virus production has been demonstrated to result from its interaction 
with core protein. Alanine substitutions for the C-terminal serine cluster in domain III of NS5A 
impaired NS5A basal phosphorylation, leading to a marked decrease in NS5A-core interaction, 
disturbance of the subcellular localization of NS5A, and disruption of virion production (Masaki 
et al., 2008). 
1.3.3.3 Host factors  
Due to the tight interplay between the HCV non-structural proteins during viral replication and 
assembly, proteomics approaches have been used to characterize these interactions (Douam 
and Ploss, 2015), which could also be targeted by antiviral therapies. Targeting NS5A, over 130 
cellular interaction partners have been identified by proteomic approaches (Tripathi et al., 
2013), of which approximately 60 proteins have been proved to function with NS5A during 
HCV life cycle. The explanation that NS5A can interact with a large number of partners is likely 
the intrinsically disordered domains II and III, which might adopt different conformations 
(Feuerstein et al., 2012). 
1.3.3.3.1 Host factors required for RNA replication  
A great number of host proteins have been shown to interact with NS5A in a manner critical 
for the replication of HCV. Firstly, HCV replication is intrinsically linked to lipid metabolism in 
hepatocytes (Kapadia and Chisari, 2005). Recruitment and activation of the lipid kinases by 
HCV is essential for integrity of the membranous web and RNA replication. Of them, NS5A 
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directly interacts and activates the phosphatidylinositol 4-kinase (PI4K) IIIα which increases the 
quantity of Phosphatidylinositol 4-phosphate (PI4P), which is required to maintain the 
membranous web (Reiss et al., 2011).  Four conserved  amino acids (PFIS) at the C-terminus of 
domain I of NS5A are responsible for this interaction resulting in the activation of kinase, but  
negatively regulating of NS5A hyperphosphorylation (Reiss et al., 2013). 
Cyclophilins, a family of peptidylprolyl isomerase (PPIase), exhibit as critical host factors for a 
variety of viruses (Kapadia and Chisari, 2005). Two isoforms CypA and CypB have been shown 
to be important for RNA replication through interaction with NS5A (Verdegem et al., 2011, 
Coelmont et al., 2010, Foster et al., 2011, Chatterji et al., 2009, Hanoulle et al., 2009a). With 
the development of several CypA inhibitors in clinical trials, the majority of research is to 
understand the molecular mechanism of NS5A-CypA  interactions (Paeshuyse et al., 2006). 
Structural analysis suggests that the active site of CypA interacts with C-terminus of domain II 
to further catalyse the cis-trans isomerisation of the peptide bond within this region (Coelmont 
et al., 2010, Grise et al., 2012). Moreover, it has been shown that CypA stimulates RNA binding 
of NS5A domain II in an isomerase dependent manner. Hence, the role of CypA in the 
enhancement of HCV RNA replication may be dependent, to some extent, on its stimulation of 
the RNA binding ability of NS5A (Foster et al., 2011). 
As has been mentioned in the section of structure of NS5A, LCSII of NS5A contains two 
polyproline motifs, providing SH3 domains binding regions. A number of cellular proteins 
contain Src homology 3 (SH3) domains which mediate protein-protein interactions with NS5A. 
Such interactions cause the regulation of apoptosis through the SH3-domain-containing kinase 
mixed lineage kinase 3 (Amako et al., 2013) and amphiphysin II (Zech et al., 2003), and 
trafficking of epidermal growth factor receptor (Mankouri et al., 2008) through the Cas ligand 
with multiple SH3 domains (Mankouri et al., 2008, Igloi et al., 2015). 
Comparison of messenger RNA (mRNA) expression levels in chronic hepatitis C (CHC) liver 
biopsies identifies that cholesterol25-hydroxylase (CH25H) mRNA is up-regulated. Moreover, a 
product produced by CH25H, 25-hydroxycholesterol (25HC), profoundly blocks HCV RNA 
replication by preventing formation of the viral replication factory via directly interacting with 
and inhibiting NS5A dimerization (Anggakusuma et al., 2015, Chen et al., 2014). Kinase Raf-1 is 
another cellular binding partner of NS5A, binding to the C-terminal domain of NS5A, which has 
been identified to be crucial for HCV replication (Burckstummer et al., 2006).  It is worthy to 
note that TBC1D20 and its cognate GTPase Rab1 play important roles in virus replication via 
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interaction with NS5A around LD, which might be involved in the recruitment of  other host 
mediators to promote the viral life cycle (Nevo-Yassaf et al., 2012). 
Mass spectrometry studies on NS5A have identified multiple phosphorylation sites within the 
NS5A LCSI and indicate a complex regulation of NS5A functions (Lemay et al., 2013, Masaki et 
al., 2014, Ross-Thriepland and Harris, 2014b). A number of host kinases have been reported to 
phosphorylate NS5A (Table 1.2). Serine 457 of NS5A domain III is likely a target for casein kinase 
II (CKII) phosphorylation and phosphorylation of this residue appears to be an important 
regulatory step in infectious virus production (Kim et al., 1999, Tellinghuisen et al., 2008a).  CKI-
α has been shown to phosphorylate S232 dependent on S229 phosphorylation (Quintavalle et 
al., 2007). Inhibition and siRNA silencing studies have confirmed the activity of CKI-α on NS5A 
in vivo indicating  that S225 and S232 may be key residues for CKI-α-mediated NS5A 
hyperphosphorylation and regulation of virion assembly (Masaki et al., 2014). Alanine 
substitution of serine 225 (S225A) in LCSI resulted in the reduction in both NS5A 
hyperphosphorylation and genome replication. Quantitative proteomic analysis of NS5A-
interacting proteins between WT and S225A revealed that nucleosome assembly protein 1-like 
1 (NAP1L1) interacting with NS5A contributes to genome replication and the distribution of 
replication complexes throughout the cytoplasm (Goonawardane et al., 2017). In reverse, 
NS5A targets NAP1L1 to modulate the innate cellular response via activating RIG-I and Toll-like 
receptor 3 (TLR3) antiviral responses (Cevik et al., 2017). Threonine 356 in domain III can be 
phosphorylated by PKA (Cordek et al., 2014). Inhibition of PKA reduces the infectivity of 
secreted virus particles with no effect on replication or the formation of intracellular infectious 
particles (Farquhar et al., 2008). PLK phosphorylates NS5A in vitro to both the 56 and 58 kDa 
forms, PLKI inhibitors reduce HCV NS5A S235 phosphorylation and further impair HCV 
replication (Lee et al., 2016, Chen et al., 2010a). The vesicle-associated membrane protein 
(VAMP)-associated protein A and B (VAP-A /B) have been identified be to also involved in 
phosphorylation of NS5A (Evans et al., 2004, Goonawardane et al., 2017, Gao et al., 2004, 
Hamamoto et al., 2005) . VAP-A interacts with both NS5A and NS5B and knockdown of VAP-A 
results in relocalisation of NS5B and a small reduction in RNA replication (Gao et al., 2004). 
There is an inverse correlation between NS5A phosphorylation and VAP-A binding, which 
suggests a possibility that hyperphosphorylation of NS5A disrupts interaction with VAP-A and 
negatively regulates viral RNA replication (Evans et al., 2004). 
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Host Protein  Functions Determinant in NS5A Reference 
AmphII 
 Inhibits 
phosphorylation of 
NS5A Unknown (Masumi et al., 2005) 
CH25H Inhibits RNA replication  Domain I  
  (Chen et al., 2014, 
Anggakusuma et al., 2015) 
CKII 
Phosphorylation of 
NS5A Serine in domain III 
(Tellinghuisen et al., 
2008a) 
CKIα 
Hyperphosphorylation 
of NS5A LCSI serine residues  
 (Masaki et al., 2014, 
Quintavalle et al., 2007) 
Cyp A RNA replication 
C-terminus of  Domain 
II and Domain III 
(Foster et al., 2011, 
Chatterji et al., 2009, 
Hanoulle et al., 2009a) 
FBP RNA replication Unknown (Zhang et al., 2008) 
FKBP8 RNA replication Unknown  (Okamoto et al., 2006) 
GPS2 RNA replication Domain I  (Xu et al., 2013) 
hB-ind1 RNA replication Unknown (Taguwa et al., 2008) 
HSP72 RNA  replication   Domain I (Chen et al., 2010b) 
NAP1L1 
Phosphorylation of 
NS5A Serine 225 in LCSI 
(Goonawardane et al., 
2017) 
PI4KIIIα 
Phosphorylation of 
NS5A,  membranous 
web formation and RNA 
replication C-terminus of domain I 
(Reiss et al., 2011, Reiss et 
al., 2013) 
Pin1 RNA replication  (Lim et al., 2011) 
PKAα 
Phosphorylation of 
NS5A 
Threonine in  
domain III (Cordek et al., 2014) 
PLKI 
Hyperphosphorylation 
of NS5A Serine  in LCS I 
(Lee et al., 2016, Chen et 
al., 2010a) 
Rab1 Replication Unknown (Nevo-Yassaf et al., 2012) 
Rab18  
Replication and virus 
release Unknown (Salloum et al., 2013) 
Raf-1  RNA replication C-terminus of NS5A 
 (Burckstummer et al., 
2006) 
TBC1D20 RNA replication  N -terminus of NS5A 
 (Sklan et al., 2007b, Nevo-
Yassaf et al., 2012) 
VAP-A 
Hyperphosphorylation 
of NS5A and RNA 
replication Serine in LCS I 
 (Evans et al., 2004, 
Goonawardane et al., 
2017, Gao et al., 2004) 
VAP-B 
Hyperphosphorylation 
of NS5A and RNA 
replication 
 N-terminus and C-
terminal polyproline 
cluster 
(Hamamoto et al., 2005, 
Goonawardane et al., 
2017) 
Table 1.2 NS5A interacting proteins required for RNA replication and NS5A phosphorylation. 
AmphII: Amphiphysin II; CH25H: Cholesterol 25-hydroxylase; CKII: Casein Kinase II; CKIα: Casein 
Kinase I-alpha;  FBP: Far upstream element of the c-myc proto- oncogene (FUSE) binding 
protein; FKBP8: FK506-binding protein; GPS2: G protein pathway suppressor 2; hB-ind1: 
Human butyrate-induced transcript 1;  HSP72: Heat shock protein 72; nucleosome assembly 
protein 1-like 1 (NAP1L1); PI4KIIIα: Phosphatidylinositol-4 kinase III alpha; Pin1: peptidyl-prolyl 
cis-trans isomerase NIMA- interacting 1; PKAα: cAMP-dependent protein kinase A-α subunit 
PKA ; PLKI: Polo-like Kinase I; Rab1/18: Ras-related protein 1 AND 18; TBC1D20:(Tre-2, Bub2, 
and Cdc16)-1 domain family, member 20; VAP-A/B: Vesicle-associated membrane protein 
(VAMP)-associated protein A/B. 
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1.3.3.3.2 Host factors required for virus assembly  
It is widely accepted that domain III of NS5A is mostly involved in virus production so that the 
protein-protein interaction of NS5A participating in virus assembly are attributed to domain III 
(Table 1.3). 
Proteomic analysis of HCV replication complexes has shown that the NS5A protein interacts 
with Annexin A2 mediated by domain III. Intriguingly, knockdown of annexin A2 does not 
impair viral RNA replication but significantly reduces infectious HCV titers with decreased 
secretion of viral core protein.  Therefore, ANXA2 might play a role in assembly rather than the 
release of infectious HCV virions but remains to be investigated (Backes et al., 2010). 
The interaction of NS5A with apolipoproteins is important for the formation of lipoparticles 
and virus assembly and maturation (Section 1.4.1). Both yeast two-hybrid system and 
biochemical analysis demonstrate that ApoE can directly interact with NS5A and furthermore 
knockdown of ApoE has shown to impair the production of virus. The interaction between 
NS5A and ApoE can be disrupted by the deletion of domain III. Moreover, mutations at the 
positions 99 to 101 or 102 to 104 of NS5A domain I (JFH1AAA99 and JFH1AAA102) were also 
identified to abrogate the interaction with ApoE, which can explain why these mutants of 
domain I failed to the produce infectious viruses (Miyanari et al., 2007, Benga et al., 2010). This 
is the only case that is related to domain I that is involved in virus assembly. Apolipoprotein J, 
a glucose-upregulated VLDL-associated molecular chaperone, can interact with HCV core and 
NS5A and stabilize the dual protein complex (Lin et al., 2014). 
Diacylglycerol acyltransferase 1 (DGAT1) was initially found to interact with HCV core protein 
and catalyse core trafficking to LD for virus assembly (Herker et al., 2010). Subsequently it was 
shown that DGAT1 could also bind NS5A, enhance interactions of NS5A with the viral capsid 
core, and enable lipid droplet localization of NS5A (Camus et al., 2013). Hence, DGAT1, core 
and NS5A interact in one complex, DGAT1 serves as a cellular hub guiding both core and NS5A 
onto the surface of LDs. A catalytically inactive mutant of DGAT1 (H426A) blocks the 
localization of NS5A, but not core, which suggests that catalytical determinants in DGAT1 are 
different for NS5A and core (Camus et al., 2013). 
Proteomics analysis with NS5A tagged with Strep-tag protein revealed that oxysterol binding 
protein (OSBP) is an NS5A interacting partner with domain I as the approximate binding site 
for OSBP. OSBP deletion mutation failed to localize NS5A to the Golgi compartment, which 
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provides a possibility that interaction of OSBP and NS5A play roles in the viral assembly and or 
secretion processes (Amako et al., 2009). 
Phosphatidylserine-specific phospholipase A1 (PLA1A) is another important host factor that is 
involved in the initiation of the viral assembly in close proximity to core-decorated LDs 
interaction with E2- NS2 complex, and NS5A-associated replication complex (Guo et al., 2015).  
Similarly,  Rab18, a member of the Rab family of small GTPases, also promotes interaction 
between NS5A and LDs and  may also enhance virion assembly by bringing sites of replication 
in close physical proximity to sites of virion assembly. In addition, the recruitment of NS5A to 
LDs could be inhibited by shRab18 RNA, but HCV core protein can localize with  LDs, suggesting 
that the interaction between core protein and LDs is Rab18-independent (Salloum et al., 2013). 
Tail-Interacting Protein 47 (TIP47), as a lipid droplet-binding protein, plays multi-roles 
throughout HCV life cycle. It is documented that overexpression of TIP47 increases the amount 
of released viruses, while silencing of TIP47 abolishes virus replication (Ploen et al., 2013). 
More evidence points out that  it is  TIP47 recruiting LD containing membranes to membranous 
web that facilitates RNA replication via interaction with NS5A (Vogt et al., 2013). 
Host protein Function   
Determinant in 
NS5A  Reference 
 Annexin A2 (ANXA2) Virus assembly Domain III 
(Backes et al., 
2010) 
Apolipoprotein E (ApoE) Virus assembly Domain I and III 
(Benga et al., 
2010) 
Apolipoprotein J (ApoJ) Virus assembly Unknown  (Lin et al., 2014) 
Diacylglycerol 
acyltransferase 1 (DGAT1) Virus assembly Unknown  
(Camus et al., 
2013) 
Oxysterol binding protein 
(OSBP) Virus assembly Domain I 
(Amako et al., 
2009) 
Phosphatidylserine-specific 
phospholipase 
A1(PLA1A) Virus assembly Unknown (Guo et al., 2015) 
 Rab18  Virus assembly Unknown 
(Salloum et al., 
2013) 
Tail-Interacting Protein 
(TIP47) Virus production Unknown 
(Ploen et al., 
2013, Vogt et al., 
2013) 
Table 1.3 NS5A interacting proteins required for virus assembly. 
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1.4 Lifecycle of HCV  
1.4.1 HCV virus particle composition 
HCV particles are enveloped and contain the viral core protein, which likely combines with the 
viral genome to form a nucleocapsid, and two surface glycoproteins, E1 and E2 (Figure 1.4A). 
Filtration and electron microscopy (EM) studies have identified predominately spherical 
particles with a heterogeneous diameter of 40-80 nm, which are more irregular in structure in 
comparison with other members of the Flaviviridae family (Bradley et al., 1985, Gastaminza et 
al., 2010, He et al., 1987, Merz et al., 2011, Catanese et al., 2013). However, despite many 
efforts, the clear architecture and composition of the HCV particle has remained enigmatic. 
The HCV life cycle is closely linked to the hepatic lipoprotein metabolism as viral particles 
associate with lipoproteins and lipids during maturation to form lipoviroparticles (LVPs) (Andre 
et al., 2002). The most striking feature of infectious HCV particles is its buoyant density, which 
is unusually low and heterogeneous for an enveloped RNA virus. Both serum-derived HCV and 
HCV derived from cell culture (HCVcc) particles with high specific infectivity have buoyant 
densities ranging between <1.06 g/ml in the case of serum-derived particles (Andre et al., 
2002) and ~1.1g/ml for HCVcc’s (Lindenbach et al., 2005, Hijikata et al., 1993, Lindenbach et 
al., 2006), which is significantly lower than those of other enveloped RNA viruses. Moreover, 
HCVcc particles produced in Huh7-derived cells show a higher buoyant density compared to in 
vivo- or primary hepatocyte-derived samples, correlating with a lower specific infectivity 
(Podevin et al., 2010, Lindenbach et al., 2006). As Huh7 cells are deficient in lipoprotein 
metabolism, they do not produce very low-density lipoproteins (VLDLs), and produce instead 
apolipoprotein B (ApoB)-containing particles that resemble low-density lipoproteins (LDLs) 
(Podevin et al., 2010, Meex et al., 2011).  
The low density of the HCV virion is tightly associated with lipoprotein components such as 
apolipoprotein A-I (apoA-I), apoB-48, apoB-100, apoC-I and apoE in low-density lipoprotein 
(LDL) or very low-density lipoproteins (VLDL) particles (Figure 1.4B) (Catanese et al., 2013, 
Thomssen et al., 1992, Kono et al., 2003, Felmlee et al., 2010, Diaz et al., 2006), and their lipid 
composition is similar to serum lipoproteins by lipid profiling of highly purified HCVcc particles 
(Merz et al., 2011). Therefore, it is proposed that HCV particles form hybrid lipoviral particles 
(LVP), either through transient interactions with serum lipoproteins in the two-particle model 
(Figure 1.4C), or by directly sharing an envelope with a low-density lipoprotein (LDL) in the 
single particle model (Figure 1.4D). The two-particle model (Figure 1.4C) is much more 
favourable as HCVcc particles chemically stripped of cholesterol lose their infectivity, which can 
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be restored by adding back exogenous cholesterol (Aizaki et al., 2008). Moreover, the buoyant 
density of HCV particles in serum rapidly shifts in relation to dietary triglycerides, suggesting 
that the interaction of HCV particles with serum lipoproteins is transient and exchangeable 
(Felmlee et al., 2010). 
 
 
 
Figure 1.4 Schematic representation of HCV virion architecture. 
A. Viral particles are composed of nucleocapsid (core) containing the viral RNA surrounded by 
a host cell-derived lipid envelope in which the E1 and E2 envelope glycoproteins are 
embedded. B. Representation of different types of serum lipoprotein particles. Both Very low-
density lipoprotein (VLDL) and low-density lipoprotein (LDL) display the large apolipoprotein 
B-100 (apoB-100) and the small apoC II) and (I and apoE on their surface, which consists of a 
phospholipid monolayer surrounding a hydrophobic core of triglycerides, cholesterol and 
cholesterol esters. High-density lipoprotein (HDL) particle mainly displays apoA-I, apoC-II 
and/or apoE. C. Two-particle model of HCV virion with transient interaction between serum 
lipoproteins and HCV particles. D. Single particle model with membrane sharing between HCV 
and low-density lipoprotein. Pictures are adapted from (Lindenbach and Rice, 2013). 
 
A B 
C D 
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1.4.2 Binding and entry of HCV 
Hepatocytes are the cellular target of HCV and the entry of HCV is a complicated multistage 
process. After infection, HCV circulates in the blood and thus has direct contact with the 
basolateral surface of hepatocytes, allowing virus to bind a number of receptors on cell surface 
(Figure 1.5). The binding to receptors will initiate clathrin-dependent endocytosis.  
The binding of HCV with low-affinity interaction such as low-density-lipoprotein receptor 
(LDLR) and glycosaminoglycans (GAGs) present on heparan sulphate proteoglycans (HSPGs) is 
the initial step of entry via the  interaction with virion-associated apoE (Agnello et al., 1999, 
Germi et al., 2002, Monazahian et al., 1999). Scavenger receptor class B member 1 (SRB1) is a 
co-receptor, which interacts with virus-associated lipoproteins to dissociate virus particles 
from lipoproteins for productive virus entry (Dao Thi et al., 2012, Zahid et al., 2013). 
Additionally, the interaction with SRB1 can expose the CD81-binding derminant on HCV E2 
glycoprotein (Scarselli et al., 2002, Dao Thi et al., 2012, Bankwitz et al., 2010).  
CD81 is a ubiquitously expressed cell surface tetraspanin that directly binds HCV E2, which 
mediates the low-pH fusion post attachment (Bertaux and Dragic, 2006, Sharma et al., 2011). 
In addition, interaction of CD81 with tight junction protein claudin 1 (CLDN1) is required for 
this function of CD81 in HCV entry (Harris et al., 2010). The tight junction is a critical cellular 
component for maintenance of tissue integrity, cellular interactions and cell-cell 
communications, and it also works as a gate for the entry of viruses (Lee and Luk, 2010).  CLDN1 
is one of the membrane proteins located on  tight junctions that  induce HCV internalisation 
via the interaction with CD81 (Evans et al., 2007). Like CLDN1, occluding (OCLN) is another tight 
junction protein also involved a post-attachment step during HCV entry, although the precise 
role is still unclear (Sourisseau et al., 2013). Another receptor transferrin receptor 1 (TFR1) and 
Niemann-Pick C1-like one (NPC1L1) are also demonstrated to be important for a post-CD81-
binding event as the inhibitions on TFR1 will impair HCV infection (Martin and Uprichard, 2013, 
Sainz et al., 2012, Jia et al., 2011).  
The interaction between CD81 and CLDN-1 is modulated by several signal transduction 
pathways including epidermal growth factor receptor (EGFR) and downstream RAS GTPase 
signalling, as well as RHO GTPases (Lupberger et al., 2011, Diao et al., 2012, Brazzoli et al., 
2008). These signalling pathways will facilitate complex HCV-CD81 and CLDN1 to induce 
clathrin- mediated endocytosis (Farquhar et al., 2012).  
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Following clathrin-mediated endocytosis, both HCV and receptors are trafficked to Rab5a 
expressing endosomal compartments (Coller et al., 2009, Farquhar et al., 2012). Subsequently 
low pH of the endosomes induces envelope directed membrane fusion and release of genomic 
RNA into the cytosol for further viral translation and replication (Sharma et al., 2011). 
Antibody treatment is an attractive therapeutic direction by targeting factors involved in HCV 
entry. A number of monoclonal antibodies directed to viral and host factors are under 
development (Zeisel et al., 2013), but are still clinically unavailable (Fukasawa et al., 2015). 
 
Figure 1.5 Binding and entry of HCV to host cell. 
1. HCV lipoviral particles interact with cell receptors including heparin sulphate proteoglycans 
(HSPGs), low-density-lipoprotein receptor (LDLR) and scavenger receptor class B member 1 
(SRB1), inducing the exposure of  the CD81-binding site in E2 ;  2. Signal transduction mediated 
by interaction of E2 with CD81 through epidermal growth factor receptor (EGFR), HRAS and 
RHO GTPases; 3. Lateral movement of HCV to sites of cell-to-cell contact; 4. HCV internalisation 
by clathrin-mediated endocytosis though interaction of CD81 with CLDN1; 5. HCV fusion and 
release of RNA in the endosome of low pH. NPC1L1: Niemann-Pick C1-like 1, OCLN: occludin.  
Picture was adapted from (Lindenbach and Rice, 2013). 
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1.4.3 Polyprotein processing  
Post release of genomic RNA into the cytosol, the positive sense RNA acts directly as mRNA to 
direct translation of polyprotein at the rough endoplasmic reticulum (ER). As HCV RNA lacks  a 
5’-terminal cap and  3’-terminal poly(A) tract but contains highly structured 5’UTR and 3’UTR 
(details in Section 1.2.1), translation of HCV is in a cap-independent manner through 
recruitment of the 40S ribosome subunit directly via interactions with the IRES in the 5’ UTR 
and associated eukaryotic initiation factors (eIF) (Jaafar et al., 2016). Binding of the HCV IRES 
to the 40S ribosomal subunit induces rotation of the head domain and opening of the mRNA 
binding channel (Spahn et al., 2001). Subsequent recruitment of the 60S ribosomal subunit 
forms an active 80S ribosome positioned directly on the HCV initiation AUG codon (Reynolds 
et al., 1996, Reynolds et al., 1995). Correct positioning of the ribosome on the start codon 
requires both sequence and structural stability of domain IV. Translation of the primary ORF 
result in a large polyprotein until an initiation AUG codon is encountered, and polyprotein is 
later cleaved into the individual proteins.  
The signal peptidase cleavage of core-E1, E1-E2, E2-p7 and p7-NS2 takes place co-or post 
translationally to leave mature core, membrane embedded E1 and E2 and transmembrane p7. 
An autoprotease activity that maps to both NS2 and NS3 cleaves at the NS2-3 boundary to free 
NS2 from the polyprotein (Figure 1.2) (Grakoui et al., 1993). The remaining NS polyprotein is 
cleaved by NS3 with its cofactor NS4A (Bartenschlager et al., 1994, Bartenschlager et al., 1995). 
Production of mature viral proteins proceed to function in genome replication, assembly and 
ultimately release of infectious virions. 
1.4.4 RNA replication  
After translation and proteolytic processing of polyprotein, the viral replicase complex (RC) is 
constituted. This translation take places rapidly followed by RNA replication and translation of 
RNA within 8 hours. From that point the intracellular levels of both viral protein and genomes 
increase exponentially until a  steady state is reached at around 24 hours (Binder et al., 2013). 
Positive-strand RNA viruses, including members of the Flaviviridae family, replicate their 
genomes in association with remodelled cytoplasmic membranes (Paul and Bartenschlager, 
2015). Replication of HCV requires non-structural proteins NS3 to NS5B, and these proteins are 
tightly associated to endoplasmic reticulum (ER) membranes and together with cellular factors  
induce, in a concerted fashion, membrane rearrangements that lead to the formation of viral 
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replication organelles termed membranous web (MW) (Miller and Krijnse-Locker, 2008, Paul 
and Bartenschlager, 2015). 
Electron microscopy (EM) and soft X-ray microscopy revealed that HCV infection contributes 
to the accumulation of membrane vesicles, mostly double membrane vesicles (DMV), 
embedded in a compact membrane network (Egger et al., 2002, Gosert et al., 2003, Romero-
Brey et al., 2012, Perez-Berna et al., 2016). Purified DMV contain active polymerase and the 
presence of both NS5A and double stranded RNA and the expression of NS3-5B alone is 
sufficient to induce DMV structure (Romero-Brey et al., 2012, Ferraris et al., 2010). Of them, 
NS4B is the major viral protein and primary inducer required for the formation of DMV, but 
the individual expression of NS4B is insufficient to induce DMVs (Egger et al., 2002, Romero-
Brey et al., 2012). Interaction of NS5A and host factor phosphatidylinositol-4 kinase-III α /β 
(PI4KIII α /β) is critical for the formation of membranous web (Reiss et al., 2011). Expression of 
NS3/4A or NS5B alone resulted in altered vesicle architectures, suggesting a less critical role in 
DMV formation (Romero-Brey et al., 2012). Apart from NS proteins of HCV, a large number of 
host factors are involved in the membranous web formation and virus replication. 
Post the formation of DMV, additional modifications to the DMV scaffold such as net increase 
of intracellular membrane surface and recruit additional accessory factors, are required for the 
functional replication factories (Paul and Bartenschlager, 2015). The increased positive 
membrane curvature requires the de novo synthesis of membrane lipids. High-throughput 
lipidomic profiling of HCV infected cells has revealed significant alterations to lipid 
compositions (Diamond et al., 2010). HCV relies on sterol regulatory element-binding protein 
(SREBP)-mediated transcriptional activation of lipogenic biosynthetic enzymes, leading to 
elevated levels of lipogenic transcripts, such as FAS (fatty acid synthase) and HMG-CoA (3-
hydroxy-3-methylglutaryl coenzyme-A) reductase (Waris et al., 2007). The phosphatidylinositol 
4-kinase IIIα (PI4KIIIα) and its product phosphatidylinositol 4-phosphate (PI4P) are other 
important components for lipid composition and integrity of HCV membrane structures 
(Trotard et al., 2009, Reiss et al., 2011, Berger et al., 2009). Upon HCV infection, subcellular 
localization of PI4KIIIα is altered presumably via interactions with NS5A and NS5B, concomitant 
with an increase in intracellular PI4P levels and a decrease of the PI4P plasma membrane pool, 
which is dispensable for DMV functionality (Figure 1.6) (Bianco et al., 2012, Reiss et al., 2011, 
Altan-Bonnet and Balla, 2012).  
HCV replication factories are significantly enriched in cholesterol over ER membranes and its 
removal from DMV reduces their size and HCV genome stability (Paul et al., 2013). Addition of 
Chapter 1: Introduction 
36 
 
PI4P to membranes also functions to recruit lipid transfer proteins for the storage of lipids. 
Oxysterol-binding protein (OSBP) and glycosphingolipid transporter four-phosphate adaptor 
protein 2 both linked with PI4P involved in nonvesicular cholesterol transport is required for 
HCV replication (Wang et al., 2014, Khan et al., 2014b). This pathway is further stimulated by 
VAP-A and VAP-B, which are recruited by NS5A (Figure 1.6) (Wang et al., 2014, Evans et al., 
2004, Gao et al., 2004, Khan et al., 2014b). OSBP interacts with VAPs via its FFAT motif, which 
is essential to promote cholesterol transport to HCV-remodelled membranes and hence viral 
replication (Mesmin et al., 2013).  
Within the well-formed replication factories, the process of genome replication is performed 
by NS5B RNA-dependent RNA polymerase (RdRp) to direct the synthesis of the negative-strand 
intermediate that serves as a template for the production of excessive amounts of new 
positive-strand RNA molecules. These RNAs can be used for polyprotein synthesis or as 
templates for new negative-strand RNAs or can be incorporated into viral particles (Appleby et 
al., 2015).  
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Figure 1.6 Model of HCV induced replication factory. 
HCV infection induces extensive remodelling of intracellular membranes, most notably double-
membrane vesicles (DMVs) and less frequently multimembrane vesicles (MMVs) involving a 
large range of host cell proteins and lipids implicated in MW biogenesis. 1. PI4KIIIα interacts 
with NS5A and NS5B to induce elevated levels of PI4P. 2. Subsequently, oxysterol-binding 
protein (OSBP) delivers cholesterol to HCV-remodelled membranes. Locally elevated PI4P 
levels as well as interactions with VAPs and NS5A facilitate OSBP recruitment. Picture is 
adapted from (Paul et al., 2014). 
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1.4.5 Assembly and release  
The lipid droplets (LDs) are organelles that are used for the storage of neutral lipids. Those are 
mainly cytosolic (cLD) along with a small nuclear population (nLD), hence LDs thoughtout 
indicate cLD in most cases. The assembly and release of HCV particles crucially depends on an 
association of core protein with cytosolic lipid droplets (cLDs) following synthesis and 
maturation on the ER. This process must bring together the viral core protein, E1, E2 and the 
viral genome to be packaged in a temporally and spatially organized manner. Nascent virus 
particles undergo maturation into low-buoyant-density particles and release from cells by 
transiting through the secretory pathway or a newly reported trans-Golgi network-to-
endosome pathway independent of VLDL secretion (Gastaminza et al., 2008, Gastaminza et al., 
2006, Mankouri et al., 2016). 
 1.4.5.1 Virus assembly 
The process of HCV assembly can be divided into two events: the formation of RNA-core 
nucleocapsid in the early stage and then this nucleocapsid is enveloped at a late stage. 
Although the early process whereby  genome RNA associated with mature, lipid droplets (LDs) 
localised core to form a nucleocapsid is still poorly defined, it is well validated that the 
association of core with LDs is critical for the production of infectious particles (Miyanari et al., 
2007, Targett-Adams et al., 2008, Boulant et al., 2008, Bartenschlager et al., 2011).  
Cytosolic lipid droplets (cLD) are cellular lipid storage organelles containing a hydrophobic core 
with a phospholipid monolayer that is derived from the outer leaflet of the ER membrane 
(Gross and Silver, 2014). Following synthesis on the ER, the mature core protein migrates to 
the surface of LDs. Trafficking of core protein to LDs requires the MAPK-regulated cytosolic 
phospholipase A2 (cPLA2) as the signalling pathway downstream of cPLA2 (Menzel et al. 2012). 
This targeting of core to LDs also can be enhanced by diacylglycerol acetyltransferase 1, DGAT1, 
which is thought to fuel LD formation at ER membranes as triglyceride-synthesizing enzymes 
(Herker et al., 2010, Yen et al., 2008). 
Multiple interactions between the HCV proteins facilitate this pathway. One of the first key 
steps in HCV assembly is the interaction of NS5A with the LD-bound core protein, by which 
viral RNA is delivered to the LDs allowing regulation between replication and assembly 
(Miyanari et al., 2007, Appel et al., 2008, Masaki et al., 2008).  Essential roles of NS5A in virus 
particle assembly largely depend on the determinants in domain III (Appel et al., 2008, 
Tellinghuisen et al., 2008a, Kim et al., 2011). Two distinct regions in domain III, comprising a 
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cluster of basic amino acids and a separate cluster of serines, are involved in recruitment of 
replication complexes to core, and transfer of HCV RNA to core respectively (Zayas et al., 2016). 
Apart from the interaction with core protein, NS5A can also interact with host factors including 
the just mentioned core-partners DGAT1, apolipoprotein E (ApoE), annexin A2 and Rab18 
(Camus et al., 2013, Benga et al., 2010, Cun et al., 2010, Backes et al., 2010, Salloum et al., 
2013), which all enhance assembly.  
In the late events of virus particle assembly, the core protein must be retrieved from the 
surface of cLDs to the site of viral budding at the ER where the E1-E2 glycoprotein complex are 
brought together with nucleocapsid.  Post translocation of RNA from replication sites to core, 
NS2 is another important non-structural protein required for organizing the virus assembly 
complex, which is achieved via recruitment of E1-E2, other non-structural proteins and core-
RNA-containing cLDs (Jirasko et al., 2010, Popescu et al., 2011, Phan et al., 2009, Boson et al., 
2011, Ma et al., 2011, Stapleford and Lindenbach, 2011). NS2 interacts with the small, 
membrane-bound NS protein p7, facilitating the localisation of core-containing cLDs to site of 
viral budding at the ER (Jirasko et al., 2010, Popescu et al., 2011). p7-NS2 complex interacts 
with the NS3‑4A enzyme, and this is a key step in the retrieval of the viral core protein from 
cLDs and into nascent virus particles (Jirasko et al., 2010, Ma et al., 2008, Jones et al., 2011) 
(Phan et al., 2009)(Figure 1.7). A host protein AP2M1 (clathrin assembly protein complex 2 
medium chain is shown to be essential for retrieval of core protein from cLDs and for virus 
assembly (Neveu et al., 2012). While for the RNA that core bound, helicase activity of NS3‑4A 
was proposed to serve to package viral RNA during nucleocapsid formation. It remains to be 
determined whether NS4B and NS5B play any role in virus assembly.  
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Figure 1.7 Model of HCV assembly. 
A. Post  translation of viral protein, RNA replication in replication complex, retention of the E1–
E2 and p7–NS2 complexes on ER, core trafficking to cytosolic lipid droplets (cLDs) is mediated 
by cPLA2 and DGAT1. B. After association of core to cLDs, viral RNA is shifted out of replication 
and translation and towards virus assembly by NS5A. The interaction of p7–NS2 with NS3-4A 
recruits viral core protein from cLDs to the late site of virus assembly. Virus particles assemble 
by recruitment of E1-E2 complexes and budding into the ER. cPLA2: cytosolic phospholipase 
A2; DGAT1: diacylglycerol O-acetyltransferase 1. Picture is adapted from (Lindenbach and Rice, 
2013). 
 
A 
B 
Chapter 1: Introduction 
41 
 
1.4.5.2 Viral budding, maturation and release  
Budding of HCV  progeny virions is believed to utilize the ESCRT (endosomal sorting complex 
required for transport) pathway which involves ubiquitination of NS2 to facilitate direct 
interactions with the ESCRT machinery (Ariumi et al., 2011, Barouch-Bentov et al., 2016, 
Corless et al., 2010, Lai et al., 2010, Tamai et al., 2012). 
 E1-E2 present on extracellular virus particles contain some complex modifications (Vieyres et 
al., 2010). Hence post assembly, virions transit through the trans-Golgi network (TGN) and 
endosome pathways in a process of maturation where the E1/E2 envelope proteins are 
glycosylated (Gastaminza et al., 2008). After glycosylation, HCV virions were released at the 
plasma membrane in a VAMP1-dependent manner (Coller et al., 2012). 
In addition to glycoprotein modifications, HCV particles may undergo post-synthetic lipidation, 
similar to the VLDL assembly pathway. There is evidence exhibiting that HCVcc in an 
intermediate buoyant density much like VLDL particles (Gastaminza et al., 2008),  and the 
inhibition of  microsomal triglyceride transfer protein (MTP) disrupt the production of HCV 
particles (Huang et al., 2007a). Both HCV and triglyceride-rich VLDLs secreted in a complex in 
different cell lines is further verified that the production of the infectious HCVcc particles in 
Huh7 cells is in an ApoE-dependent and ApoB-independent manner (Jiang and Luo, 2009, 
Jammart et al., 2013). However, a more recent research points out that the release of HCV 
particles is via a trans-Golgi network-to-endosome pathway, which is independent of VLDL 
secretion (Mankouri et al., 2016). 
1.5 Systems for the study of HCV 
1.5.1 Cell culture systems 
Cell culture systems for efficient viral propagation are crucial to obtain a detailed 
understanding of intracellular life cycle and the virus host cell interaction. Originally cloned in 
1989 (Choo et al., 1989), the viral genome of HCV is now well characterized. Despite the 
availability of cloned infectious genomes, molecular studies of HCV replication and the 
development of antiviral drugs have been hampered by the low efficiencies of currently 
available cell culture systems and by the fact that the only animal model is the chimpanzee. 
For HCV, the development of permissive and authentic culture models has been and continues 
to be a challenging task. Here it is time to discuss the different types of systems available for 
investigating HCV. 
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The ability to study HCV life cycle was realized since the development of the first sub-genomic 
replicon (SGR) system capable of reproducing the HCV replication cycle (Lohmann et al., 
1999a). It was a bicistronic system wherein the first ORF, driven by the HCV IRES from the 
5’UTR, encoded for a reporter gene followed by the EMCV IRES driving the expression of the 
non-structural genes either NS2-5B or NS3-5B in addition to the non-coding 3’UTR (Figure 1.8). 
A neomycin phosphotransferase (NTP) reporter gene was initially used as it allowed for positive 
selection of replication.  The use of NPT reporter for the resistance to the G418 drove the 
selection for culture adaptive mutations (CAMs) which were important for achieving the 
detectable levels of replication (Lohmann and Bartenschlager, 2014). The minimal requirement 
of polyprotein for HCV RNA replication is NS3-NS5B as there is a detrimental effect on the 
replication ability when NS2 was incorporated into SGR (Lohmann et al., 1999a, Bartenschlager 
and Sparacio, 2007). 
 A  genotype 2a strain of HCV from a patient with fulminant hepatitis, termed JFH1 was 
identified in 2003, which significantly improved replication level in the absence of adaptive 
mutations (Kato et al., 2003). The incorporation of a firefly luciferase (luc) instead of npt gene 
allows  for the easy and accurate quantification of replication kinetics and facilitates the high 
throughput screening of anti-HCV compounds for the first time (Targett-Adams and 
McLauchlan, 2005). Since then, the majority of antivirals against HCV replication have used 
JFH1 or culture-adapted genotype 1 SGR spanning NS3-NS5B (Kwong, 2014). 
To investigate entire HCV lifecycle, full JFH1 virus construct was successfully developed, thus 
allowing studies on the entire lifecycle from virus entry to release in the hepatocellular 
carcinoma cell line Huh7 (Zhong et al., 2005, Wakita et al., 2005). Jc1, a chimeric virus, 
composed of structural genes (5’UTR to p7) from the genotype 2a J6CF and non-structural 
proteins (NS2-3’UTR) showed a significant increase in virus release over JFH1 (Figure 1.8) 
(Pietschmann et al., 2006). To take advantage of this chimeric approach, a series of chimeric 
viruses all based on JFH1 non-structural elements were constructed with different levels of 
virus release for all major genotypes (Vieyres and Pietschmann, 2013, Bartenschlager and 
Sparacio, 2007). 
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Figure 1.8 Structure of current SGR and virus constructs. 
Both SGR-neo and SGR-Luc are two common subgenomic replicon system. SGRs incorporated 
with neomycin phosphotransferase (NTP) are used for the selection of stable cell lines using 
G418. SGR-neo has the constructs spanning either NS2-5B or NS3-NS5B. SGR with firefly 
luciferase (Luc) gives an easy and sensitive reporter but requires transient electroporation into 
cells. The genotype 2a JFH1 isolate and chimeric JC1 are common virus constructs.  
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HCV replicates primarily in human hepatocytes, but multiple reports suggest that also 
extrahepatic reservoirs exist which may include the lymphatic system, gut and the brain 
(Blackard et al., 2006). The most permissive cell line for efficient RNA replication in vitro is the 
human hepatoma cell line Huh7 and its clonal descendants (Nakabayashi et al., 1982, 
Steinmann and Pietschmann, 2013). To some extent, HCV replication appears to be restricted 
in Huh7 cell line although adaptive mutations in the HCV nonstructural proteins typically 
enhance the replicative capacity. In order to obtain cell lines more permissive for HCV 
replication in the absence of G418 selection or adaptive mutations, clearing selectable SGR 
from Huh7 cell line with prolonged treatment of IFN-α therefore yields a population of cells, 
more permissive to the HCV lifecycle, termed Huh7.5, which allows us to examine replication 
of subgenomic replicons lacking neo as well as full-length HCV after transfection (Blight et al., 
2002). The enhanced replication capacity in Huh7.5 can be partially attributed to the defective 
RIG-I so that IFN-α/ β and ISGs pathway cannot be activated by RIG-I as a signal transducer and 
HCV RNA PAMP receptor (Sumpter et al., 2005). It was documented that secondary or tertiary 
RNA structures of HCV viral RNA acting as the pathogen-associated molecular pattern (PAMP) 
could be recognized by RIG-I . The binding of RIG-I to viral RNA activates the IRF3 via RIG-I 
CARD-homology domain, followed by the activation of innate antiviral defence pathways  IFN-
α/ β and ISGs via phosphorylation of IRF3 (McWhirter et al., 2004, Foy et al., 2003, Sumpter et 
al., 2005).   
1.5.2 Animal models 
Besides humans, chimpanzees  were the only other species to be susceptible to HCV infection 
(Bassett et al., 1998).  That is why the development and evaluation of effective therapies and 
vaccines for HCV and the study of its interactions with the mammalian host have been 
hindered for a long time (Bukh, 2004). It was found that genomes that acquired cell culture 
adaptive mutations were highly attenuated in chimpanzees, or even reverted to the wildtype 
when injected in chimeric mice with humanized liver. This underscores the discrepancies of 
infections between tissue culture and animal models and the limitations of the biological 
relevance of in vitro systems (Bukh et al., 2002, Kaul et al., 2007). Additionally, chimpanzees 
inoculated with JFH1 only caused limited viremia and was cleared in 3 days, that is why few  
chimpanzees can evolve to the chronic infection in the clinical course (Boonstra et al., 2009).  
Apart from chimpanzees, a lot of work has tried to establish mice model for the research of 
HCV lifecycle. To adapt HCV to the mouse environment, genetic manipulation of the host can 
be used to knock down murine factors that hamper productive HCV infection or to 
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complement the mouse with human factors that are essential for this process. Hence, by 
transient expression of the human restriction factors CD81 and OCLN into mice, lifecycle of 
HCV has been recapitulated (Dorner et al., 2011). Liver chimeric mice in which human 
hepatocytes are xenografted is another important innovation for the study of HCV (Mercer et 
al., 2001, Bissig et al., 2010). However, Human-liver chimeric mice in their current state 
completely lack or contain only very limited cellular immunity, and therefore are not yet useful 
for vaccine studies. Therefore, more efforts need to be exerted to improve HCV animal models 
until HCV has been eradicated worldwide. 
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1.6 Aims and objectives 
HCV infects more than 70 million people worldwide, causing long-term liver disease (Polaris 
Observatory, 2017). Recently new therapies comprising direct-acting antivirals (DAAs), small 
molecule inhibitors of virus proteins, have revolutionised treatment for infected patients. 
Despite this, we have a limited understanding of how the virus replicates in infected liver cells. 
NS5A protein is critical during the virus lifecycle with a number of unknown functions, one of 
which is the hypothesised link between HCV replication and assembly. This study aimed to 
address the current lack of knowledge in these areas. NS5A is comprised of three domains. 
Previously it was thought that domain I was only involved in replicating the virus genome, and 
functions of virus assembly were mainly mapped to domain II and III. However, based on both 
structural and sequence analysis, domain I is the most highly conserved and structured region 
in NS5A compared with domain II and III.  Domain I is also the site for mutations that confer 
resistance to DAAs.  Hence, I suspected that domain I might be involved in more important 
functions during HCV lifecycle, which are common in HCV genotypes and in related 
Hepaciviruses. Hence, my project aimed to address this deficiency by conducting a rational 
mutagenic analysis of domain I. 
In this study, a mutagenic study was performed within the context of a JFH1-derived sub-
genomic replicon and infectious virus based on analyses of sequence alignment and three-
dimensional structures. Phenotypes of domain I mutants were further investigated taking 
advantages of high-resolution confocal microscopy and a series of biochemical analyses. 
Finally, comparative proteomic approach was utilised to identify the protein-protein 
interaction pathways involved by NS5A domain I. As domain I is the putative target for one 
class of DAAs, our observations may have implications for the yet undefined mode of action of 
these compounds. 
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2.1 General materials 
2.1.1 Bacterial strains  
Escherichia coli (E. coli) DH5α: Genotype F- Φ80lacZΔM15 Δ (lacZYA-argF) U169 recA1 endA1 
hsdR17 (rk-, mk-) phoA supE44 λ- thi-1 gyrA96 relA1 were used for molecular cloning.  
BL21 (DE3) pLysS: Genotype F- ompT gal dcm lon hsdSB (rB- mB-) λ (DE3) pLysS (cmR) were 
used for protein expression. 
2.1.2 Mammalian cell lines 
Huh7 (human hepatocellular carcinoma) (Nakabayashi et al., 1982) cells and Huh7.5 (a HCV 
cured cell line) (Blight et al., 2002) were used for electroporation and infection assays 
throughout, respectively. A polyclonal population of cells stably expressing SGR-Neo-JFH1 or 
SGR-Neo-JFH1 (NS5A-OST) were produced in Huh7.5 cells by Douglas Ross-Thriepland at the 
University of Leeds. 
2.1.3 Plasmid and virus constructs 
All the DNA constructs and HCV isolates are listed in Appendix Tables 9.1 and 9.2. DNA 
constructs of either sub-genomic replicon with luciferase reporter (mSGR-luc-JFH1) (Hughes et 
al., 2009b) or full-length virus mJFH1 (Wakita et al., 2005) were used. pcDNA3.1 (+) was used 
as the vector to subclone the BamHI/HindIII JFH1 NS5A fragment for site-directed 
mutagenesis. The pCMV10-NS3-5B (JFH1) was constructed by a previous colleague (Ross-
Thriepland et al., 2013).  mJFH1 digested with both NsiI and BsrGI were inserted with NS5A 
containing  One-Strep-tag fragments with corresponding mutations digested from SGR-Neo-
JFH1(NS5A-OST)(Amako et al., 2009).  
pET28a-SUMO plasmid, a kind gift from John Barr, and pGEX6P-2 were used as the vectors for 
the construction of NS5A domain I expression plasmids. DNA fragments flanked with BamHI 
and Xhol restriction sites encompassing NS5A domain I amino acids  35 to 215 and 35 to 249 
were amplified by PCR using wildtype or mutant JFH1 SGRs as templates.  PCR products were 
cleaved with BamHI and Xhol and cloned into either pET28a-SUMO or pGEX6P-2 vectors to 
allow expression of domain I N-terminally fused to either a His-SUMO or GST affinity tag. 
2.1.4 Oligonucleotide primers  
DNA oligonucleotides were ordered from Integrated DNA Technologies and resuspended in 
deionised water to 100 µM and stored at -20°C. All primers used are listed in Appendix Tables 
9.3-9.5. 
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2.1.5 Antibodies 
The following primary antibodies were used: sheep anti-NS5A (in-house polyclonal antiserum), 
mouse anti-NS5A (9E10) (kind gift from Tim Tellinghuisen, Scripps Florida), rabbit anti-core 
(polyclonal serum R4210) and sheep anti-ADRP (kind gifts from John McLauchlan, Centre for 
Virus Research, Glasgow), sheep anti-GST (in-house),  mouse anti-DGAT1 (Santa Cruz), mouse 
anti-Rab18, anti-ApoE (Santa Cruz) anti-β-Actin and anti-His (Sigma Aldrich). 
Secondary antibodies were also as listed below: donkey anti-sheep (800nm) (Li-Cor), donkey 
anti-mouse (700nm) (Li-Cor), donkey anti-rabbit (800nm) (Li-Cor) were used in western blot; 
Alexa Fluor labelled donkey anti-sheep (488, 594 or 647nm), donkey anti- mouse (488 or 
594nm) and donkey anti-rabbit (488nm or 594nm) (life technologies) at dilution 1:750. 
2.1.6 Chromatography columns and resins  
Glutathione Sepharose 4B and HisTrap™ HP 1ml columns were purchased from GE Healthcare, 
Strep-Tactin® Sepharose® and  GFP-Trap® were from IBA and ChromoTek, respectively. 
2.2 Basic techniques of molecular biology 
2.2.1 Manipulation of nucleic acid 
2.2.1.1 Preparation of plasmid DNA from bacteria 
100µl chemically competent bacteria DH5α were mixed with plasmid DNA or ligation products 
at a volume ratio of 100:1 (plasmid DNA, 1µg) or 100:20 (ligation products, 20µl) respectively, 
and kept on ice for 30 min followed by the incubation for 60 min at 37 °C by adding 900µl Luria 
broth (LB) medium (Inoue et al., 1990). Transformed bacteria post incubation were coated on 
the agar plates supplemented with the appropriate antibiotics and incubated at 30 or 37°C 
overnight. Subsequently, single colonies were picked from these agar plates into LB medium 
with the same antibiotic, cultures were grown at 30 or 37°C with 180 rpm agitation overnight. 
Transformation of DNA containing HCV NS5A fragment were grown and cultured at 30 °C and 
all other transformations were grown at 37°C. Bacterial cultures were pelleted at 4000 g (RCF) 
for 30 min at 4 °C, and supernatants were discarded. Bacteria cell pellets were processed for 
purification of DNA plasmid using commercial Miniprep or Midiprep Kit following 
manufacturer’s instructions (Qiagen). Long-term storage of DNA was as glycerol preparations 
of bacterial cultures by taking 700 µl bacterial culture with 300 µl glycerol and then freezing to 
-80°C. 
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2.2.1.2 Polymerase chain reaction (PCR) 
The polymerase chain reaction was used to amplify DNA from plasmid DNA or reverse 
transcribed RNA in site-directed mutagenesis (Section 2.2.1.3) or PCR cloning. PCR reaction 
mixtures (50 µl ) comprised of  100 ng template DNA, 10 µM forward and reverse primers, 1 
mM dNTP and 1 U vent ® DNA polymerase with 5µl Thermopol ® reaction buffer (NEB). 
Reactions were initially denatured at 94°C for 1min followed by 40 cycles of a second 
denaturation at 94 °C for 30 sec, annealing step at 55 °C for 60 sec and extension step at 72°C 
for 1 min/Kb. Finally, last extension step were performed at 72 °C 10 min. 
2.2.1.3 Site directed mutagenesis  reactions  
In order to introduce single amino acid mutations into HCV NS5A protein, primers used for 
Quickchange site-directed mutagenesis were complementary based on the HCV NS5A 
sequence, 30-45 nucleotides in length with required mutations centrally. Mutagenesis PCR 
were performed with an initial denaturation at 95 °C for 30 sec, then 5 cycles of denaturation 
at 95 °C for 30 sec, annealing at 52 °C for 60 sec and extension at 68 °C for 25 min followed by 
a further 13 cycles with an elevated annealing temperature at 55 °C following the manufacturer 
instruction of pfuTurbo Polymerase (Agilent). Reaction mixtures were supplemented with DpnI 
at 37°C for 1h to remove Parental DNA and then transformed into component DH5α described 
in section 2.2.1.1. 
2.2.1.4 DNA agarose gel electrophoresis  
DNA agarose gels were prepared by adding 1% (w/v) agarose into 1x TAE buffer (40 mM Tris, 
20 mM Acetate and  1 mM EDTA) heated until the agarose melted and supplemented with 
SYBR® safe DNA gel Stain (Invitrogen) 1:10,000. After loading with DNA samples containing gel 
loading buffer together with Hyper ladder I marker (Bioline), gels were run in 1x TAE buffer at 
a constant voltage of 100 V for 50 min. DNA was visualised by ultraviolet illumination using a 
Gene Genius  bio-imaging system (Syngene). 
2.2.1.5 DNA sequencing and sequence analysis 
All DNA constructs were sequenced by Beckman Coulter Genomics Sequence Company using 
Sanger sequencing with custom primers directed to relevant sequences. DNA sequences were 
aligned and analysed in DNA Dynamo Sequence Analysis Software. 
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2.2.1.6 DNA purification from DNA agarose gel 
After running agarose gels, DNA bands were visualised in a darkroom by UV excitation.  These 
bands were cut out with minimal agarose and placed into 1.5ml microtube. DNA purification 
was performed using QIAquick Gel Extraction Kit (QIAGEN) following manufacturer’s 
instructions. 
2.2.1.7 Endonuclease digestion of DNA 
Restriction Endonucleases throughout were purchased from New England Biolab (NEB). 
Typically, digestion reactions containing 3-10 µg DNA were carried out in 50 µl volume using 
relevant commercial buffers and enzymes at 37°C for at least 1 hr. Digested DNA fragments 
were separated by DNA agarose gel electrophoresis and extracted as described in section 
2.2.1.4. 
2.2.1.8 Ligation of DNA  
After digestion with restriction enzymes, vector and DNA inserts with same cohesive ends were 
ligated at 1:3 molar ratio by T4 DNA ligase in 20 µl reaction and incubated at 25°C or 16°C for 
1-16 hrs. Subsequently, the ligation reaction mixture was subjected to transformation into 
competent DH5α. 
2.2.1.9 Phenol: Chloroform purification of DNA 
DNA used for in vitro transcription were purified from solutions contaminated with proteins 
by addition of an equal volume of phenol: chloroform: isoamyl alcohol (25:24:1), vortexed 
thoroughly and centrifuged at 13,000 rpm for 5 min at 4 °C. Upper Aqueous phase layer was 
carefully removed and transferred to a fresh tube.  An equal volume of chloroform was then 
added and vortexed for centrifugation at 13,000 rpm at 4°C. DNA in second aqueous phase 
was precipitated with 2 volumes of 100% ethanol and 0.1 volume 3M ammonium acetate 
(pH5.2) followed by incubation at -20 °C for 20 min and pelleted at 13,000 rpm for 20 min. 
Recovered DNA pellet was washed in 70% ethanol and then resuspended in 20 µl deionised 
water after centrifugation and air dry. 
 2.2.1.10 DNA quantification 
Concentration and purity of nucleic acid were quantified by measuring absorbance at 260 and 
280nm using Nanodrop spectrophotometer (Thermo Scientific). Ratio of absorbance at 260 
nm to 280 nm (260/280) was used for checking purity of DNA. 
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2.2.1.11 In vitro transcription of RNA  
Before in vitro transcription of RNA, DNA template constructs (e.g. mSGR-Luc JFH1 or mJFH1) 
were firstly linearized in a 50 µl reaction with XbaI at 37°C overnight. To get rid of overhanging 
ends from linearized DNA, reactions were treated with Mung Bean Nuclease (NEB) at 30°C for 
an extra 30 min. Linearized DNA was then phenol/chloroform extracted and used as the 
template for transcription of RNA. 
In vitro transcription was performed using 1 µg of linear DNA as template following the 
manufacturer’s instructions of T7 RiboMax Express kit (Promega). Post treatment with DNase 
for 30 min, RNA transcripts were purified using phenol/chloroform (pH 5.2) extraction. After 
centrifugation, aqueous phase was mixed and vortexed together with 1 volume of 
phenol/chloroform again. Then aqueous phase was extracted, precipitated with 0.1 volume 
3M sodium acetate (pH5.2) and 1 volume isopropanol and placed on ice for 2-5 min before 
centrifugation at 13,000 rpm for 10min. RNA pellets were washed in 1ml 70% ethanol and 
resuspended in 20 µl Diethyl pyrocarbonate (DEPC)-treated water. Concentration of RNA can 
was quantified by absorbance at 260 nm using a Nanodrop spectrophotometer (Thermo 
Scientific). RNA purity was also analysed by RNA agarose gel electrophoresis. 
2.2.1.12 RNA agarose gel electrophoresis 
RNA agarose gels were prepared by adding 1% (w/v) agarose into 30 ml MOPS (3-(N-
morpholino) propanesulphonic acid) buffer (40 mM MOPS, 10 mM sodium acetate, 1 mM 
EDTA) and microwaved at 340 W for 2 min until it dissolved. 6.5% (v/v) of formaldehyde and 
SYBR® safe DNA gel Stain (Invitrogen) (1:10,000) were added and poured into the gel cast. 1 
µg of RNA samples in RNA loading buffer (47.5% Formamide, 9 mM EDTA, and 0.0125% SDS, 
Xylene Cyanol, and Bromophenol Blue (w/v)) were heated at 65°C for 10 min before loading 
into gels with 1 µg ssRNA ladder (NEB) alongside. Gel was electrophoresed at 70 V for 1 hr. 
2.2.2 Protein technology  
2.2.2.1 Quantification of protein  
Protein samples from cell lysates were quantified using the Pierce BCA protein assay kit 
(Thermo Scientific) taking advantage of the bovine serum albumin (BSA) standard curve. Firstly, 
protein samples were diluted (1:10) in dH2O to 50 µl in 96-well plates For the preparation of 
BSA standard samples, BSA was prepared to 1 mg/ml in dH2O and diluted serially by 2-fold for 
8 concentrations.   Both protein samples and BSA standard were added with 50 µl BCA solution 
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following the manufacturer’s instructions. 96-well plates were incubated at 37°C for 30 min 
before measuring absorbance at 570 nm using the Infinite F50 plate reader and Magellan for 
F50 software (Tecan). Protein concentrations could be calculated manually using a linear 
regression equation. 
For the purified protein samples, their concentration was measured by absorbance at 280 nm 
using Nanodrop spectrophotometer (Thermo Scientific) taking Molecular Weight (MW) and 
Extinction Coefficients into account. 
2.2.2.2 Preparation of SDS-PAGE  
Separation gel (7.5% -15%, percentage depending on experiment) was firstly made by adding 
7.5% -15% (v/v) acrylamide,  376 mM Tris-HCl (pH 8.8), 0.1%( w/v) ammonium persulphate 
(APS), 0.1%( w/v) SDS and 0.01% (v/v) Tetramethylethylenediamine (TEMED). After 
solidification, stacking gel (6% acrylamide,   376 mM Tris-HCl (pH 6.8), 0.1% APS, 0.1% SDS, 
0.01% TEMED) was poured on top of the separating gel and a gel comb inserted in the stacking 
gel. Protein samples were mixed with SDS gel-loading buffer (62.5 mM Tris-HCl, pH 6.8, 10% 
(v/v) Glycerol, 2% (w/v) SDS, 0.01 % (w/v) Bromophenol blue, 5% (v/v) ß-mercaptoethanol) 
and boiled at 95 °C for 10 min before loading. Gels were run in 1x SDS-PAGE running buffer (25 
mM Tris, 192 mM Glycine, 0.01(w/v) SDS) at 180 V for 1 hr. Color Prestained Protein Standard, 
Broad Range (11–245 kDa) was loaded alongside for comparison of protein size. 
2.2.2.3 Coomassie blue staining  
Gels were stained with 0.25% Coomassie Blue R250 in 10% (v/v) acetic acid, 50% (v/v) 
methanol, and 40% H2O for the minimum time (typically less than one hour) necessary to 
visualize the bands of interest. Destaining of the gels were performed by soaking them in 10% 
acetic acid, 50% methanol, and 40% H2O for at least 2 hrs with changes of this solvent until the 
background was nearly clear. 
2.2.2.4 Western blot  
After gel electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF), 
Immobilon-FL Transfer Membrane pre-soaked in transfer buffer (25 mM Tris, 192 mM Glycine, 
20% (v/v) methanol). After then, membranes were blocked in 50 % (v/v) Odyssey blocking 
buffer (Li-Cor) in TBS (25 mM Tris-HCl, pH7.4, 137 mM NaCl) for 1 hr at room temperature (RT). 
Membranes were incubated with primary antibodies diluted in 25 % (v/v) Odyssey blocking 
buffer in TBS for at least 1 hr at RT or 4°C overnight and then washed  with TBST (TBS 
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supplemented with 0.1% (v/v)Tween-20) for at least 3 times and 5 min per wash. Membranes 
were further incubated with the recommended dilution of conjugated secondary antibody in 
25% Odyssey blocking buffer at room temperature for at least 1 hr or 4°C overnight. Following 
removal of unbound antibodies by washing with TBST, membranes were allowed to dry before 
imaging on a Li-Cor Odyssey Sa Imager (Li-Cor). 
2.2.2.5 Concentration of purified protein  
Protein samples were concentrated using Amicon® Ultra 15 mL centrifugal filter (Merck) by 
centrifugation at 4,000 rpm at 4°C until reaching the required concentration. 
 2.3 Mammalian tissue culture techniques  
2.3.1 Passaging of mammalian cells 
Huh7 and Huh7.5 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM, Sigma) 
supplemented with 10 % (v/v) fetal bovine serum (FBS), 100 µg/ml streptomycin, 100 IU 
penicillin/ml, and 1 % non-essential amino acids (Lonza) (complete medium) typically in T175 
flasks incubated in a humidified incubator at 37 °C with 5 % CO2. When cells reached 
confluency, media was removed and washed with phosphate buffered saline (PBS). Trypsin-
EDTA solution was then used to detach cells by incubating for 5 min at 37 °C before inactivating 
trypsin through the addition of excess complete media to resuspend and reseed cells for next 
passage or for certain experiment. Complete medium needs to be supplemented with 25 mM 
HEPES for virus propagation. 
2.3.2 RNA electroporation  
Huh7 or Huh7.5 cells were washed twice in DEPC-treated PBS and counted before 
electroporating 4x106 cells in ice cold DEPC-PBS with 2 µg RNA at 950 µF and 270 V in the 
chilled 4mm electroporation cuvette (Geneflow). Cells were resuspended in an appropriate 
volume of complete medium and then seeded into 96-well plates and 6-well plates at required 
density for luciferase assay and western blot analyses, respectively.  
2.3.3 Transfection of DNA  
FuGene6 transfection reagent (Promega) was used for transfection of DNA into mammalian 
cells according to the manufacturer’s instructions. In brief, prior to transfection, cells were 
seeded in 6-well plates at the density of 2x105/well for 24 hrs. On the day of transfection, 1 µg 
DNA was diluted into 96 µl Opti-MEM (Life Technology) followed by the addition of 3 µl 
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FuGene6 reagent. Transfection reaction was gently mixed and incubated for 30 min at RT 
before adding to seeded cells. 
2.3.4 Harvest of cell lysate 
Post electroporation or transfection at appropriate time points, cells were washed twice in PBS 
and scraped in PBS by cell scraper followed by centrifugation at 1500 rpm for 5min at 4°C. Cell 
pellets were lysed by resuspension in Glasgow lysis buffer (GLB, 10 mM PIPES, pH 7.2, 120 mM 
KCl, 30 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 10% Glycerol) supplemented with protease 
and phosphatase inhibitors, and then incubated on ice for 30 min. Cell debris was pelleted by 
centrifugation at 15,000 rpm for 5 min at 4°C. Supernatants were used for western blot analysis 
or other required experiment. 
2.4 Subgenomic replicon assays 
2.4.1 Transient replication assay  
After 4, 24, 48 and 72 hours post electroporation (hpe), cells were harvested with 30 µl or 200 
µl passive lysis buffer (PLB, Promega), for 96-well or 6-well plates and placed on ice for 30 min 
or stored in -20°C freezer. Luciferase activity was measured using a BMG plate reader by 
automated addition of 50 µl LARI regent (Promega) and value of light emission was measured. 
2.4.2 Drug efficacy assay  
Huh7.5 cells were electroporated and seeded as described above to check replication levels in 
96-well plates by luciferase activity. Daclatasvir (DCV) to be used was diluted serially 10 fold 
from 10 µM in DMSO for 12 dilutions in 96- well plates. At 4 hpe, cells were treated with serially 
diluted DCV and incubated in normal tissue culture conditions. At 72 hpe, medium was 
removed and washed in PBS 3 times followed by addition of 30 µl PLB.  Luciferase activity was 
determined using BMG plate reader by adding 50 µl LAR-1 reagent and recording light emission 
over 6 seconds. Data were modelled using the model of log (agonist) vs. response model and 
EC50 were calculated through Graphpad Prism 7. 
2.5 JFH1 full-length virus assays 
2.5.1 Electroporation of JFH1 constructs into cells 
8x106 of Huh7 and Huh7.5 cells in ice-cold DEPC-PBS were electroporated with 10 µg RNA at 
950 µF and 270 V using 4mm electroporation cuvette (Geneflow). After resuspension in 
complete media supplemented with 25 mM HEPES, cells were seed in both 6-well plates (3 x 
105) and T75cm2 Flasks (remaining cells) and incubated for 48 hrs and 72 hrs, respectively. Cells 
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in 6- well plates at 48 hpe were fixed in 4% (w/v) paraformaldehyde (PFA) used for IncuCyte 
ZOOM to check virus replication and in T75 cm2 Flask were subjected to virus harvest for 
titration. After 72 hpe, supernatant was removed and kept in 4°C fridge as extracellular virus. 
Cells were washed in 10 ml PBS and then scrapped in 1ml PBS before storing at -80 °C. 
2.5.2 Use of the IncuCyte ZOOM 
Following immunofluorescence staining for viral antigens, with an Alexa Fluor 594-conjugated 
(“red”) secondary antibody, fixed microtitre plates were imaged with the IncuCyte ZOOM 
(Essen BioScience)  to determine the total number of virus-positive cells/well (Stewart et al., 
2015). Viral titres were obtained by multiplying the number of virus-positive cells/well by the 
reciprocal of the corresponding dilution factor, corrected for input volume. As this method 
measures the absolute number of infected cells, rather than the number of foci of infected 
cells, the titre is represented as infectious units per mL (IU/mL). 
2.5.3 Titration of virus  
Culture supernatants in T75 flasks were harvested at 72 hpe, and extracellular virus titres were 
determined. Cell lysates harvested in PBS were freeze-thawed for 5 times and centrifuged at 
3000 rpm for 5 min and supernatant was harvested as intracellular virus and store at -80 °C. 
Naïve Huh7 and Huh7.5 cells were seeded into 96 well plates (8.0x103 cells/well, 100 µL total 
volume) and allowed to adhere for 6 hrs. Clarified virus was serially diluted two-fold into the 
existing media (final volume 100 µL per well). Cells were incubated for 48 hrs post infection 
(hpi) before the detection of viral antigens by indirect immunofluorescence. Virus-positive cells 
were counted using IncuCyte ZOOM and the titre (IU/mL) was calculated from the wells of 
multiple virus dilutions. 
2.5.4 Purification of HCV particles 
Culture medium from JFH1 infected cells was concentrated 100-fold using 10% PEG 8000 (w/v) 
(Fisher Scientific) and centrifugation at 3000 g for 30 min.  The pellet was resuspended in 1ml 
of PBS and overlaid over a 1 ml cushion (20% sucrose, w/v, in PBS), followed by 
ultracentrifugation at 150,000 g for 3 hrs at 4°C in an S55S rotor. The resulting pellet was 
resuspended in 200 μl PBS and then loaded on a 10-40% iodixanol gradient in 2.2 mL tubes 
followed by centrifugation at 150,000 g for 4 hrs at 4°C. The gradient was fractionated into 12 
fractions of 180 μl each. Each fraction was used for virus titration as well as RNA extraction for 
qRT-PCR analysis, the remainder of each fraction was mixed with ice-cold methanol (1:3) and 
proteins precipitated at -80°C overnight. Precipitated proteins were recovered by 
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centrifugation at 13,000 rpm for 30 min at 4°C, and pellets were resuspended in 25 µl SDS-
PAGE loading buffer, prior to western blot analysis. 
2.5.5 Genome quantification by qRT-PCR 
Total cell RNA was extracted using TRIzol following manufacturer’s instructions (Invitrogen). In 
qRT-PCR reactions, 200ng extracted RNA (200 ng) was analysed using a One-step RT qPCR 
mastermix directed by the manufacturer (Eurogentec). Reaction was performed at 65°C for 30 
min for reverse transcription and then 95°C for 10 mins denaturation followed by 40 cycles of 
amplification at 95°C for 15 sec then 60°C for 30 sec to harvest signal. For the preparation of 
standard curve, in vitro transcribed mJFH1 RNA was quantified and diluted by 10-fold for 12 
dilutions. 2 µL of each dilution was added into this reaction. The primers and probes were 
designed against the HCV JFH1 5’UTR shown in Appendix Table 9.5.  
2.5.6 Immunofluorescence analyses 
Virus RNA electroporated cells were seeded onto 19 mm glass coverslips in 12 well plates, at 
72 hpe cells were fixed in 4 % PFA and cellular membranes were permeabilised with 0.1 % (v/v) 
Triton X-100 (Sigma-Aldrich) in PBS for 7 min. Coverslips were washed twice in PBS and the 
primary antibody applied at the relevant dilution in 10 % (v/v) FBS in PBS and incubated for 2 
hrs at RT. To remove any unbound primary antibody, cells were washed three times in PBS 
before the application of the relevant Alexa Fluor-488, 594 or 647 conjugated secondary 
antibodies diluted 1:750 in 10 % (v/v) FBS in PBS followed by 2 hrs incubation at RT in the dark. 
Lipid droplets were stained using BODIPY (558/568)-C12 dye at 1:1000 (Life Technology). The 
coverslips were washed three times in PBS before the nucleus was stained by the addition of 
4’, 6’-diamidino-2-phenylindole dihydrochloride (DAPI) diluted 1:10 000 in PBS for 30 min at RT 
in the dark. Coverslips were washed three times in PBS and mounted on a glass microscope 
slide in ProLong Gold antifade reagents (Invitrogen, Molecular Probes) and sealed with nail 
varnish. Slides were stored at 4oC in the dark until required and examined. Confocal microscopy 
images were acquired on a Zeiss LSM880 microscope with Airyscan, post-acquisition analysis 
was conducted using Zen software (Zen version 2015 black edition 2.3, Zeiss) or Fiji (v1.49) 
software. 
2.5.7 Co-localisation analysis 
For co-localisation analysis, Manders' overlap coefficient was calculated using Fiji ImageJ 
software with Just Another Co-localisation Plugin (JACoP) (National Institutes of Health). 
Coefficient M1 reports the fraction of the LD signal that overlaps either the anti-NS5A or anti-
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core signal or the fraction of anti-core signal that overlaps the anti-NS5A signal. Coefficient M2 
reports the fraction of either the anti-NS5A or anti-core signal that overlaps the LD signal or 
the fraction of anti-NS5A that overlaps the anti-core signal. Coefficient values range from 0 to 
1, corresponding to non-overlapping images and 100% co-localization images, respectively. Co-
localisation calculations were performed on >10 cells from at least two independent 
experiments. 
2.5.8 Quantification of LD distribution and size 
For the quantification of LD spatial arrangement, images were acquired with the same 
acquisition parameters, but with variable gain to ensure correct exposure. The two-
dimensional coordinates of the centroids of LDs were calculated using the Analyze Particles 
module of Fiji (ImageJ). The distance of each particle to the edge of the cell’s nucleus, visualised 
using DAPI stain, was looked up using a Euclidean distance map computed with the Distance 
Transform module of Fiji and exported as a list of distance 2D measurements via the Analyze 
Particle function. Box and whisker plots of these distance measurements were constructed 
using GraphPad Prism and compared between samples using a one-way ANOVA and 
Bonferroni-corrected post-hoc t-tests.  
Two-dimensional areas of the LDs were also measured using the Analyze Particles function in 
Fiji. Lists of the area measurements were used for constructing frequency histograms using a 
custom-written programme implemented in IDL. The shapes of these histograms were 
compared using a chi-squared test, implemented in IDL. 
2.5.9 Isolation of lipid droplets 
Four 10cm2 dishes of Huh7.5 cells electroporated with mJFH1 virus RNA (80% confluent) were 
scraped into 10 mL of PBS at 72 hpe. The cells were pelleted by centrifugation at 1,500 rpm for 
5 min and then resuspended with 500 µL buffer A (20 mM Tricine, 250 mM sucrose, pH 7.8) 
supplemented with protease and phosphatase inhibitors and kept on ice for 20 min. The 
suspension was homogenized with a plastic tissue grinder homogenizer. Samples after 
homogenization were centrifuged at 3000 g for 10 min at 4°C to remove nuclei and the post 
nuclear supernatant (PNS) was collected, transferred into 2.2 mL tubes and overlaid with 1 mL 
of buffer B (20 mM HEPES, 100 mM KCl and 2 mM MgCl2 pH 7.4) plus protease inhibitors. Tubes 
were centrifuged in a S55S rotor at 100,000 g for 1 hr at 4°C. After centrifugation, the LD 
fraction on the top of the gradient was recovered in buffer B and washed twice by 
centrifugation at 20,000 g for 5 min at 4°C to separate the LDs from the buffer. Underlying 
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solution was removed and discarded. Proteins and lipids in LD samples were separated with 2 
volumes of ice-cold acetone and chloroform (1:1) to precipitate proteins. The collected LD 
fraction was dissolved in 50μL of SDS sample loading buffer for western blot. 
2.5.10 Proximity Ligation Assay (PLA) 
Cells were washed with PBS before fixation for 15 min at room temperature in 4% (wt/vol) 
paraformaldehyde (PFA); cells were subsequently permeabilized in 0.1% (vol/vol) Triton X-100 
–PBS and blocked with PBS-Tween (PBS-T) and 5% (wt/vol) bovine serum albumin (BSA) before 
immunostaining for anti-NS5A (Sheep polyclonal, 1:1,000) and  anti-ApoE (Mouse monoclonal, 
1:100) overnight at 4 °C. Coverslips were washed 3 times for 5 min in PBS-T buffer under gentle 
shaking and incubated with proximity ligation assay (PLA) probes Duolink In Situ PLA Probe 
Anti-Mouse PLUS (DUO92001; Sigma-Aldrich) and Duolink In Situ PLA Probe Anti-Sheep MINUS 
(DUO92005) for 2 hrs at 37°C. For PLA, all incubations were performed in a preheated humidity 
chamber and according to  manufacturer’s recommendations using a Duolink In Situ Detection 
Reagents Red kit (DUO92008). Coverslips were washed 3 times for 5 min in PBS-T buffer under 
gentle shaking and incubated with a DNA ligase previously diluted in ligation buffer for 30 min 
at 37°C. Coverslips were washed 3 times for 5 min in PBS-T buffer under gentle shaking and 
incubated with a DNA polymerase previously diluted in amplification buffer for 90 min at 37°C. 
Finally, coverslips were washed for 20 min under gentle shaking and then washed for 2 min 
with PBS and air dried. Coverslips were mounted with Duolink In Situ mounting medium with 
4’,6’-diamidino-2-phenylindole (DAPI), and fluorescence was visualized with a Zeiss LSM880 
upright microscope. 
2.5.11 Purification of OST-NS5A 
In vitro transcribed JFH1-5A-OST RNAs were electroporated into Huh7.5 cells and seeded in 
10cm x10cm dishes. Cells were washed twice in PBS 72 hpe, pelleted at 1500 g for 5 min at RT, 
before lysis in GLB (1ml per dish). Lysates were clarified by centrifugation at 10,000 g for 5 min 
at 4°C. Supernatants were applied to 100 µL of Strep-Tactin Sepharose for batch affinity 
purification of NS5A-OST following the manufacturer’s instructions. After incubation overnight 
at 4 °C, the mixtures were washed with wash buffer (100 mM Tris-HCl, pH 8.0, 150 mM NaCl 
1mM EDTA) three times. Bound protein was eluted with 50 µL of SDS sample buffer and heated 
for 10 min at 95 °C for western blot analysis. 
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2.6 In vitro protein assays 
2.6.1 Purification of NS5A domain I  
DNA fragments flanked with BamHI and Xhol restriction sites encompassing amino acids 35 to 
215 and 35 to 249 of NS5A were amplified by PCR using wildtype or mutant JFH1 SGRs as 
templates (primer sequences are available in Appendix Table 9.4).  PCR products were cleaved 
with BamHI and Xhol and cloned into pET28a-SUMO vector to allow expression of Domain I N-
terminally fused to a His-SUMO affinity tag. The resulting plasmids were transformed into 
cultures of Escherichia coli BL21 (DE3) pLysS, which were grown to OD600 0.6-0.8 at 37 °C and 
induced with 100 μM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 18°C for 6 hrs. Cells were 
recovered by centrifugation and resuspended in 20ml His-SUMO-Domain I (His-SUMO-DI) lysis 
buffer (binding buffer (100 mM Tris pH 8.2, 200 mM NaCl, 20 mM imidazole) supplemented 
with 40 μl DNase, 40 μl RNaseA, 2 mg/ml Lysozyme and protease inhibitors (Roche)) per 1 L of 
pelleted culture. Cell suspension were placed on ice for 30 min and lysed by sonication on ice 
at amplitude of 10 microns for 12 pulses of 20 sec separated by 20 sec. The extract was clarified 
by centrifugation at 18,000 rpm for 30 min at 4 °C twice and then supernatant was filtered 
through a 0.45 µm syringe filter. His-SUMO-DI protein samples were applied to wash buffer 
equilibrated HisTrap column (GE Healthcare). The column was washed 3 times with 5 column 
volumes binding buffer and eluted using the same buffer with 250 mM imidazole. Elution 
fractions of His-SUMO-DI proteins were then dialyzed into dialysis buffer (20 mM Tris-HCl, pH 
8.2, 150 mM NaCl and 10% (v/v) glycerol) prior to addition of SUMO protease. After SUMO 
protease cleavage, the His-SUMO tag and SUMO protease were removed from the cleavage 
sample by passing it through a second HisTrap column. After checking by SDS-PAGE, The flow-
through and wash fractions containing domain I were pooled and concentrated using 10 kDa 
molecular mass centrifugal concentrators (Merck) and stored at -80 °C after flash freezing in 
liquid nitrogen. 
For the expression and purification of Domain I (35-249) with GST tag, DNA fragments flanked 
with BamHI and Xhol restriction sites were cloned into either pGEX6P-2 vector to allow 
expression of Domain I N-terminally fused to either GST. The resulting plasmids were 
transformed into cultures of E. coli BL21 (DE3) pLysS and induced for expression at 18°C for 6 
hrs as described above. Cells were recovered by centrifugation and resuspended in 20 mL GST-
Domain I (GST-DI) lysis buffer (50mM Tris-HCl, pH 8.0, 100mM NaCl, 10% glycerol) 
supplemented with 40 μl DNase, 40 μl RNaseA, 2 mg/ml Lysozyme and protease inhibitors 
(Roche) per 1L of pelleted culture. Cell suspensions were placed on ice for 30 min and lysed by 
Chapter 2: Materials and Methods 
62 
 
sonication followed by centrifugation at 18,000 rpm for 30 min at 4 °C twice and then 
supernatant was filtered through a 0.45 µm filter. GST-DI protein was applied to glutathione 
Sepharose 4B resin (GE Healthcare) following the manufacturer’s instructions.  The resin was 
eluted with  elution buffer (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0) and the 
eluates were dialyzed against dialysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM 
MgCl2, 10% glycerol, 0.5% NP-40). The purified proteins were aliquoted and stored at -80 °C. 
2.6.2 Size exclusion chromatography  
Size-exclusion chromatography (SEC) is a type of liquid chromatography commonly used for 
analysis of polymeric status of NS5A Domain I. HiLoad Superdex 75 pg column (GE Healthcare) 
was used and connected to AKTA Prime pump system at 4 °C. Absorbance at 280 nm was 
measured to monitor protein eltutions. All the buffers containing distilled water, gel filtration 
running buffer and 70% ethanol were filtered through 0.45 µm membranefilters (Millipore)and 
degassed. After thorough wash by water, the Superdex 75 pg column was equilibrated with gel 
filtration running buffer (20 mM Tris-HCl, pH 8.2, 150 mM NaCl and 10% (v/v) glycerol). 5 ml 
concentrated domain I protein sample was then filtered through a 0.2 µm syringe filter before 
being injected into the column with 5 mL loop. The column was eluted  and fractions (3 ml/ 
fraction) were collected until a full column of volume of running buffer (320 ml) was loaded. 
According to the recording of A280, each fraction collected was analysed by SDS-PAGE.  
2.6.3 Protein identification by mass spectrometry 
2.6.3.1 Gel processing and tryptic digestion 
Gel bands were excised and chopped into small pieces (~ 1 mm3 ), covered with 30 % ethanol 
in a 1.5 mL microcentrifuge and heated to 70 °C for 30 min with shaking. The supernatant was 
removed and replaced with fresh ethanol solution and again heated to 70 °C for 30 min with 
shaking. This was repeated until all Coomassie stain was removed from the gel. The gel slices 
were covered with 25 mM ammonium bicarbonate/50% acetonitrile and incubated for 10 min 
with shaking.  The gel slices were then covered with 100% acetonitrile and left for five minutes 
before the supernatant was discarded and replaced with a fresh aliquot of acetonitrile. 100 µL 
20 mM DTT solution was then added and the sample was incubated at 57 °C for 1 hr with 
shaking. The supernatent was removed and once the gel pieces were at room temperature 100 
µL 55 mM iodoacetic acid was added. The samples were then incubated at room temperature 
in the dark for 30 min with shaking. After removing the supernatant, the gel slices were then 
covered with 100% acetonitrile and left for 5 min. The acetonitrile was removed and the gel 
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pieces were left to dry in a laminar flow hood for 60 min.  Once dry, the gel slices were cooled 
on ice then they were covered with ice-cold trypsin solution (20 ng µL-1 in 25 mM ammonium 
bicarbonate) and left on ice for 10 min to rehydrate.  Excess trypsin solution was removed and 
the gel slices were covered with a minimal amount of 25 mM ammonium bicarbonate.  After 
briefly vortexing and centrifuging, the gel slices were incubated at 37 °C with shaking for 18 
hrs.  The resulting digest was vortexed and centrifuged. The supernatant was recovered and 
added to an eppendorf containing 5 µL acetonitrile/ water/ formic acid (60/35/5; v/v).  50 µL 
acetonitrile/ water/ formic acid (60/35/5; v/v) was added to the gel slices and vortexed for an 
additional 10 min.  The supernatant was pooled with the previous wash and one additional 
wash of the gel slices was performed.  The pool of three washes was dried by vacuum 
centrifugation.  The peptides were reconstituted in 20 µL 0.1% aqueous trifluoroacetic acid. 
2.6.3.2 Liquid chromatography-mass spectrometry (LC-MS) 
LC separation of the peptide mixtures was performed on an ACQUITY M-Class UPLC (Waters 
UK, Manchester).  1 µL of each sample was loaded onto a Symmetry C18 trap column (180 µM 
i.d. * 20 mm) and washed with 1% acetonitrile/0.1% formic acid for 5 min at 5 µL /min.  After 
valve switching, the peptides were then separated on a HSS T3 C18, 75 µm i.d. x 150 mm 
analytical column (Waters UK, Manchester) by gradient elution of 1-60% solvent B in A over 30 
min at 0.3 µL /min. Solvent A was 0.1% formic acid in water, solvent B was 0.1% formic acid in 
acetonitrile. 
The column eluant was directly interfaced to a quadrupole-ion mobility - orthogonal time of 
flight mass spectrometer (Synapt G2Si, Waters UK, Manchester) via a Z-spray nanoflow 
electrospray source.  The MS was operated in positive TOF mode using a capillary voltage of 
3.0 kV, cone voltage of 40 V, source offset of 80 V, backing pressure of 3.58 mbar and a trap 
bias of 2 V. The source temperature was 80°C.  Argon was used as the buffer gas at a pressure 
of 8.6 × 10-3mbar in the trap and transfer regions.    Mass calibration was performed using Glu-
fibrinopeptide (GFP) at a concentration of 250 fmol /µL.  GFP was also used as a lock mass 
calibrant with a one second lock spray scan taken every 30 s during acquisition. Ten scans were 
averaged to determine the lock mass correction factor.  Data acquisition was using data 
dependent analysis with a 0.2 sec scan MS over m/z 350-2000 being followed by five 0.5 sec 
MS/MS taken of the five most intense ions in the MS spectrum.  CE applied was dependent 
upon charge state and mass of the ion selected.  Dynamic exclusion of 60 sec was used. Data 
processing was performed using the MassLynx v4.1 suite of software supplied with the mass 
spectrometer. Peptide MS/MS data were processed with PEAKS Studio (Bioinformatic Solutions 
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Inc, Waterloo, Ontario, Canada) and compared with NS5A domain I sequence. 
Carbamiodomethylation was selected as a fixed modification, variable modifications were set 
for oxidation of methionine and deamidation of glutamine and asparagine. MS mass tolerance 
was 20 ppm, and fragment ion mass tolerance was 0.05 Da. The false discovery rate was set to 
1%. 
2.6.4 SEC-MALLS 
SEC-MALLS was carried out by Maren Thomsen (School of Biomedical Sciences, University of 
Leeds). 
2.6.5 GST-pull down assay 
After purification, GST-Domain I (GST-DI) and His-SUMO-Domain I (His-SUMO-DI) were 
dialyzed against dialysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 10% 
glycerol, 0.5% NP-40).  Meanwhile, 10 μg of GST or GST-fusion proteins were mixed with 5 μg 
of His-SUMO-DI in binding buffer (20mM Tris-HCl, pH 7.2, 0.5 M NaCl, 200 Mm KCl, and 1% NP-
40) for 3 hrs at 4 °C on a rotating platform. Then the mixture was added to glutathione beads 
and incubated overnight at 4°C. After washes using binding buffer, bound material was eluted 
with 50 µL of SDS sample buffer and heated for 10 min at 95 °C. After centrifugation, these 
samples were analysed by western blot using anti-GST and anti-His antibodies. 
2.6.6 In vitro transcription and labelling of RNA probe 
The 3’UTR of HCV genotype 2a (JFH1) (9443-9678), amplified and flanked with HindIII and XbaI 
was cloned into pcDNA3.1 vector. As negative control, an aptamer selected against the foot-
and-mouth disease virus (FMDV) 3D RNA-dependent RNA polymerase was used (5’-
GGGAAAGGAUCCACAUCUACGAAUUCGGCUCAAAAAUAGUCCGCACCAUACAUUCACUGCAGAC
UUGACGAAGCUU-3’). Complementary oligonucleotides with BamHI and XbaI were 
synthesized. Post annealing, the fragment of this aptamer was digested with NheI and XbaI 
and then inserted into pcDNA3.1 vector with same adhensive ends. pcDNA3.1 -3’UTR and 
pcDNA3.1 –FMDV 3D aptamer were linearized by XbaI as a template for in vitro transcription. 
In vitro transcription reactions consisted of 500 µM each of  ATP, CTP, and GTP; 20 µM UTP; 50 
µCi (α-32P) UTP; 40 U of T7 RNA polymerase; 2µl 10x T7 transcription buffer  (Roche); 40 U of 
RNaseOUT RNase (Invitrogen) and 1µg linearized DNA template). Reactions were incubated for 
1.5 hrs at 37°C before addition of 1U RQ1 DNase (Promega) to remove template DNA. RNA 
transcripts were then purified using NucAway spin columns (Ambion) before extraction with 
acidified phenol-chloroform and ethanol precipitation described in section 2.2.1.11. Purified 
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RNA transcripts were analysed on 1 % RNA agarose gels. Concentrations of radioactive RNAs 
were determined by absorbance at 260 nm. 
2.6.7 RNA filter binding assay 
His-SUMO-DI proteins were cleaved with SUMO protease to produce native domain I.  
Following purification in 2.6.1, domain I was incubated with in vitro transcribed (α-32P) 
radiolabelled RNAs. Then aliquots of each binding reaction were applied to a pre-assembled 
slot blot apparatus and filtered through firstly a nitrocellulose membrane (Schleicher & 
Schuell) to capture soluble protein-RNA complexes, and secondly a Hybond-N nylon 
membrane (Amersham Biosciences) to bind free RNA. After washing and air drying of both 
membranes, quantification of radioactivity was performed by phosphoimaging using an FLA 
5000 Imaging system (Fuji), and ImageJ software. These data were fitted to the hyperbolic 
equation "R=Rmax×P/(Kd+P)". R is the percentage of bound RNA, Rmax is the maximal 
percentage of RNA competent for binding, P is the concentration of domain I, and Kd is the 
dissociation constant. 
2.6.8 Tandem Mass Tag (TMT) comparative proteomic analysis 
TMT mass spectrometry was carried out by Kate Heesom (University of Bristol Proteomics 
Facility) and analysed against both positive and negative control samples. 
In brief, for multiplexed comparative proteomics 100 µg of each cell lysate was digested with 
trypsin and labelled with tandem mass tag (TMT) reagents according to the manufacturer’s 
protocol (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The labelled samples were 
then pooled, evaporated to dryness and resuspended prior to fractionation by high pH 
reversed-phase chromatography using an Ultimate 3000 liquid chromatography system 
(Thermo Fisher Scientific). After high pH reversed-phase chromatography, fractions were 
further subjected to the Nano-LC Mass Spectrometry. The raw data files were processed and 
quantified using Proteome Discoverer software v1.4 (Thermo Scientific) and searched against 
the Uniporter Human database (134169 sequences) plus HCV protein sequences using the 
SEQUEST algorithm.  All peptide data was filtered to satisfy false discovery rate (FDR) of 5%.     
2.7 Statistical analysis of data 
Statistical analysis of data was carried out using a Students t-test assuming a two-tailed 
distribution with an unequal variance. Error bars presented on all graphs illustrate the Standard 
Error (SE) of the Mean. 
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3.1 Introduction 
Following uncoating and release of the HCV RNA genome into the cytoplasm post infection, 
the RNA is translated at the rough ER, which contains the cellular proteases that cleave part of 
the polyprotein. HCV replicase proteins (NS3-NS5B), presumably in concert with host cell 
factors, induce massive rearrangement  of intracellular membranes, including the formation of 
double-membraned vesicles (Wang and Tai, 2016). These membranous structures exhibit as 
vesicle clusters that designate the membranous web and constitute the sites of HCV RNA 
replication (Penin et al., 2004). Replication of all positive strand RNA viruses is associated with 
cellular membranes, and depending on the virus replication might occur on altered 
membranes derived from the ER, Golgi apparatus, mitochondria or even lysosomes. In HCV 
infected cells, NS5A localizes to the endoplasmic reticulum (ER), virus-induced multiple-
membrane vesicles (MMV) that host RNA replication complexes (also called the membranous 
web), and to lipid droplets. The MMV contain the NS proteins NS3-NS5B and virus RNA and 
represent sites of active genome replication, which are called replication complexes (RCs) (Paul 
and Bartenschlager, 2013, Egger et al., 2002, Gosert et al., 2003, Paul et al., 2014, Romero-Brey 
et al., 2012).  
Within RC, NS5A is indispensable for RNA replication, which is mediated by binding to viral RNA 
(Foster et al., 2010, Huang et al., 2005), and interactions with other NS proteins and various 
cellular factors, including vesicle-associated membrane protein-associated proteins A and B 
(VAP-A, VAP-B), cyclophilin A (CypA) and phosphatidylinositol-4-kinase IIIα (PI4KIIIα) as 
described in Section 1.3.2 (Berger et al., 2009, Gao et al., 2004, Hamamoto et al., 2005, Ngure 
et al., 2016, Goonawardane et al., 2017). Nevertheless, most investigations of the mechanism 
of RNA replication are focused on domain II and III, so it remains to be determined how domain 
I functions during RNA replication.  
By primary sequence comparison, domain I of NS5A shares a high sequence homology among 
both primate and non-primate species (Burbelo et al., 2012, Kapoor et al., 2011, Kapoor et al., 
2013, Lauck et al., 2013)， while domain II and III exhibit a lower level of homology. Secondary 
structure predictions using PSIPRED indicated a similar topology consisting of two α-helices 
and three β-strands across domain I, and tertiary modelling supported high structural similarity 
between zinc-binding motifs with predicted β-strands arranging to form an antiparallel β-sheet 
in all hepaciviruses including GHV and GBV-B (Arumugaswami et al., 2008). However, domain 
II and III share a low homology. These observations suggest that domain I has critical and well-
conserved functions that are common to all hepaciviruses, whereas the functions of the other 
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two domains may be specific to individual genotypes. Consistent with this hypothesis, 
transposon mutagenesis demonstrated that very few insertion sites in domain I were tolerated 
(in comparison to domains II and III) (Arumugaswami et al., 2008). Later, saturation 
mutagenesis in combination with next-generation sequencing technology systematically 
quantified the effect of every possible amino acid substitution in the N-terminus of domain I, 
the potential drug-targeted region.  The relative fitness and drug sensitivity profiles results 
revealed that very few residues in the N-terminus of domain I (amino acids 18-103) can tolerate 
substitutions (Qi et al., 2014). 
Moreover, domain I is highly structured in comparison with domain II and III. There are four 
different dimeric forms of NS5A domain I from genotype 1a and 1b by three independent 
groups. All the structures agreed on the same monomeric unit, but the monomers assembly 
into dimers with different rotations and interfaces (Lambert et al., 2014, Love et al., 2009, 
Tellinghuisen et al., 2005). The ‘claw-like’ dimer of NS5A domain I from genotype 1b revealed 
by Tellinghuisen (Tellinghuisen et al., 2005),  designated as “open” conformation (1ZH1) (Ross-
Thriepland and Harris, 2014b),  generated a groove facing away from the membrane, where it 
could accommodate either single- or double-stranded RNA. The deep, highly basic portion of 
the groove could favour contacts with RNA whereas the ‘arms’ extending out past this groove 
are more acidic, and might serve to prevent RNA from exiting the groove (Tellinghuisen et al., 
2005). RNA binding properties of NS5A and domain I have been confirmed biochemically in 
vitro (Foster et al., 2010, Huang et al., 2005). However, how domain I is involved in RNA 
replication is still not well understood yet. The other “closed”  conformation exhibited an 
extensive buried surface area to form the dimer interface by residues 92 to 99, 112 to 116, 139 
to 143, 146 to 149, and 160 to 161 from each monomer (Love et al., 2009).  It is suspected that 
these two alternate structural forms of domain I reflect two different functional states of 
membrane-anchored NS5A and the differential exposure of surface features of both dimers 
would allow an alternative set of interactions between domain I and other HCV or host 
proteins. The “open” dimeric state, with its suggestive binding cleft, might promote RNA 
binding during NS5A’s participation in the replication phase, whereas the  “closed” dimeric 
state might be a prerequisite for NS5A roles in lipid droplets (LDs) association and/or particle 
assembly (Love et al., 2009, Ross-Thriepland and Harris, 2014b). Nevertheless, all the crystal 
structures of domain I are from HCV genotype 1, and there are no more crystal structures from 
other genotypes so far. Hence, both the “open “and “closed” dimeric structures were used as 
the model for analysis in my research. 
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Based on these observations, it was suggested that domain I has critical and well-conserved 
functions that are common to all hepaciviruses, whereas the functions of the other two 
domains may be specific to individual genotypes  In this regard, it is generally accepted that 
the function(s) of domain I are required exclusively for genome replication, and the majority 
of domain II together with all of domain III are dispensable for replication.  In this study, I 
present evidence that domain I of NS5A plays a key role in genome replication in details by 
combining analyses of both sequences alignment from 7 HCV genotypes and dimeric 
structures.  
3.2 Results  
3.2.1 Generating a panel of alanine mutations in domain I 
In comparison with domain II and domain III (domain organization and position in NS5A was 
presented in Figure 3.1A), domain I of NS5A is highly conserved throughout all HCV isolates, 
and is also well conserved in related viruses such as GB virus type B (GBV-B) and the novel 
hepaciviruses that have recently been identified in a variety of species (Figure 3.1B).  In 
addition, the structure of domain I has been determined by three independent studies (Huang 
et al., 2007b, Ross-Thriepland et al., 2013, Tellinghuisen et al., 2004) - all three studies agree 
on the monomer structure but show these monomers assembling into dimers with different 
monomer orientations and dimer interfaces (Figure 3.2).  In this study, I initially set out to 
define residues in domain I that were required for viral genome replication. To this end, amino 
acid sequences of NS5A domain I were first aligned from 29 isolates representing all 7 HCV 
genotypes, together with 10 related viruses such as bat hepacivirus (BHV), GB virus-B (GBV-B), 
guereza hepacivirus (GHV), non-primate hepacivirus (NPHV) and rodent hepacivirus (RHV) 
(Appendix Table 9.2) . This analysis revealed 24 absolutely conserved residues (Table 3.1). Then 
these conserved residues were mapped on to the two genotype 1b monomeric structures (PDB 
1ZH1 and 3FQM) of domain I to identify surface exposed residues, particularly those that are 
charged (Figure 3.2).  This analysis revealed 11 residues that were then targeted for alanine 
scanning mutagenesis and subsequent profiling in the context of the JFH1 sub-genomic 
replicon (SGR).  In addition, a conserved surface exposed cluster (residues 153 to 158) was 
mutated collectively to alanine as these residues were located in close proximity on the tertiary 
structure (Table 3.1).   
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Figure 3.1 Alignment of NS5A sequences from 7 HCV genotypes and related hepaciviruses.  
A. Schematic representation of the domain organization of NS5A showing the locations of the 
three domains (I-III), the linking low complexity sequences (LCSI and II), and the membrane 
anchoring amphipathic helix (AH).  Numbers indicate positions of amino acids in the JFH1 
genotype 2a NS5A sequence. B. Conservation of three different NS5A domains from 15 HCV 
isolates representing each genotype and related hepaciviruses.  Isolates used for conservation 
analysis of whole NS5A are listed and underlined in Appendix Table 9.2. Filled bars in different 
colours indicate the percentage conservation at each residue as indicated in the key below. 
Gaps refer to locations where there are insertions in the JFH1 sequence, compared to 
consensus, particularly the 18 amino acid insertion between residues 432-450.  
A 
B
 
 
A 
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Figure 3.2 Analysis of the three dimensional structures of domain I. 
Analysis of the three dimensional structures of domain I (1ZH1 – open conformation - and 
3FQM – close conformation) using Pymol. Residues highlighted are the conserved amino acids 
that are located on the surface of two dimeric conformations at positions indicated in Table 
3.1. 
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Conserved residues Surface(1ZH1) Surface(3FQM) Mutation 
P35 + + + 
C39 ++ ++    
Y43 + + + 
G45 + + + 
W47 + + + 
G51 + + + 
C57 ++ ++   
C59 ++ ++ + 
G60 + + + 
V67 + + + 
C80       
P89       
I90       
N91   +   
G96 + + + 
P100       
G132       
T134 + + + 
P145 + + + 
V153 + + 
+ 
D154 + + 
G155 + + 
V156 + + 
L158 + + 
Table 3.1 Summary of selection of residues for mutation in NS5A domain I and their 
phenotypes.  
‘+’ indicates that the residue is located on the surface of domain I. 
‘++’ indicates that the residue is both surface exposed and at the zinc-binding site. 
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3.2.2 The role of domain I in genome replication  
To investigate the role of the selected conserved residues in domain I, the mutants were cloned 
into a previously described JFH1 derived SGR (mSGR-luc-JFH1) in which the NS5A coding 
sequence was flanked by unique restriction sites to facilitate sub-cloning. RNAs transcribed 
from the mutant panel were electroporated into Huh7 cells and luciferase activity was 
measured at 4, 24, 48 and 72 hpe. The luciferase activity at 4 hpe correlates with translation 
of input transcripts prior to onset of replication and subsequent time points were normalized 
to the 4 hpe signal to account for electroporation efficiency. As a negative control an inactive 
mutant of the NS5B polymerase was used (GND) (Appel et al., 2008, Penin et al., 2004) . 
Nine of the mutations (Y43A, G45A, W47A, G51A, C59A, G60A, G96A, T134A and 153-158A) 
were shown to completely disrupt the ability of the mSGR-luc-JFH1 to replicate in Huh7 cells 
(Figure 3.3A and B), being indistinguishable from the GND negative control.  However, three 
mutants (P35A, V67A and P145A) were able to replicate, albeit at levels lower than wildtype 
(WT). P35A exhibited a modest but non-significant defect, in contrast V67A and P145A 
replicated at significantly lower levels than WT (p<0.05) (Figure 3.3A and B). All mutants 
showed broadly comparable luciferase activity at 4 hpe, demonstrating that the replication 
phenotypes observed were not due to differences in electroporation efficiency (Figure 3.3A). 
To further support the luciferase data, total protein at 72 hpe was analysed by SDS-
PAGE/western blot for both NS5A and GAPDH (Figure 3.3C). The western blot result showed 
that NS5A of P35A could be detected at low levels, but only in the basal phosphorylated form. 
For V67A and P145A, the absence of NS5A was expected, due to the very low levels of 
replication. 
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Figure 3.3 Genome replication phenotypes of NS5A domain I mutants in Huh7 cells.   
A. In vitro transcripts of mSGR-luc-JFH1 containing the indicated mutations were 
electroporated into Huh7 cells.  Luciferase activity was measured at 4, 24, 48 and 72 hpe and 
was normalized to 4 hpe (B). C.  Cell lysates at 72 hpe were analysed by SDS-PAGE/western blot 
with anti-NS5A and anti-GAPDH. For non-replicating mutants, the expression of NS5A cannot 
be detected. For partially defective mutants, the NS5A (P35A) only can be detected at low 
levels, and NS5A (V67A and P145A) is not detectable because of the low replication levels. ns 
indicates not statistically significant. Data from three independent experiments are shown and 
error bars represent the standard error of the mean.  
 
I then assessed whether the replication defects exhibited by these mutants could be a result 
of an innate immune response, rather than a lack of replicative capacity.  It was reasoned that 
if mutants had a reduced replication capacity they might be more sensitive to inhibition by 
cytoplasmic innate immune sensors such as RIG-I, a pathogen receptor that binds HCV RNA 
and activates the IRF3 signalling pathway. To test this I evaluated the mutation panel in Huh7.5 
cells which were derived from Huh7 cells and have an inactivating, dominant negative, 
mutation in one copy of the RIG-I gene (Tellinghuisen and Foss, 2008, Tellinghuisen et al., 
2008b).  This renders them highly permissive for HCV genome replication.  As shown in Fig 3.4, 
those mutants that were unable to replicate in Huh7 cells (Y43A, G45A, W47A, G51A, C59A, 
G60A, G96A, T134A and 153-158A) exhibited the same phenotype in Huh7.5 cells, confirming 
that these residues are absolutely required for the function of NS5A in genome replication.  
However, the three mutants that were able to replicate in Huh7 cells, albeit at a lower level 
than WT, (P35A, V67A and P145A) were able to replicate more efficiently in Huh7.5 cells, 
reaching levels almost equivalent to the WT with modest but non-significant impairment 
(Figure 3.4A and B).  The western blot result showed that the NS5A expression level of P35A, 
V67A and P145A had increased significantly. The hyperphosphorylated NS5A can be detected 
for P35A. For V67A and P145A, the NS5A can now be detected in basal form (Figure 3.4C). It is 
likely that the RIG-I deletion in Huh7.5 attenuates the innate response to early replication 
events allowing mutants with a partial defect to replicate with high efficiency. 
C 
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Figure 3.4 Genome replication phenotypes of NS5A domain I mutants in Huh7.5 cells.   
A. In vitro transcripts of mSGR-luc-JFH1 containing the indicated mutations were 
electroporated into Huh7.5 cells.  Luciferase activity was measured at 4, 24, 48 and 72 hpe and 
was normalized to 4 hpe (B). C.  Cell lysates at 72 hpe were analysed by SDS-PAGE/western blot 
with anti-NS5A and anti-GAPDH. For non-replicating mutants, the expression of NS5A cannot 
be detected. For partially defective mutants, the NS5A of P35A can be detected in both basal 
and hyperphosphorylated forms, and NS5A (V67A and P145A) can only be detectable in basal 
form because of the low replication levels. D. A Comparison of replication of NS5A mutants in 
both Huh7 and Huh7.5 cells over 72 hpe. WT represents the wildtype mSGR-luc-JFH1.  P35A, 
V67A, and P145A are the mutants of domain I which can replicate at lower levels than WT in 
Huh7 cells; D329 is located at the C terminus of NS5A domain II (Ross-Thriepland et al., 2013). 
Data from three independent experiments are shown and error bars represent the standard 
error of the mean. ns: no statistically significant difference from WT. 
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However, it was important to confirm that this permissiveness mediated by the RIG-I defect in 
Huh7.5 cells was not a phenomenon that was specific for domain I.  To this end, an SGR 
containing a mutation (D329A) within NS5A domain II (Ross-Thriepland et al., 2013), which was 
previously reported replicated approximately 5-fold lower than WT, was electroporated into 
both Huh7 and Huh7.5 cells.  As shown in Figure 3.4D, D329A was also able to replicate more 
efficiently in Huh7.5, demonstrating that this effect was not specific for domain I. 
 
3.2.3 Lethal mutations do not disrupt polyprotein processing. 
To investigate whether the defect in replication observed in the remaining mutants resulted 
from the loss or disruption of a specific function of NS5A, or disruption of polyprotein 
translation or proteolytic processing, all 12 mutants were cloned into an expression construct 
in which the NS3-5B coding sequencing of JFH1 were expressed from a human cytomegalovirus 
(CMV) promoter (pCMV10-NS3-5B), thus allowing replication - independent expression of 
replicase proteins. 
These plasmids were transfected into Huh7.5 cells. After protein quantification, cell lysates 
were analysed for protein expression by western blot at 48 hours post transfection (hpt), taking 
HCV NS3 as polyprotein processing control. All 12 mutants expressed levels of NS5A 
comparable to WT (p ≥0.1) (Figure 3.5). This confirmed that the lethal replication phenotype 
for these mutants results from loss or disruption of a specific function of NS5A rather than the 
global effects on NS5A translation and polyprotein cleavage. Nevertheless, the 
hyperphosphorylated NS5A form for most mutants (except P35A) was detected either at low 
levels (V67A, G96A, T134A, P145A and 153-158A) or was undetectable. This suggests that 
some mechanisms to regulate NS5A phosphorylation are affected by these mutations, which 
needs to be further investigated. 
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Figure 3.5 Expression of NS5A from pCMV10-NS3-5B expression vector in Huh7.5 cells  
A. Huh7.5 cells were transfected with pCMV10-NS3-NS5B expression vector containing the 
corresponding mutations. At 48hpt, cell lysates were harvested in GLB and analysed by SDS-
PAGE and western blot with anti-NS5A (sheep) and anti-NS3 (mouse). B. The ratio of NS5A:NS3 
was calculated following quantification of western blot signals using a Li-Cor Odyssey Sa 
infrared imaging system. Data from three independent experiments are shown and error bars 
represent the standard error of the mean. 
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3.2.4 Distribution of compartments in replication complex 
As all the mutants cannot disrupt cleavage of polyprotein from NS3-NS5B, I wondered whether 
there is potential redistribution of the replication complexes caused by the mutations. As we 
know, NS3, the viral protease/helicase, is another key component of genome replication 
complexes. Therefore, NS5A and NS3 were coimmuno-stained in pCMV10-NS3-NS5B 
transfected cells with antibodies to both NS5A (sheep α-NS5A) and NS3 (mouse α-NS3) 
followed by a donkey α-sheep (488 nm) and donkey α-Mouse (594 nm) secondary antibodies. 
Cells were then stained with DAPI by the addition of Prolonged Gold and imaged. As expected, 
NS3 can colocalize with NS5A in most cases, both distributing throughout the cytoplasm 
(Figure 3.6), which suggested that NS5A could interact with NS3 or other NS proteins involving 
in replication complex. However, in G45A, G51A and (153-158) A mutants transfected cells, 
NS3 showed significantly reduced co-localisation with NS5A. NS3 exhibited a restricted 
perinuclear distribution, whereas NS5A spread around cytoplasm. In this case, we can suspect 
that NS5A with G45A, G51A and (153-158) A mutations impaired the interaction with NS3 and 
cannot drift the functional replication complex to function as normal. As for the mechanism 
underlying this interaction, it is still unknown.  
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Figure 3.6 Co-localisation of NS5A of domain I mutants with NS3.  
Huh7.5 cells were transfected with either pCMV10-NS3-NS5B wildtype or NS5A mutants and 
seed onto coverslips. At 48h post transfection, cells were fixed and immunostained for NS5A 
(green) and NS3 (red), nucleus labelled with DAPI (blue). Scale bar, 5 µm. The scatter plots on 
the right show the co-localization of NS5A and NS3 of individual microscopy images (x and y 
axes respectively, pixel intensity) and the correlation value (R) is shown for each image. 
Chapter 3: The role of NS5A domain I in virus replication 
84 
 
3.2.5 Trans-complementation  
Several research groups have previously demonstrated that some NS5A mutants can be 
rescued by providing wildtype NS5A in trans in the context of a NS3-NS5B replication 
competent (WT) or incompetent (GND) replicon (Appel et al., 2005a, Herod et al., 2014, Fridell 
et al., 2013).  
To analyse whether HCV NS5A could be complemented in trans, transient trans-
complementation was performed to examine whether the replicative capacity for the mSGR-
luc-JFH1 NS5A mutants could be rescued upon co-transfection with a helper RNA, SGR-Neo-
JFH1 (WT or GND), relying on supplying functional counterparts of proteins in trans that are 
expressed from separate transcripts to rescue defective NS3-5B replicase units. The helper 
replicon can translate functional NS5A but does not express firefly luciferase activity. On the 
other hand, the rescued SGR-Luc-JFH1 (P35A, V67A, P145A or GND) showed reduced luciferase 
activity because of the defective NS5A. When co-electroporated with helper and rescued 
replicon RNAs, if the trans-complementation occurs, defective NS5A within the rescued 
replicon might be exchanged with functional NS5A from the helper replicon (SGR-Neo-JFH1), 
luciferase activity of the rescued replicon would be increased, which suggested that the 
function of NS5A could be provided by the helper replicon in trans (Appel et al., 2005a). In my 
experiment, the RNAs were used at a ratio of 5:1; helper: rescue genome (Figure 3.7A and B). 
The SGR-luc-JFH1 (P341A/P342A/P343A) (SGR-luc-JFH1(PPP)) NS5A , which has been shown to 
be trans-complemented to some extent (Hughes, 2010), was used as a positive control. As 
shown in Figure 3.7B, none of mutants of domain I were complemented either by SGR-Neo-
JFH1(WT) or GND, while SGR-luc-JFH1(PPP) could be partially trans-complemented by SGR-
Neo-JFH1(GND) compared with the  GND replication level without helper replicon, but not by 
SGR-Neo-JFH1(WT) (Figure 3.7B), which is consistent with  previously reported results 
operated by previous colleagues (Hughes, 2010). More recently, an improved system has been 
developed, in which an intragenomic HCV replicons that carry two ORFs, each driven by 
separate IRES elements, allowing that the complementing viral proteins are provided in trans 
from distinct translation units but encoded in cis from the same RNA molecule (Gomes et al., 
2015).  Previously SGR-luc-JFH1(PPP) was shown to be trans-complemented (Hughes, 2010) 
and used as positive control, but it was not significantly rescued in trans in my system, this 
assay thus needs to be further confirmed with the intragenomic HCV replicons developed by 
Gomes. 
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Figure 3.7 Trans-complementation of mSGR-luc-JFH1 mutants.  
A. Helper and rescued replicon RNAs used for transient trans-complementation assays were 
listed. SGR-neo-JFH1 (WT) or SGR-neo-JFH1 (GND) was taken as helper replicon, respectively. 
SGR-Luc-JFH1(WT), GND (negative control), SGR-Luc-JFH1 NS5A defective mutant (P35A, V67A 
and P145A) or SGR-Luc-JFH1 (P341A/P342A/P343A) (positive control) (Hughes, 2010) was used 
as rescued replicon to check whether they can be rescued by helper replicon. B. Schematic 
drawing of the experimental approach used to analyse trans-complementation. The helper 
genome was either a SGR-Neo-JFH1(WT) or (GND) and co-electroporated in a ratio of 5:1 with 
the rescue genome SGR-Luc-JFH1(WT), GND, SGR-Luc-JFH1 NS5A defective mutant (P35A, 
V67A and P145A) or SGR-Luc-JFH1 (P341A/P342A/P343A), respectively. C. Trans-
complementation assay results.  Luciferase activity was measured at 4, 24, 48 and 72 hpe and 
was normalized to 4 hpe to determine trans-complementation of NS5A domain I mutants. 
A 
C 
B 
Chapter 3: The role of NS5A domain I in virus replication 
86 
 
3.3 Discussion 
Compared with domain II and domain III, NS5A domain I is highly structured and the most 
highly conserved throughout all HCV isolates. It is also well conserved in related viruses such 
as GBV-B and the new hepaciviruses that have recently been identified in a variety of species. 
Therefore, this conserved domain must have common functions in the virus life cycle among 
these 7 genotypes of HCV isolates and related hepaciviruses. To investigate these functions, 12 
conserved and surface exposed residues were selected for mutagenic analysis.  
Using a subgenomic replicon (SGR) system, 9 conserved residues were identified within this 
region that were necessary for viral genome replication, as substitution of these amino acids 
to alanine eliminated genome replication in SGRs. A further three mutations resulted in a 
significant inhibition of replication, implying that, although these residues are not absolutely 
essential, they do contribute to genome replication. In next chapter, these three mutations will 
be cloned into the full-length infectious JFH1 virus molecular clone to examine whether they 
influence virus assembly and release.  
In comparison to the replication results in Huh7.5 cells with those from Huh7 cells, 9 
replication-deficient mutants identified from Huh7 cells could not replicate in Huh7.5 cells as 
well, whereas the SGRs which could replicate in Huh7 cells (WT, P35A, V67A and P145A) all had 
10-100 fold of increased replication activity. Especially for V67A and P145A, replication was 
significantly increased in Huh7.5 cells albeit still lower than WT. One known reason is that the 
Huh7.5 cell line is RIG-I defective. RIG-I is a pathogen receptor that can bind HCV RNA and then 
activate IRF3 signalling pathway. Therefore, RIG-I defective cell line-Huh7.5, exhibit a highly 
permissiveness to HCV replication by inactivation of IRF3 innate immune pathway, allowing 
both NS5A domain I mutants and domain III mutant (D329A) to replicate with high efficiency. 
Of note, V67A and P145A showed a more significant increased replication than P35A and 
D329A in Huh7.5, which suggested that residues V67 and P145 might be involved in a certain 
innate immune pathway in Huh7.5 cells.  Once mutated, V67A and P145A abrogated the 
activation of these pathways. Hence, why the dramatic increase in replication was observed in 
V67A and P145A electroporated Huh7.5 cells needs to be further investigated. 
For the mutations that did not replicate in neither Huh7 nor Huh7.5 cells, lack of replication 
could be likely due to two reasons. One is that the mutation disrupts polyprotein translation 
or proteolytic processing. The other is the loss or disruption of a specific function of NS5A. My 
data showed that the lethal replication phenotype of these mutations was a direct result of a 
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loss of NS5A function and was not due to global effects on NS5A structure or inhibition of 
polyprotein processing. However, co-localisation result showed that G45A, G51A and (153-
158) A of 8 non-replicating mutants, disrupted the interaction between NS5A and NS3, which 
means that they cannot form into functional replication complexes. As for the other non-
replicating mutants, the reason why they cannot replicate still needs to be further investigated. 
What kind of specific NS5A function are these residues involved in? As described above, NS5A 
is an important element in the HCV replication complex (RC). It was reported that NS5A is a 
RNA-binding phosphoprotein, and all three domains can bind the genomic (positive-strand) 
3’UTR, which is  the initiation site for negative-strand RNA synthesis (Foster et al., 2010). The 
dimeric structures of NS5A domain I could provide us some clues (Figure 3.2).  First of all, 
domain I has been crystallized in different forms (Lambert et al., 2014, Love et al., 2009, 
Tellinghuisen et al., 2005). The structure of the NS5A domain I monomer found in each 
crystallographic form is highly conserved but presents a unique symmetrical dimer interface. 
These forms are hypothesized to assemble into a polymer network by alternating 
crystallographic interfaces (Lambert et al., 2014, Love et al., 2009). Two main dimeric structural 
conformations of NS5A domain I are “closed” (3FQM) (Love et al., 2009)and “open” (1ZH1) 
(Tellinghuisen et al., 2005), respectively. The open dimer can provide an attractive RNA-binding 
groove facing away from the membrane, where it could interact with RNA.  Modelling suggests 
the groove is of sufficient dimensions to bind to either single- or double-stranded RNA, which 
may be dominant in RNA replication (Huang et al., 2004, Tellinghuisen et al., 2008b). In the 
closed conformation with more residues in the interfaces, a proximal residue, E148 (conserved 
in both JFH1 and Con1), forms an intramolecular contact via hydrogen bond with R112 on the 
other monomer. It did not show the pocket for RNA binding and might be inefficient in RNA 
binding and replication and involved in other functions of HCV life cycle. A hypothesis has been 
put forward that the closed conformation can be switched into open conformation by changing 
the dimer interfaces (Ross-Thriepland and Harris, 2014b). For example, it was suspected that 
S146 phosphorylation could disrupt the interaction between R112 and E148, thereby 
promoting a switch from the closed to the open conformation. P35 is located in the P29-P35 
loop interactions, via which NS5A monomers propagate into NS5A helical hexamer (Sun et al., 
2015). Moreover, for P145, it is close to S146 mentioned above and the mutation of this 
position may be involved in the change of the dimeric conformation. In summary, P35A and 
P145A may affect the dimeric conformation disturbing the binding to RNA and further affect 
RNA replication. The position of V67 is exposed on the surface of both dimer structures, which 
is of high possibility to interact with both host and viral proteins involving in RNA replication 
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(Figure 3.2). RNA binding assays and analysis of dimerization will be performed in order to 
provide more detailed molecular information about the interaction in Chapter 5.  
Apart from RNA binding activity, when NS5A is involved in the replication complex it can 
interact with various cellular factors and viral proteins, which is required for HCV replication 
(Paul et al., 2014). In the replication complex, the phosphorylation of NS5B RdRp was activated 
by NS5A, at least in vitro. This activation might be mediated by the RNA-binding ability of NS5A 
or by direct interaction with NS5B (Quezada and Kane, 2013, Shirota et al., 2002). Recent 
research demonstrated that NS4B and NS5A are two critical replication complex components. 
Additionally, domain I of NS5A was sufficient to mediate its interaction with NS4B, and then 
affect viral genome replication (David et al., 2015). The conserved residues on the surface of 
NS5A domain I are much more available to interact with other proteins. Whether the 
mutations could disrupt the interaction between NS5A and other viral proteins will be 
investigated using proteomic analysis in Chapter 6. 
In trans-complementation assays, expression of a polyprotein encompassing NS3 to NS5A was 
sufficient to rescue replication of an NS5A replicon mutant, whereas NS5A expressed on its 
own did not support trans-complementation, which suggest that the other nonstructural 
proteins, NS3, NS4A, and NS4B, affect folding of NS5A in a highly ordered complex to produce 
a functional NS5A protein. With only properly folded NS5A, RNA replication could be able to 
rescue in trans, but mutations affecting the overall folding could not be rescued (Appel et al., 
2005a). From the result of transfection of pCMV10-NS3-NS5A, most of these mutants only 
could be detected in the basal phosphorylation state, while the expression of 
hyperphosphorylated NS5A was dramatically reduced or undetectable, indicating a more 
profound effect on the conformation of the protein (Koch and Bartenschlager, 1999). Together 
with the trans-complementation result, none of these mutations could be complemented. The 
reason maybe that mutations in this domain affecting the phosphorylation may therefore 
result in an NS5A that is non-productively associated with other components of the RC, making 
trans-complementation very difficult. However, the mechanism of phosphorylation of NS5A 
domain I is complicated and differential phosphorylation could regulate the various roles of 
the protein, which remain unclear and need to be investigated with joint efforts. 
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4.1 Introduction 
Following RNA replication, nascent viral genomes need to be transported from the sites of RNA 
replication to distinct, as yet poorly characterised, sites of virus assembly. Here infectious virus 
particles are generated, bringing together the structural proteins and the viral genome to be 
packaged in a temporally and spatially organized manner (Gastaminza et al., 2008, Lindenbach 
and Rice, 2013). An increasing body of evidence points to a role of NS5A in coordinating this 
process, possibly by transporting the genome RNA to assembly sites and delivering it to the 
core protein for encapsidation. A further level of complexity arises from the fact that, 
compared to other enveloped positive-strand viruses, a key feature of infectious HCV particles 
is that they exhibit unusually low buoyant densities, while particles with higher buoyant 
densities are less infectious (Lindenbach et al., 2005, Lindenbach, 2013, Wakita et al., 2005). 
Indeed highly purified HCV particles are rich in lipids and cholesterol resembling very-low 
density lipoproteins (VLDL) (Merz et al., 2011, Miyanari et al., 2007). This property requires 
that cellular lipid droplets (LDs), lipid storage organelles surrounded by a phospholipid 
monolayer, are involved in HCV assembly. 
Of the virus structural proteins, core trafficking to LDs is functionally tied to specific lipid 
metabolism events and serves to sequester the core protein until it is needed for virus 
assembly, as mutations that prevent trafficking of the core protein to LDs strongly inhibit virus 
assembly (Boulant et al., 2007, Miyanari et al., 2007, Shavinskaya et al., 2007). High-resolution 
immunofluorescence microscopy clearly showed that core was completely colocalized with 
ADRP, residing on the surface of LDs, thus indicating that core also directly associates with the 
surface of LDs. More importantly, NS5A signal mainly localized around the core positive area, 
resulting in a doughnut-shaped signal with a diameter slightly larger than that of core. The LD-
proximal NS5A signal partially overlapped with the core signal. This concentric staining pattern 
was also observed with the other NS proteins, indicating that NS proteins associate with core 
on the surface of LDs (Miyanari et al., 2007) (Figure 4.1). The core-NS5A co-localization may 
suggest  an interaction of the replicase complex with the core protein to deliver the RNA 
genome and to initiate nucleocapsid formation (Shavinskaya et al., 2007). There is a model of 
HCV production put forward that core mainly localizes on the monolayer membrane that 
surrounds the LD, core recruits NS proteins, as well as replication complexes, to the LD-
associated membrane and NS proteins around the LD can then participate in infectious virus 
production (Miyanari et al., 2007).   
 
Chapter 4: NS5A domain I is required for virus assembly 
92 
 
 
                                 
Figure 4.1. Spatial distribution of core and NS5A relative to the LD. 
A. The localizations of core and NS5A around the lipid droplets (LDs) in JFH1 replicon-bearing 
cells were analysed using immunofluorescence microscopy. Scale bars, 1 μm. B. Typical images 
of the localization of LDs, core, NS5A and merged images are shown with the relative scale of 
each image. Picture is adapted from (Miyanari et al., 2007). 
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Of three domains of NS5A in HCV life cycle, it is well documented that the RNA binding domain 
I  is essential for RNA replication (Huang et al., 2005); most of domain II is dispensable for the 
viral replication cycle in cell culture, whereas domain III is required for HCV assembly 
(Tellinghuisen and Foss, 2008, Appel et al., 2008, Masaki et al., 2008, Tellinghuisen et al., 
2008b). Domain III appears to be phosphorylated by casein kinase II at a C-terminal serine 
residue and this modification might regulate interaction with the core protein and thus virion 
formation (Tellinghuisen and Foss, 2008, Masaki et al., 2008). Most function of NS5A in virus 
assembly have been mapped to domain III, as mutations close to the C-terminus of domain III 
disrupt the ability of NS5A to interact with core, abrogate infectious particle formation and 
lead to an enhanced accumulation of core on the surface of LDs (Appel et al., 2008).   
In addition to interacting with other viral proteins, a number of cellular NS5A-interacting 
partners have been implicated in LD function/targeting and virus assembly. These include 
Apolipoprotein E (ApoE), diacylglycerol acyltransferase-1 (DGAT-1), Annexin A2 and Rab18 
(Backes et al., 2010, Benga et al., 2010, Camus et al., 2013, Herker et al., 2010, Salloum et al., 
2013). NS5A interacts with ApoE, an apolipoprotein (Apo) that is required for virus assembly. 
Two alanine mutants in domain I of NS5A - JFH1AAA99 or JFH1AAA102 failed to interact with 
ApoE and impaired recruitment of the other non-structural proteins to the surface of LDs. 
ApoE-NS5A binding is thus assumed to have a crucial function in the production of infectious 
particles, and the determinants of this interaction are located on domain I of NS5A (Cun et al., 
2010, Benga et al., 2010).  Annexin A2, a cellular membrane sorting protein, can enhance virus 
assembly by being recruited by NS5A domain III (Backes et al., 2010).  Of note, both DGAT-1 
and Rab18 have been reported to recruit NS5A on to LDs and are proposed to play roles in 
transporting NS5A and genome RNA between replication sites and LDs/assembly sites (Camus 
et al., 2013, Salloum et al., 2013).  DGAT1 as a host factor for HCV infection  has been  reported 
to catalyse core and NS5A proteins trafficking from ER membrane to LDs and enhance 
interactions of NS5A with core protein but via different determinants of DGAT1 and different 
processes (Camus et al., 2013, Herker et al., 2010). Rab18 showed a direct association with 
NS5A promoting the interaction between HCV membranous webs and LDs and might enhance 
virion assembly by bringing sites of replication in close physical proximity to sites of virion 
assembly, either on the LD surface or on membranes apposed to the LD. Therefore, HCV 
particles assemble by budding into ER. An important early step in this process is the interaction 
between cLD-associated core and NS5A proteins, which might serve to shift RNA out of 
replication or translation and into virus assembly (Appel et al., 2008, Lindenbach and Rice, 
2013, Masaki et al., 2008, Miyanari et al., 2007). 
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Although virus encapsidation could occur at the LD, it is noteworthy that LD surface is not 
bound with a conventional phospholipid bilayer ER membrane but delimited by a phospholipid 
monolayer (Fujimoto and Parton, 2011), therefore the virions cannot obtain their lipid 
envelope from them. Assembly of an infectious enveloped HCV virion particle must ultimately 
require that core and virion RNA are transported from LDs (Paul et al., 2014) to a membranous 
compartment, possibly involving the ESCRT (endosomal sorting complex required for 
transport) and/or endosomal pathways for viral budding (Ariumi et al., 2011, Corless et al., 
2010, Tamai et al., 2012). 
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4.2 Results 
4.2.1 The role of domain I in virus production. 
To determine whether the attenuation of genome replication for P35A, V67A and P145A in 
Huh7 cells was also observed in the context of infectious virus, these mutations were sub-
cloned into the full-length mJFH1 infectious clone (Hughes et al., 2009b). Following 
electroporation of full-length virus transcripts into Huh7 cells virus genome replication activity 
was determined by quantification of the number of NS5A positive cells using the IncuCyte 
ZOOM at 48 hpe as previously described (Stewart et al., 2015)(Figure 4.2A). As expected, 
replication of P35A, V67A and P145A in the context of infectious virus was consistent with the 
observations in SGRs (Figure 4.2B and 3.3). P35A exhibited a modest reduction, which was not 
significant, whereas V67A and P145A showed a ~100-fold reduction in replication, 
indistinguishable from the GND negative control. Consistent with this replication phenotype, 
neither V67A nor P145A produced any infectious virus particles, either within the cells 
(intracellular virus), or released into the supernatant (extracellular virus) (Figure 4.2C).  
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Figure 4.2.  Mutations in NS5A domain I disrupt the production of infectious virus in Huh7 
cells.  
A. In vitro transcripts of mJFH1 containing the indicated mutations were electroporated into 
Huh7 cells. Cells were fixed at 48 hpe, immunostained with anti-NS5A antibody and visualised 
by using the IncuCyte ZOOM. B. Virus genome replication and protein expression was assayed 
by quantification of NS5A positive cells from IncuCyte ZOOM. C. Intracellular and extracellular 
infectious virus was titrated at 72 hpe. IU indicates infectious unit of virus.  ns indicates not 
statistically significant, * and ** indicate significant (P<0.05) and very significant (P<0.01) 
differences from the results for titre (IU/ml) of mJFH1 WT virus, respectively. For B-C, data 
from three independent experiments are shown and error bars represent the standard error 
of the mean. 
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A different picture emerged when these mutant virus RNAs were electroporated into Huh7.5 
cells.  As shown in Figure 4.3A (upper panel) and B, replication of P35A was indistinguishable 
from WT, whereas both V67A and P145A showed only a modest defect. This result was 
confirmed by western blot analysis for NS5A and core expression (Figure 4.3C). However, 
despite the restoration of genome replication to WT levels, V67A and P145A were unable to 
produce any infectious virus (Figure 4.3A lower panels and D). This phenotype mirrored that 
of the additional control used in this experiment, ΔE1-E2 (a deletion within the envelope 
glycoprotein coding region previously shown to be unable to assemble infectious virus) (Appel 
et al., 2008, Hughes et al., 2009b). 
I conclude from these data that the two residues V67 and P145 are partially required for 
genome replication, as mutations of these residues resulted in a reduction of replication that 
could be rescued by the Huh7.5 RIG-I defect.  In contrast these two residues are absolutely 
required for the assembly of infectious HCV particles.  This result was surprising, as it is widely 
accepted that domain I of NS5A is exclusively involved in genome replication. The one 
exception to this is the report 10 years ago showing that alanine scanning mutagenesis of 
residues 99-101 or 102-104 had no effect on genome replication, but blocked release of 
infectious virus from Huh7.5 cells (Miyanari et al., 2007), although whether these mutants 
affected assembly of intracellular infectious virus was not determined. It was reasoned that 
the ability of V67A and P145A to replicate to near WT levels in Huh7.5 cells offered the 
opportunity to assess the role of domain I in virus assembly, without any confounding 
replication defect that would make interpretation of the data difficult.  
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Figure 4.3. Mutations in NS5A domain I disrupt the production of infectious virus in Huh7.5 
cells.  
A. In vitro transcripts of mJFH1 containing the indicated mutations were electroporated into 
Huh7.5 cells.  Virus genome replication and infection images obtained from Incucyte ZOOM. 
B. Virus genome replication and protein expression was assayed by quantification of NS5A 
positive cells 48 hpe for Huh7.5 cells by using the Incucyte ZOOM. C.  Huh7.5 cell lysates at 72 
hpe were analysed by western blot with anti-NS5A, anti-core and anti-β-actin antibodies. D. 
Intracellular and extracellular infectious virus was titrated at 72 hpe. IU indicates infectious 
unit of virus. ns indicates not statistically significant and * and ** indicate significant (P<0.05) 
and very significant (P<0.01) differences from the results for titre (IU/ml) of mJFH1 WT virus. 
For B and D, data from three independent experiments are shown and error bars represent the 
standard error of the mean.   
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However, before analysing the phenotype of V67A and P145A in more detail, I confirmed that 
the phenotypes of these mutants were not due to the acquisition of an additional 
compensatory mutation during the cloning process. To do this, I generated revertant viruses in 
which the WT NS5A coding sequence was sub-cloned back into the V67A and P145A virus 
backbones. As shown in Figure 4.4, following electroporation of revertant RNA into Huh7.5 
cells, both genome replication (Figure 4.4A) and production of both intracellular and 
extracellular virus (Figure 4.4B) was restored to WT levels.  
                
                  
Figure 4.4. Phenotypes of V67A and P145A are not derived from acquisition of an additional 
compensatory mutation during the cloning process. 
A. Revertants were generated by cloning a WT NS5A fragment back into the mJFH1 V67A or 
P145A mutant plasmids.  Huh7.5 cells were electroporated with in vitro transcripts of the 
resulting V67 or P145 revertants. Virus genome replication and protein expression was assayed 
by quantification of NS5A positive cells 48 hpe by using the Incucyte ZOOM. B. Intracellular 
and extracellular infectious virus was titrated at 72 hpe. Data from three independent 
experiments are shown and error bars represent the standard error of the mean. 
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4.2.2 The role of domain I in the assembly of infectious virus 
It was considered that the failure of V67A and P145A to produce infectious virus was either 
due to a gross assembly defect such that no virus particles were generated, or that virus 
particles were assembled but were non-infectious. Such non-infectious particles might be 
empty, lacking the genome, or could exhibit some other more subtle defect such as a failure 
to associate with lipids. To test this hypothesis, culture medium from Huh7.5 cells 
electroporated with JFH1 WT, P35A, V67A and P145A RNA was concentrated and fractionated 
by iodixanol density-gradient centrifugation. As controls, cells were electroporated with GND 
and ΔE1/E2 RNAs. Each fraction was analysed by quantitative RT-PCR (Figure 4.5A) to 
determine the presence of genomic RNA, and infectivity was measured using the IncuCyte 
ZOOM as described (Figure 4.5B). As expected WT JFH1 showed a broad peak of infectivity at 
a low density (1.064 g/ml) that coincided with a genomic RNA peak, a second larger RNA peak 
at a higher density (1.1005 g/ml) was less infectious, consistent with previous reports (Merz et 
al., 2011, Miyanari et al., 2007). P35A also showed two coincident peaks of infectivity and RNA, 
although the majority of the viral RNA was associated with the higher density fraction which 
exhibited less infectivity. In contrast, no genomic RNA or infectivity could be detected for either 
V67A or P145A, these two mutants were indistinguishable from the two negative controls 
(GND and ΔE1/E2). Gradient fractions were concentrated by methanol precipitation prior to 
analysis for the presence of core by western blot. This analysis (Figure 4.5C) revealed a 
complete lack of any core protein in fractions from either V67A or P145A, again in common 
with the negative controls. In contrast both WT and P35A exhibited core protein correlating 
with the peaks of infectivity and virus RNA. It was concluded that both V67A and P145A 
mutations block the assembly of infectious virus particles at an early stage. 
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Figure 4.5. Density gradient analysis of mutant viruses.  
Huh7.5 cells were electroporated with in vitro transcripts of the indicated virus mutants. 
Concentrated culture medium was fractionated using 10-40% iodixanol density-gradient 
centrifugation. For each fraction, HCV RNA (A) and infectivity (B) were plotted against the 
buoyant density (n=3), and core protein in each fraction was detected by western blot (C). 
Lanes 1 to 12 in (C) indicated the fractions collected from top to bottom with the buoyant 
density indicated in (A) and (B). The result of a representative of three independent 
experiments is shown. 
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4.2.3 A role for NS5A domain I in the redistribution of LD during infection 
To shed light on the phenotype of the V67A and P145A mutations, we applied an imaging 
approach, using high-resolution confocal microscopy (Airyscan) to assess the distribution of 
both viral and cellular factors during infection. In this regard, lipid droplets (LD) are important 
organelles for the assembly of infectious HCV particles, although their precise role remains to 
be elucidated (Miyanari et al., 2007).  Both core and NS5A have been shown to localise with 
LDs and infection with HCV results in dramatic changes to the distribution and size of LDs.  This 
is demonstrated in Figure 4.6: Huh7.5 cells were electroporated with WT JFH1 RNA and 
analysed by Airyscan confocal microscopy for the distribution of LD, core and NS5A at various 
time-points up to 72 hpe (Figure 4.6A). The number (Figure 4.6B), and total area of LDs (Figure 
4.6C), together with their distance from the nuclear membrane (Figure 4.6D), were 
determined. During the first 12 h the number of LDs declined slightly, but then increased at 24 
h, followed by a further dramatic decline by 48/72 h. Importantly however, the total area of 
LDs within the cytoplasm (a measure of the amount of lipids stored in LDs) increased 
significantly at 48/72 h, indicative of an increase in the size of LDs. There were more subtle 
changes to the distribution of LDs: at early times (12/24 h) - they scattered throughout the 
cytoplasm, whereas later the distribution was more restricted to the perinuclear area (48 h) 
and exhibited a clustering (72 h). As previously documented, both core and NS5A were 
associated with LDs at later time points. Core can be seen to completely coat the surface of 
LDs whereas NS5A is restricted to punctate areas on the surface. The same pattern of changes 
in cells infected with JFH1 was observed (Figure 4.7). 
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Figure 4.6. Time-course immunofluorescence analysis of LDs, NS5A and core in WT 
transfected cells.  
 A. Huh7.5 cells were electroporated with an in vitro transcript of mJFH1 WT. At the indicated 
hpe cells were fixed and stained with anti-NS5A and core antibodies, BODIPY 558/568-C12, 
and DAPI. B-D. Spatial data for LDs were determined from 10 cells for each time point using 
Fiji. These data were used to determine the number of LDs per cell (B), the average size of LDs 
(C) and the distance of each LD from nucleus at different time points (D). C. To determine the 
total area of LD, the grayscale rendered 16-bit tagged image file format (TIFF) images were 
subjected to threshold-based analysis of LD areas for 10 randomly selected cells for each 
sample. Two-dimensional (2D) masks of the labelled regions were constructed and were used 
for computing the 2D area of LDs. Two-dimensional areas (μm2) of the LDs were also measured 
using the Analyze Particles function in Fiji.  D. The distance of the centroid of each LD to the 
edge of the cell’s nucleus, visualised using DAPI stain, was looked up using a Euclidean distance 
map computed with the Distance Transform module of Fiji and exported as a list of distance 
2D measurements via the Analyze Particle function. Two-dimensional measurements in this 
experiment was used as a proxy for the 3D distance from the LD to the nucleus. **** indicates 
significant difference (P<0.0001) from the results for LDs in untransfected cells. The scale bars 
are 5µm and 0.5 µm, respectively. This work was performed by Niluka Goonawardane. 
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Figure 4.7 Time-course immunofluorescence analysis of LDs in JFH1 WT virus infected cells.  
Huh7.5 cells were infected with JFH1 virus at MOI =0.5. At the indicated hpe cells were fixed 
and stained with anti-NS5A, BODIPY 558/568-C12, and DAPI. Image showed here is LD in red 
and DAPI in blue of NS5A positive cells. NS5A staining channel is not showed to highlight the 
phenotype of LD. The scale bars are 5µm and 0.5 µm, respectively. This work was performed 
by Niluka Goonawardane. 
 
The distribution of LDs was then examined, core and NS5A at 72 hpe in Huh7.5 cells 
electroporated with RNA for the three domain I mutants, P35A, V67A and P145A (Figure 4.8).  
Airyscan imaging of these cells revealed some striking differences: P35A was largely 
indistinguishable from WT but V67A and P145A exhibited distinct phenotypes. The most 
notable difference was that for V67A and P145A the size of the LDs was dramatically reduced 
compared to WT and P35A (Figure 4.8).  Quantification confirmed this visual conclusion (Figure 
4.9), in WT and P35A transfected cells, the majority of LDs had an area of between 0.2-0.6 µm2, 
whereas for V67A and P145A the majority were below 0.2 µm2. Compared to the phenotype 
of LDs in the untransfected Huh7.5 mock cells, V67A and P145A followed the similar pattern 
that such size of LDs did not get enlarged. Hence, it can be deduced that V67A and P145A might 
fail to produce infectious virus that abrogate to activate the LDs biogenesis, following the 
phenotype of LDs within virus uninfected cells. 
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Figure 4.8 Subcellular distribution of core and NS5A relative to the LDs in infected cells is 
disrupted by domain I mutations V67A and P145A.  
Spatial distribution of core and NS5A relative to the LD in Huh7.5 cells electroporated with in 
vitro transcripts of either wild-type mJFH1, or NS5A mutants P35A, V67A and P145A. Cells were 
seeded onto coverslips and incubated for 72 hpe prior to fixation and immunostaining for core 
(rabbit, 1:500), NS5A (sheep, 1:2000) and LD (BODIPY 558/568-C12, 1:1000), and imaging by 
confocal microscopy. The scale bars are 5µm and 0.5 µm, respectively.  This work was 
performed by Niluka Goonawardane. 
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Figure 4.9 V67A and P145A mutations disrupt the HCV-mediated increase in LD size.  
A. LDs in Huh7.5 cells electroporated with the indicated JFH1 constructs were visualized by 
staining with BODIPY 558/568-C12. B. To determine the total area of LD, the grayscale rendered 
16-bit tagged image file format (TIFF) images were subjected to threshold-based analysis of LD 
areas for 10 randomly selected cells for each variant. 2D masks of the labelled regions were 
constructed and were used for computing the 2D area of LDs. The size of individual LD was 
determined and plotted as a histogram. The area (µm2) is taken as an indication of the three-
dimensional volume of the LD. For comparison similar data was determined from the 
uninfected Huh7.5 cells. This work was performed by Niluka Goonawardane. 
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In addition, there were some other differences between WT/P35A and V67A/P145A: in 
particular the amount of NS5A localised at the surface of lipid droplets appears to be much 
less for the latter two mutants.  This was confirmed by quantitative analysis (Figure 4.10A), the 
percentage of NS5A fluorescence that co-localised with LD was significantly reduced. However, 
the reciprocal analysis (percentage of LD that co-localised with NS5A) showed no differences. 
This suggested that the proportion of LDs that were associated with NS5A was no different to 
WT.  However, compared to WT, the majority of NS5A did not associate with LDs. Quantitative 
analysis of the NS5A: core co-localisation revealed a similar trend whereby the percentage of 
NS5A co-localised with core was significantly less for V67A and P145A (Figure 4.10B).  In 
contrast, although the percentage of core that co-localised with LD was significantly reduced 
for V67A and P145A, the reduction was much less dramatic (Figure 4.10C). Lastly, it was 
observed that there were differences in the distribution of LDs: for both V67A and P145A the 
LDs were significantly closer to the nucleus, albeit not as close as in either GND-electroporated 
or mock control cells (Figure 4.10D). 
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Figure 4.10 V67A and P145A disrupt the co-localization between NS5A and core or LDs.  
A. Quantification of the percentages of NS5A colocalized with LD (white blocks), or LD 
colocalized with NS5A (red blocks).  B. Quantification of the percentages of NS5A colocalized 
with core (white blocks), or core colocalized with NS5A (green blocks). C. Quantification of the 
percentages of core colocalized with LD (green blocks), or LD colocalized with core (red blocks). 
D. Spatial data for the distance of LDs from the nuclear envelope were determined from 10 
cells for each construct using Fiji. **** indicates significant difference (P<0.0001) from the 
results for WT. This work was performed by Niluka Goonawardane. 
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4.2.4 A role for NS5A domain I in formation of lipid droplets during infection 
To further check the formation of lipid droplets (LDs), this imaging analysis was complemented 
by investigating the composition of LDs.  LDs were purified from electroporated cells by density 
gradient centrifugation and analysed by western blot for NS5A and core, using antibody to the 
LD-associated adipose differentiation-related protein (ADRP, also known as adipophilin or 
perilipin 2) (Boulant et al., 2008, Miyanari et al., 2007) as a marker for LDs. The integrity of the 
LDs and lack of contamination with other cellular components was demonstrated by the 
absence of GAPDH (Wang et al., 2015).  
As shown in Figure 4.11, ADRP was exclusively present in the LD fraction (not in the cytosolic 
or membrane fractions) and western blot for GAPDH confirmed the absence of cytosol and 
other membranes in the LD fraction. GAPDH can only be detected in fractions of cytosol and 
cytoplasmic membranes and showed in reduced level compared with that in total cytoplasm 
because of the dilution by LD purification buffers (see 2.5.9).  Both NS5A and core were also 
detected in the LD fractions, however the relative distribution and amounts of these two viral 
proteins differed between the mutants and WT (Figure 4.11 and 4.12). Both V67A and P145A 
showed significantly less NS5A in the LD fraction (Figure 4.11 and 4.12A), consistent with the 
fluorescence data (Figure 4.8 and 10A).  In contrast the amount of core in the LD fraction of 
V67A and P145A was increased (Figure 4.11 and 4.12B). These data are consistent with a 
scenario whereby NS5A transports nascent genomes to LDs where it is transferred to the core 
protein for subsequent movement to assembly sites. 
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Figure 4.11 V67A and P145A disrupt the recruitment of NS5A and core to LDs.  
Huh7.5 cells were electroporated with in vitro transcript of mJFH1 WT and mJFH1 mutants. 
Cells were harvest for LD purification 72 hpe. Western blot analysis of NS5A and core proteins 
and the LD marker protein ADRP and GAPDH in purified LD fractions compared with whole 
cytoplasm, cytoplasmic membrane and cytosolic fractions. 
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Figure 4.12 Quantification of the abundance of NS5A and core in LDs.  
A-B The abundance of NS5A (B) and core (C) in the LD fractions was quantified and normalised 
to the LD fraction ADRP value acquired by western blot using a Li-Cor Odyssey Sa, enabling 
highly accurate quantification. Error bars represent the standard error of the mean of three 
independent experiments.  ** indicates significant difference (P<0.01) from WT. 
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4.2.5 Recruitment of viral RNA into LD and viral particles  
As shown above, recruitment of NS5A was prohibited into LDs, which will lead to the disruption 
of recruitment of NS5A into intact viral particle and finally failure of virus assembly. As the RNA 
binding protein, NS5A serves as the vector to transport RNA from RC into viral particles. Given 
that the RNA binding protein-NS5A cannot interact with LD and core protein, I wondered 
whether RNA can still be recruited into LDs or viral particles. 
To confirm this, I used qRT-PCR to quantify the amount of viral RNA in the LD fractions.  This 
analysis revealed that for both V67A and P145A there was a significant reduction in genomic 
RNA associated with LDs (Figure 4.13A). In addition, core immunoprecipitates revealed 
significant reductions in the amount of genomic RNA bound to core  for V67A and P145A 
(Figure 4.13B). Moreover, the amount of genomic RNA bound to NS5A in the context of each 
mutation will be discussed in Chapter 5. These analyses were consistent with a scenario 
whereby NS5A transports nascent genomes to LDs where it is transferred to the core protein 
for subsequent movement to assembly sites. 
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Figure 4.13 RNA levels in LDs and bound to viral core protein were decreased for V67A and 
P145A mutant transfected cells. 
A. Post purification of LDs from each JFH1 transfected cells, the amount of viral RNA in LD 
fractions was determined by qRT-PCR. B. Cells were lysed at 72 hpe and core was 
immunoprecipitated from cell lysates.  After enough washing, the beads were subjected to 
analysis by western blot and RNA extraction. qRT-PCR were performed to quantify the level of 
positive genome RNA bound with viral protein-core. The binding capacity of core is shown in 
the ratio of RNA copies to NS5A (n=2). Error bars represent the standard error of the mean of 
two independent experiments.  ** indicates significant difference (P<0.01) from WT. 
A 
B 
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4.3 Discussion 
4.3.1 Domain I of NS5A is involved in HCV assembly  
In chapter 3, I analysed 12 residues that are both conserved and surface exposed in domain I 
by site directed mutagenesis within JFH1 subgenomic replicons. Most of them were absolutely 
required for genome replication. However, three residues (P35A, V67A and P145A) were 
identified in NS5A domain I for which alanine substitution had a modest effect on genome 
replication, keeping partial replication phenotype, while replication of them even reached to 
almost wild type level in Huh7.5 cells, a permissive cell line. 
In this chapter, P35A, V67A and P145A were introduced into JFH1 full-length virus backbone 
to check whether they are involved in virus production pathways. Firstly, these mutants 
together with JFH1 wildtype and negative control GND were electroporated into Huh7 cells. 
Virus replication was first analysed by IncuCyte Zoom method (Stewart et al., 2015), this result 
is consistent with the observation in SGRs (Section 3.2.2). Then both intracellular and 
extracellular viruses were harvested and titrated in naïve Huh7 cells. Compared with WT and 
GND, P35A could be detected by both intra and extracellular viruses but with about 10-fold 
reduction, which can make sense because of the inhibition of replication level. However, V67A 
and P145A mutants failed to produce intracellular infectious virus. This result might stem from 
the extremely low replication, so that the virus level is hard to be detected, or due to the failure 
to produce virus.  To exclude the former possibility, permissive cell line, Huh7.5 were utilised 
to perform virus transfection and titration. Replication of V67A and P145A virus was increased 
to WT level as expected. Based on this level, virus harvested was then titrated on naïve Huh7.5 
cells and no virus was detected as well, which confirmed that V67A and P145A impaired 
production of virus.  Previously, domain I has been assumed only to function during genome 
replication, and to our knowledge this is the first detailed analysis of a role for domain I in virus 
assembly, which is an important and new finding since JFH1AAA99 were reported to be 
involved in HCV release (Miyanari et al., 2007). 
I reasoned that mutants of V67A and P145A could either assemble into virus non-infectious 
particles or they could prevent the formation of intact viral particles. To test these two options, 
100-fold concentrated virus culture medium (extracellular virus) were subjected to analyses of 
viral protein (core), RNA and virus infectivity. All these results consistently exhibited that there 
are no viral particles released. Thus, these phenotypes were attributed to assembly defect to 
the mutations of V67A and P145A. 
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4.3.2 Domain I of NS5A is required for the recruitment of NS5A to lipid droplets 
As for the HCV assembly pathway, it is well accepted that lipid droplets are the important 
organelles that provide the place for virus assembly (Miyanari et al., 2007). In this pathway, 
core protein is initially transferred onto the surface of LDs where it can recruit NS proteins 
including NS5A and viral genomes from replication complexes (Bartenschlager et al., 2011, 
Miyanari et al., 2007). Utilizing this model, I checked the co-localization of N5SA, core and LD 
using high-resolution microscopy, Airyscan (Korobchevskaya et al., 2017, Huff, 2016, Huff, 
2015). 
Firstly, taking JFH1 HCV wildtype as example, the biological changes of LDs in Huh7.5 cells were 
analysed after either post transfection or infection with HCV. With virus infection, the size of 
lipid droplets get enlarged while the number of them decrease and the distribution was more 
restricted to the perinuclear area typically after 24 hours post transfection or infection.  
Especially at 72 hpe, the size of LDs is significantly bigger than that in non-transfected cells, 
which suggested that some reactions related to HCV happen in LDs. As described previously, 
LD is the place for virus assembly (Miyanari et al., 2007, Filipe and McLauchlan, 2015). Thus, 
there is tight relationship between LD biogenesis and virus production. This evidence 
prompted us to further investigate the phenotype of LDs in V67A and P145A transfected cells 
together with the distribution of core and NS5A proteins, which are associated with LDs. As 
expected, LDs in V67A and P145A transfected cells are reduced in both their size and the 
number compared to wild type. P35A, which can produce infectious viruses, exhibited 
indistinguishable LDs from wild type. More importantly, it was also found that the co-
localization between NS5A and LDs or core protein is significantly disrupted for V67A and 
P145A. Based on the HCV assembly pathway in which core associated LDs will recruit NS5A to 
participate in viral assembly, the disruption of co-localization of NS5A with LDs or core 
suggested that recruitment of NS5A to LDs might be inhibited.  
To support this hypothesis, I set up a biochemical analysis of purified LDs from each JFH1 
mutant transfected cell using ultracentrifugation. Compared with the expression level of NS5A 
in whole cell lysates, nuclei or membrane fractions, both V67A and P145A showed a dramatic 
reduction of NS5A in LDs. This result is consistent with what was initially hypothesised that 
recruitment of NS5A to LDs is more likely to be impaired. As supporting evidence, recruitment 
of RNA to both LDs and viral particles (core protein) was also disrupted in V67A and P145A 
transfected cells, which confirmed that NS5A domain I with V67A and P145A mutations 
impaired virus assembly by abrogating recruitment of both NS5A and genomic RNA to viral 
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assembly sites-LDs. For the relationship between LDs and core, one apparent discrepancy in 
my data relates to the co-localisation of core with LDs. Specifically, the imaging data (Figures 
4.8 and 4.10) showed a modest reduction in core: LD co-localisation for V67A and P145A, 
whereas these mutants showed higher levels of core co-purified with LDs (Figure 4.11 and 
4.12).  Two factors may help to explain this discrepancy: firstly, it is possible that in the case of 
V67A and P145A, core associates more strongly with LDs, possibly because it has not been 
displaced by NS5A.  Secondly, V67A and P145A infected cells exhibit larger numbers of smaller 
LDs, thus the available LD surface area for interaction with core is also likely to be larger, 
allowing more core to associate.   
These observations imply that domain I of NS5A plays multiple roles in virus assembly. It is 
required for the association of NS5A with LD as well as the increase in LD size and altered 
distribution (movement away from the nuclear membrane) that is also seen during HCV 
infection. In addition, it was noticed that the phenotype of LDs of V67A and P145A is more like 
that of WT at the earliest transfection time point (24 hpe). Hence it was suspected that V67A 
and P145A are trapped in the early virus process such as replication and cannot transferred 
from replication complex and proceed into next virus assembly sites-LDs, which can explain 
why the phenotype of LDs for V67A and P145A at 72hpe is more like that of WT at 24 hpe and 
why there are no virus particles produced for V67A and P145A. Furthermore, viral RNA is 
inhibited to shifting into LDs and viral particle as well. As expected, NS5A is the RNA binding 
protein that can transfer RNA from replication sites into assembly sites. Significantly, reduced 
RNA levels associated in both LDs and viral particles in mutants (V167A and P145A) may 
indicate that NS5A together with genome RNA was inhibited from interacting with LDs and 
failed into viral assembly. However, what is the exact mechanism of NS5A domain I involved in 
virus assembly pathway?  More research needs be done to answer this question.
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5.1 Introduction  
As mentioned previously, domain I of NS5A is the most highly structured of the three domains. 
The domain I monomer can be divided into two subdomains: the N-terminal subdomain IA and 
the C-terminal subdomain IB (Figure 5.1). Subdomain IA consists of an N-terminal extended 
loop lying adjacent to a three-stranded anti-parallel β-sheet (strands B1–B3), with α-helix H2 
(designated H2 to allow numbering of the N-terminal membrane-anchoring helix as H1) at the 
C terminus of the third β-strand. These elements comprise the structural scaffold for a four-
cysteine zinc-atom-coordination site (Cys 39, Cys 57, Cys 59 and Cys 80) at one end of the β-
sheet (Tellinghuisen et al., 2005). Subdomain IB consists of a four-strand anti-parallel β-sheet 
(B4–B7) and a small, two-strand anti-parallel β-sheet (B8 and B9) near the C terminus, 
surrounded by extensive random coil structure. Additionally, the presence of a disulphide bond 
near the C terminus of domain I connecting the sidechains of the conserved Cys 142 and Cys 
190 is important for the structure of domain I. 
The other unique feature of domain I is that it exhibits dimeric structures. Although the exact 
function of dimerization has not yet been determined, four different dimeric structures of 
Domain I were solved by three independent research groups (Tellinghuisen et al., 2005, Love 
et al., 2009, Lambert et al., 2014). All the dimers were formed with the same monomers, but 
they interact with each other with different interfaces and orientations. There is evidence 
showing that different dimers might be assigned with different functions mainly by 
transformation between open and closed conformations of domain I (Tellinghuisen et al., 2005, 
Love et al., 2009, Lambert et al., 2014, Sun et al., 2015, Ross-Thriepland and Harris, 2014b). 
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Figure 5.1 An overview of the detailed NS5A domain I structures. 
Ribbon diagram of the structure of domain I. The polypeptide chain is coloured from the N 
terminus (green) to C terminus (orange). β-sheets (B1-B3) and H2 of Subdomain IA are in green. 
β-sheets of Subdomain IB (B4-B9) are in orange. Cys 39, Cys 57, Cys 59 and Cys 80 are shown 
in red in Subdomain IA and the coordinated zinc atom is shown in yellow. The C-terminal 
disulphide bond is labelled. 
 
Of the four structures of domain I dimers, there are two dimeric forms from genotype 1b. One 
is NS5A (36-198) reported by Tellinghuisen in 2005 (Figure 5.2A) (Tellinghuisen et al., 2005). 
The crystal asymmetric unit (PDB accession code: 1ZH1) is composed of two identical domain 
I monomers in a dimeric conformation that forms a large, positively charged groove. This 
architecture reveals conserved external surfaces that might interact with other proteins, as 
well as a highly basic channel that might be involved in RNA binding (Lindenbach and Rice, 
2005). When this structure was computationally modelled with the N-terminal amphipathic 
helix on a phospholipid membrane, it was predicted that NS5A would be anchored to the 
membrane  such that the putative RNA binding groove was projected outwards in a manner 
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that could facilitate the binding of RNA, illustrated in (Tellinghuisen et al., 2005). Atomic 
absorption spectroscopy confirmed that domain I bound a single atom of zinc, whilst 
mutations in the tetracysteine motif abolished this interaction and abrogated genome 
replication in the SGR system. Zinc binding therefore appears to be essential for HCV RNA 
replication (Tellinghuisen et al., 2004).   
The second model of domain I of NS5A (33-202) also from genotype 1b was described in 2009 
by Love et al (PDB accession code: 3FQM) (Figure 5.2B) (Love et al., 2009). The association of 
the monomers within the dimer of NS5A (33-202) is significantly different from that in the 
previous structure of NS5A (36-198) (Tellinghuisen et al., 2005).  In NS5A (33-202), the long 
axes of the monomers are nearly parallel, with numerous interactions along the entire side of 
each monomer. The two N termini are found on the same end of the dimer (Figure 5.2B), 
implying a co-localisation of the two amphipathic N-terminal helices, and this is a feature 
shared with the previous structure (1ZH1). The polypeptide fold within each monomer of the 
dimer of NS5A (33-202) is very similar to that reported previously for NS5A (36-198); the zinc-
binding site displays the same coordination geometry as observed earlier. Interestingly the 
disulphide bond present in the Tellinghuisen et al. structure, between Cys142 and Cys190, was 
not present in this structure although the thiol groups remained in close proximity. The 
monomer-monomer interface of NS5A (33-202) features an extensive buried surface area 
involving the most-highly conserved face of each monomer. The two alternative structural 
forms of domain I now available may be indicative of the multiple roles emerging for NS5A in 
viral RNA replication and viral particle assembly. 
Subsequently another structural study, using a genotype 1a NS5A domain I, revealed two new 
dimeric forms of this domain (PDB accession code: 4CL1) (Figure 5.2C and D). One of them 
displays a similar interface to that previously reported in the Love’s model) (Love et al., 2009), 
but the orientation of one of the monomer is reversed creating a head-to-tail conformation, 
rather than head-to-head (Figure 5.2C) (Lambert et al., 2014). The other form shows an 
approximately twofold symmetry axis, composed of the monomers aligned in a head-to-head 
conformation (Figure 5.2D). The physical and chemical properties and the dimensions of the 
cleft between the head-to-head dimer match well with that of the daclatasvir (DCV) molecule, 
a new direct acting antiviral (DAA). The new dimer models observed in the genotype 1a NS5A 
structure not only extends our knowledge of interactional surfaces that could play a role in the 
action of symmetrical NS5A inhibitors, but supports the notion that NS5A dimers play a critical 
physiological role in the viral life cycle. 
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Figure 5.2 Summary of dimeric conformations of NS5A domain I from genotype 1b and 1a 
(1ZH1, 3FQM and 4CL1).  
Monomers are shown in red and blue. A and B are genotype 1b dimers, C and D are genotype 
1a dimers.  A. The first crystal structure from Tellinghuisen et al is NS5A (36-198) (Tellinghuisen 
et al., 2005). B. The second genotype 1b dimer NS5A (33-202) is juxtaposed in parallel from 
Love et al (Love et al., 2009). C. Two monomers from genotype 1a NS5A domain I crystal 
structure share the same interface as the Love et al. dimer shown in B but with the monomers 
in an antiparallel arrangement (Lambert et al., 2014). D. Monomers form an N-terminal, head-
to-head dimer fashion (Lambert et al., 2014). N-terminus of each dimer is in yellow and C-
terminus is in green. 
 
 
 
 
 
A B 
C D 
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These observations are consistent with the notion that the structure of the NS5A domain I 
monomer in each crystallographic form is highly conserved, but the different crystal 
asymmetric units present unique symmetrical dimer interfaces. These forms are hypothesized 
to assemble into a polymer network by alternating crystallographic interfaces (Love et al., 
2009, Lambert et al., 2014, Sun et al., 2015). However, to date there is no biochemical evidence 
for NS5A dimerization in infected cells. Indirect evidence provided by Lim et al demonstrated 
that NS5A dimerization, RNA binding and HCV replication are correlated (Lim et al., 2012). HCV 
RNA replication was greatly impacted when any of the cysteines (Cys-39, Cys-57, Cys59, and 
Cys-80) in the domain I is mutated, and these cysteine mutants of domain I failed to dimerize 
in vitro  (Lim et al., 2012). Hence, it is likely that the best or even a unique way to definitely 
demonstrate that NS5A dimerization is vital for HCV replication would be to identify specific 
inhibitors of NS5A dimerization and to test them for their capacities to block viral replication 
(Lim et al., 2012). Following that, other indirect evidence comes from the observations that 
daclatasvir (DCV) is symmetrical and can dock across the dimer interface of domain I between 
and under the 28-35 loops to disrupt the natural packing of the NS5A N termini (Tellinghuisen 
et al., 2005, Sun et al., 2015). DCV resistance mutations, which are typically smaller amino acids 
(L31V, Y93H) (Fridell et al., 2010), partially compensate for the DCV-induced disturbance and 
are able to restore HCV replication function in the presence of bound inhibitors. However, 
synergistic binding of the NS5A inhibitor analogue (Syn-395) can potentiate the effect of DCV 
to introduce a conformational change that resensitizes the resistant NS5A towards inhibition 
(Sun et al., 2015). In addition, investigation of NS5A phosphorylation also put forward that 
S146 phosphorylation of NS5A might affect the NS5A conformation  at the point of 
dimerization or be involved in switching between open conformation and closed conformation 
(Ross-Thriepland and Harris, 2014b). Although the relationship between dimerization and 
phosphorylation needs to be further investigated,  all these findings provide indirect evidence 
of a dimeric structure for domain I. Up to date, all the research about dimerization and RNA 
binding ability of NS5A domain I are focused on in vitro analysis. It lacks direct evidence about 
how domain I behaves in cell culture to support this hypothesis. 
In the previous chapter, I presented data demonstrating that domain I plays roles in HCV 
assembly by affecting the recruitment of NS5A to the assembly site-Lipid Droplets. In order to 
investigate the molecular mechanism of the recruitment, I performed biochemical analysis 
focused on dimeric notion and RNA binding of domain I. Moreover, these results in vitro were 
applied to cell cultures to demonstrate further. In addition, effects of these mutations in 
protein- protein interactions of NS5A were investigated in Chapter 6. Utilizing this information, 
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this chapter will present the dimerization and RNA binding activity of V67A and P145A using 
in vitro purified domain I proteins and try to verify them in HCV infected cell cultures. 
5.2 Results  
5.2.1 Purification of NS5A domain I  
5.2.1.1 Cloning of NS5A domain I ORF into pET28a-SUMO expression vector 
Domain I ORFs spanning from 35 to 215 amino acids were amplified from JFH1 virus constructs 
and cloned into pET28a-SUMO vector. These recombinant constructs will be referred to 
pET28a-SUMO-Domain I and result in the expression of the His-SUMO tagged NS5A domain I 
fusion protein (His-SUMO-Domain I). Following cleavage of the His-SUMO tag with SUMO 
protease, two non-native residues (Gly-Ser) remained at the N-terminus of domain I. A 
schematic representation of pET28a-SUMO-NS5A-Domain I is shown in (Figure 5.3). 
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Figure 5.3 Strategy for construction and purification of NS5A domain I. 
NS5A domain I  fragments  flanked with BamHI and XhoI were amplified from JFH1 virus 
constructs and cloned into pET28a-SUMO vector, which express His-SUMO tagged  domain I 
under the induction of IPTG in BL21 PLysS competent E.coli. Fusion protein His-SUMO-Domain 
I will be purified using His trap column followed cleavage with SUMO protease. Post second 
round of His Trap column, native NS5A domain I was harvested.  
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5.2.1.2 Optimization of expression of HCV NS5A domain I  
His-SUMO-Domain I was expressed in BL21 plysS cells by IPTG induction at 18°C for 6 hours at 
different concentrations. Cells were harvested by centrifugation and resuspended in lysis 
buffer. Post sonication, cell lysates were clarified by centrifugation at 18,000 rpm for 1h at 4°C. 
Both supernatants and pellets were subjected to SDS-PAGE analysis. This result showed that 
His-SUMO-Domain I was well expressed in the soluble fractions after the induction with 0.1 
mM IPTG, although there was a large amount of insoluble His-SUMO-Domain I (Figure 5.4). 
The predicted molecular weight of His-SUMO-Domain I is 34 kDa. 
 
Figure 5.4 Optimization of conditions for expression of His-SUMO-Domain I. 
IPTG with different concentrations (0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM) were used for 
induction of the expression of His-SUMO-Domain I (34 KDa) at 18°C for 6 h. Bacterial cell lysates 
were harvested by centrifugation and lysed in lysis buffer for sonication. Both supernatant and 
inclusion body pellet after centrifugation were analysed by SDS-PAGE and Coomassie Brilliant 
Blue staining. Lane 1: Un-induced supernatant, Lane 2-6: Supernatants after induction with 
0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM IPTG; Lane 7: Un-induced inclusion body pellet, Lane 
2-6: Inclusion body pellet after induction with 0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM IPTG.  
 
5.2.1.3 Purification of NS5A domain I  
Following expression of His-SUMO-Domain I, HisTrap™ HP was used to purify His-SUMO-
Domain I from supernatant of bacterial cell lysates. HisTrap™ HP is a prepacked, ready-to-use 
column for the preparative purification of His-tagged recombinant proteins by immobilized 
metal affinity chromatography (IMAC). HisTrap™ HP was firstly pre-equilibrated with wash 
buffer and then loaded with clarified and filtered supernatants of bacterial cell lysates allowing 
His-SUMO-Domain I binding to Ni+ resin and let the unbound proteins go through from the 
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column. After 3 washes with wash buffer (each 5x the column volume), bound His-SUMO-
Domain I in column was eluted using elution buffer (Figure 5.5). 
Eluted fractions of His-SUMO-Domain I  were dialysed in dialysis buffer (20mM Tris, pH8.2, 
150mM NaCl, 10% glycerol) together with His tagged SUMO protease to cleave His-SUMO tag 
at 4°C overnight. For further purification of NS5A domain I to separate the fully cleaved domain 
I from fusion protein His-SUMO-Domain I, His-SUMO and SUMO protease (His tagged), these 
mixtures were centrifuged to remove the precipitates and clarified supernatants were loaded 
onto a pre-equilibrated HisTrap™ HP for second round of purification by collecting flowthrough 
and wash fractions containing native domain I protein (Figure 5.5). Fractions containing 
cleaved domain I were concentrated using Amicon® Ultra Centrifugal filters (10,000 NMWL). 
All of these processes resulted in the purification of a ~ 21-kDa protein (the correct predicted 
molecular weight for NS5A domain I) when visualised by SDS-PAGE and Coomassie staining 
(Figure 5.5). 
 
Figure 5.5 Expression of His-SUMO-Domain I and removal of the His-SUMO tag. 
Purification of SUMO protease cleavage of His-SUMO-Domain I resulted in the release of 
soluble NS5A domain I with an apparent molecular weight (MW) of 21kDa. SDS-PAGE showed 
the purification of His-SUMO-Domain I by HisTrap™ HP affinity chromatography and cleavage 
of His-SUMO-Domain I with SUMO protease to release NS5A domain I. Lane 1 : Input of 
induced supernatant; Lane 2: Flowthrough; Lane 3-9: Wash fractions with 20 mM imidazole; 
Lane 10-11: Eluted fractions with 250 mM imidazole; Lane 12: pooled fractions of eluted before 
SUMO protease cleavage;  Lane 13: SUMO protease; Lane 14-15: Cleavage with SUMO 
protease; Lane 16: Floughthrow containing cleaved domain I; Lane 17: Wash fraction 
containing cleaved domain I; Lane 18: Pooled and concentrated domain I from  Lane 16 and 
17. 
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5.2.1.4 Characterization of domain I by mass spectrometry  
Purified domain I protein was analysed using mass spectrometry to confirm its identity. 
Domain I exhibited 100% coverage of the known domain I sequence (Figure 5.6), confirming 
that NS5A domain I was expressed correctly and could be used for further analysis. 
 
Figure 5.6 Identification of protein ID.  
Protein peptides digested by trypsin were analysed by mass spectrometry and then compared 
with the known expressed protein sequence and protein database. The sequence at the top is 
the translated domain I amino acid sequence. A series of peptides below in blue are the 
digested domain I fragments for mass spectrometry. 
 
5.2.1.5 Size exclusion chromatography  
After removal of the His-SUMO tag and SUMO protease, further purification of NS5A domain I 
was aimed to remove protein contaminants and to analyse the oligomeric status of domain I. 
To achieve this, size exclusion chromatography (SEC) was carried out. The principle of SEC is 
based on the size of the protein that larger proteins and multimers are eluted first as they 
cannot enter the pores in the beads and pass straight through the column; smaller proteins 
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are eluted afterwards as they interact with the pores in the beads and take longer time to pass 
through  the column. 
The size exclusion column was equilibrated in gel filtration buffer overnight and then domain I 
protein was concentrated to 5ml and injected into Kata column. The column was run at a flow 
rate of 2ml/min, fractions were collected from around 90ml until a full column volume of buffer 
(~320ml) had eluted (Figure 5.7A). Three peaks of protein were observed and the fractions 
from each peak were analysed by SDS-PAGE (Figure 5.7B). The result demonstrated that all the 
fractions from three peaks (1-3) contained domain I protein. For Peak 3, it should be 
monomeric domain I (~20 kDa), which is expected and can be used for further analysis. 
However, peak 1 and 2 also exhibited in domain I, which suggested domain I can form into 
different oligomers. As NS5A domain I is dimeric in vitro as reported previously (Tellinghuisen 
et al., 2005, Love et al., 2009, Lambert et al., 2014) , it could be speculated that fractions of 
peak 2 might be dimers of domain I. Whereas,  peak 1 that was eluted first is more likely to 
represent the aggregation of domain I, as domain I protein is not stable in the solution and 
precipitates at room temperature. 
The limitation of SDS-PAGE is its denaturation of proteins prior to electrophoresis so that 
protein binding interactions and oligomeric protein generally cannot be determined on 
proteins isolated by SDS-PAGE. To further determine the nature of forms of domain I protein, 
pooled fractions from peaks 1 to 3 were analysed by native gel, which can assay native protein 
properties. Surprisingly, all of the peaks contained three different forms of Domain I after 
native gel electrophoresis (Figure 5.7C).  This result suggested that domain I of NS5A co-exists 
in three different forms - precipitates (Figure 5.7C-III), dimers (Figure 5.7C-II) and monomers 
(Figure 5.7C-I), consistent with the observations in SEC analysis. For proteins from Peak 1, it 
contained precipitates, dimer and monomer of domain I as well two non-specific proteins 
eluted; proteins from Peak 2 were also separated in three forms including precipitates, dimer 
and monomers but dimer was predominant; Whereas, Peak 3 which was predicted as 
monomer showed in common with Peaks 1 and 2 comprising more dimeric forms than 
monomeric domain I.  
To summarize, dimer of domain I is predicted to be the predominant and natural status of NS5A 
domain I in vitro as monomeric domain I tends to dimerize and the proportion of dimer in Peak 
3 is significantly more than other two forms (Figure 5.7C). This suspicion was confirmed by SEC-
MALLS in next section (Figure 5.8). Nevertheless, how it behaves in vivo, still remains unclear.  
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Figure 5.7 Size exclusion chromatography of the cleaved domain I  
A. The absorbance peaks at 280nm (A280) indicated protein eluted mainly in 3 peaks: protein 
of Peak 1 eluted at 114mL, which might be oligomer of domain I; protein of Peak 2 eluted at 
150 mL; protein of Peak 3 eluted at 180mL. B. SDS-PAGE analysis of fractions from SEC with 
each peak labelled. NS5A domain I, 20kDa, appeared in all fractions analysed. Fractions from 
Peak 3 (about 170-190ml at elution volume) were polled together and analysed by SEC-MALLS 
(see Figure 5.8) C. Native gel analysis of protein from each labelled SEC peak. Asterisks in red 
indicated three forms of domain I protein in common in three peaks. I is the monomeric 
domain I, II is dimeric and III might be the aggregated domain I. 
A 
B 
C 
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5.2.1.6 Analysis of domain I by SEC-MALLS 
When light passes through a medium such as a solvent, even a transparent one, interaction 
with the molecules leads to scattering of the axis of the light beam. This may be observed by 
a sensitive detector and its intensity measured at different angles to the beam. If a solute of 
different refractive index is present this will lead to excess scattering dependent on the 
concentration of solute but also on its molar mass and for large particles, on the scattering 
angle. In a suitably calibrated system, this may be used to determine the molar mass of the 
solute.  Based on this principle, the combination of Size Exclusion Chromatography with Multi-
Angle Laser Light Scattering analysis (SEC-MALLS) - is a technique for determining molar mass 
in solution, overcoming the limitations of column calibration. 
Protein pooled from Peak 3 fractions in the last step was analysed by SEC-MALLS to confirm 
the exact molecular weight of different domain I forms. As suspected, LS (light scattering) peak 
at Peak 1 at the void volume (5min) showed that this is likely to represent aggregates of domain 
I. LS (light scattering), UV (ultraviolet) and dRI (differential refractive index) peaks overlapped 
at about 11.5min means that protein in this form is of good quality and solubility (Figure 5.8). 
Combining these factors, molecular weight of this form of domain I was determined 
approximately at 44kDa ±11.522%, suggesting that this is a dimer of domain I.  Whereas, 
protein under SEC-MALLS is the fraction from Peak 3 in SEC (5.2.1.5) which was previously 
predicted as monomer. Intriguingly, SEC-MALLS did not detect the signal of protein around 20 
kDa.  It might be due to the low proportion of monomeric domain I (Figure 5.7 C-I), or the 
monomer has dimerized into dimeric domain I.  
Combining these observations in section 5.2.1.5 and 5.2.1.6 together with previous research 
of NS5A domain I, I speculate that dimer is the natural unit of domain I in vitro as monomer of 
domain I is not stable in nature and tend to dimerize, whereas it needs to be further 
investigated whether NS5A is dimeric in its life cycle (replication complex formation, RNA 
replication, budding, viral assembly, etc.). 
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Figure 5.8 SEC-MALLS analysis of purified domain I to determine the molecular weight. 
A. SEC-MALLS chromatogram of SEC peak 3 (Figure 5.7) purified NS5A domain I. LS peak 1 
observed at the void volume (5 min) indicated the degree of aggregation of protein; LS, UV and 
dRI peaks at 11.5 min is the main formation of domain I, which can be used to calculate the 
correct molecular weight of domain I showed in B. Alignment of the LS, UV and dRI peaks, and 
a correct molecular weight (MW) was calculated (MW=MW= 44.4 kDa±11.522%). LS: Light 
scattering; UV: Ultraviolet; dRI: Differential refractive index; QELS: Quasi elastic light scattering; 
aRI: absolute refractive index. 
A 
B 
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5.2.2 Purification of domain I of mutants  
5.2.2.1 Expression and purification of mutated domain I  
NS5A domain I ORF spanning from 35 to 215aa with corresponding single mutation (P35A, 
V67A and P145A) was amplified from JFH1 mutants (see 4.2.1) and cloned into pET28a-SUMO 
vector to generate pET28a-SUMO-Domain I expression plasmids. Following the same 
expression and purification protocol of wildtype, domain I of P35A, V67A and P145A were 
purified and analysed by SDS-PAGE (Figure 5.9A) and western blot using NS5A polyclonal 
antibody (Figure 5.9B).  
 
 
Figure 5.9 Expression of WT and domain I mutants  
Purification of domain I (35-215) with corresponding mutations analysed by SDS-PAGE (A) 
western blot (B) using an anti-His antibody. All domain I proteins are of the correct size 
(~20kDa). 
 
5.2.2.2 Purification of His tagged domain I and GST tagged domain I  
SEC-MALLS result above suggested that domain I of NS5A is a dimeric protein, GST pull down 
assay was conducted to visualize whether domain I mutants could dimerize. To set up GST pull 
down assay, GST tagged domain I and His tagged domain I needed to be constructed and 
purified. Domain I ORFs flanked with BamHI and XhoI spanning from 35aa to 249aa were 
amplified from mJFH1 virus constructs. After digestion with BamHI and XhoI, domain I 
fragments were ligated into either His-SUMO vector or pGEX-6p-2 vector to generate 
recombinant constructs that can express His-SUMO-Domain I and GST-Domain I.  
A B 
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Expression of His-SUMO tagged and GST-tagged domain I proteins were performed in the BL21 
(PlysS) strain of E. coli after induction with 0.1mM isopropyl -D-thiogalactopyranoside (IPTG).  
They were purified following the protocol described in section 2.7.5. Purified His-SUMO-
Domain I (His-SUMO-DI) and GST-Domain I (GST-DI) with their corresponding mutations were 
analysed by western blot using anti-His and anti-GST monoclonal antibodies (Figure 5.10). 
                                     
                     
Figure 5.10 Expression of WT and domain I mutants for GST pull down assay  
A. Purification of His-SUMO-Domain I (35-249) analysed by western blot using an anti-His 
antibody. B. Purification of GST control protein and GST-Domain I (35-249) analysed by western 
blot using an anti-GST antibody.   
 
5.2.3 Characterization of dimerization of domain I  
5.2.3.1 GST pull down assay 
NS5A has also been reported to dimerize, both in the published crystal structures and in 
biochemical analyses (Lim et al., 2012). Examination of the different dimer structures revealed 
that P35 was located at the dimer interface of the ‘open’ conformation (Lambert et al., 2014, 
Love et al., 2009, Tellinghuisen et al., 2005). P145 was located at the interface of the ‘closed’ 
conformation (Lambert et al., 2014, Love et al., 2009, Tellinghuisen et al., 2005, Ross-
Thriepland and Harris, 2014b). In contrast, V67 was distal to the dimer interfaces in both 
A 
B 
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conformations (Figure 5.11). Note that these mutants were initially selected to be on the 
surface of the domain I monomer (see section 3.2.1). 
 
Figure 5.11 Summary of the position and potential role of domain I mutants.   
The two different dimeric conformations of NS5A domain I are shown, “open” (1ZH1) (left, 
blue/red) (Tellinghuisen et al., 2005) and “closed” (3FQM) (right, grey/red) (Love et al., 2009). 
P35 highlighted in aquamarine is located in the P29-P35 interaction loop of NS5A dimers in the 
open conformation; V67 in green is exposed on the surface of both dimer structures; P145 in 
burlywood is at the interaction surface of the closed dimer.  It is likely that P35 can interact 
with A92 (orange) from the other monomer that is involved in dimerization of the open 
conformation. P145 and A146 in the closed dimer face each other across the interaction 
surface and could possibly exert an effect on dimer interactions. 
 
To test the effects of the three mutations on dimerization, I conducted GST pull down assays 
using GST-tagged domain I as bait to precipitate His-tagged domain I. We observed that GST-
domain I (WT), but not GST alone, precipitated His-Domain I (WT) which means that domain I 
can dimerize (Figure 5.12A).  Firstly, His-tagged domain I (WT) was incubated with GST-Domain 
I mutant, separately. Both GST-Domain I-P35A and V67A could precipitate His-tagged domain 
I (WT), while GST-Domain I (P145A) failed (Figure 5.12).  
Next was to investigate whether these three mutants could dimerize without presence of 
wildtype domain I. Similar level of His-Domain I proteins was used as input. Then GST pull down 
assays described above were conducted using GST or mutated GST-Domain I as baits and 
corresponding mutated His-Domain I NS5A as preys. Compared with WT, GST-Domain I (P35A) 
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was also able to precipitate His-Domain I (P35A) with a modest but non-significant reduction 
in binding. In contrast, both V67A and P145A mutant GST-Domain I proteins were significantly 
inhibited to precipitate the cognate His-Domain I proteins (Figure 5.13A and B), indicating that 
these two residues are required for dimerization of domain I and implicating a role for NS5A 
dimerization in virus assembly. The faint band of His-Domain I in P145A lane (Figure 5.13A) 
might be due to the inadequate wash of the glutathione beads in this trial, as His-Domain I of 
P145A could not be detected in the repeated trials. 
 
 
Figure 5.12 Domain I of P145A fails to dimerize with WT domain I. 
A. His-tagged domain I (WT) was used as prey in pull down assays with GST or GST-Domain I 
with corresponding mutations as baits. Precipitated proteins were analysed by western blot 
using anti-His and anti-GST antibodies.  B. The His:GST ratio was calculated following 
quantification of western blot signals using a Li-Cor Odyssey Sa infrared imaging system and 
represented graphically as a measure of the dimerization activity. ** indicates significant 
difference (P<0.01) from WT. 
B 
 
 A 
 A 
A
 
 A 
 A 
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Figure 5.13 Residues at positions V67 and P145 of domain I are involved in NS5A 
dimerization. 
A. His-tagged domain I proteins with mutations was used as prey in pull down assays incubated 
with corresponding GST-Domain I proteins. Precipitated proteins were also analysed by 
western blot using anti-His and anti-GST antibodies. B. Quantification of His to GST signals 
using a Li-Cor Odyssey Sa infrared imaging system and represented graphically as a measure of 
the dimerization activity.  These data were representative of three independent experiments 
using different batches of purified domain I proteins. ** indicates significant difference 
(P<0.01) from WT. 
A
 
 A 
B
 
 A 
Chapter 5: Biochemical analysis of domain I 
140 
 
5.2.3.2 Identification of dimerization by SEC-MALLS 
The combination of both GST-pull down assay and SEC-MALLS (Figure 5.8 and 5.12) revealed 
that WT NSSA domain I was able to dimerize in vitro. However, the GST pull down assay 
revealed a defect in dimerization for V67A and P145A (Figure 5.13). To support the pull down 
assay result, purified domain I of P145A was analysed by SEC-MALLS in parallel with WT (Figure 
5.8 in Section 5.2.1.6). As shown in Figure 5.14, P145A exhibited a very different profile to WT. 
Even the accurate molecular weight could not be determined, the main peak of domain I 
(P145A) at 16 min eluted later than WT (at 11.5 min) for 4 minutes, which means that the size 
of P145A domain I is much smaller than WT. Therefore, it was concluded that the predominant 
form of P145A was a monomer, which is consistent with the GST pull down assay in section 
5.2.3.1 (Figure 5.13).  
 
       
Figure 5.14 SEC-MALLS verifies that P145A disrupts dimerization of domain I.  
SEC-MALLS chromatogram of purified domain I (35-215) (WT) (A) and domain I (35-215) 
(P145A) (B). A. LS peak at the void volume (5 min) indicated the level of aggregation, the 
multiple LS, UV and dRI peaks at 11.5 min with 44kDa exhibited the main form of domain I 
(WT) –Dimer (see details in Figure 5.8A). B. Domain I (P145A) aggregated and the peak came 
out at 5min as well, main UV and dRI peaks exhibited at 16min, later than WT domain I.  
 
 
A
 
 A 
B
 
 A 
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5.2.4 Dimerization of domain I in cell cultures  
To the best of our knowledge, despite the fact that X-ray crystallography data showed that 
NS5A domain I was a dimer in vitro as early as 2005 (Tellinghuisen et al., 2005, Love et al., 
2009, Lambert et al., 2014), in 12 years of research since then no-one has been able to 
demonstrate that NS5A dimerizes in intact cells. Dimerization has only been convincingly 
shown using purified proteins in vitro (Lim et al., 2012).   
I did attempt to identify dimerization in cultured cells using a variety of approaches. Firstly, 
Huh7.5 cells stably harbouring the SGR-Neo-JFH1 (Figure 5.15, Lane 2) or SGR-Neo-JFH1 
(NS5A- OST) (Figure 5.15, Lane 3) replicons that can stably express NS5A, were electroporated 
with mSGR-Luc-JFH1(GFP). The other is the transient electroporation assay, in which both 
mSGR-Luc-JFH1 (GFP) and pCMV10-NS3-NS5B (Figure 5.15, Lane 4) or mSGR-Luc-JFH1 RNA 
(Figure 5.15, Lane 5 and 6) were co-electroporated or co-transfected (Figure 5.15, Lane 7) into 
Huh7.5 cells. If dimerization of NS5A occurs in vivo, GFP-NS5A expressed from mSGR-Luc-JFH1 
(GFP) replicon and untagged NS5A from pCMV10-NS3-NS5B or mSGR-Luc-JFH1 replicon would 
dimerize with each other in the replicons cultured cells. In this case, cell lysates of each sample 
harvested 72 hpe or 48 hpt were subjected to GFP pull down assay following the GFP-Trap® 
(ChromoTek) protocol so that GFP tagged NS5A (GFP-NS5A) together with its interacting 
partners can be precipitated and detected with α -NS5A antibody (Sheep). The result of input 
panel suggested that both electroporation and transfection of mSGR-Luc-JFH1 (GFP), mSGR-
Luc-JFH1 and pCMV10-NS3-NS5B were successful as both GFP-NS5A and untagged NS5A were 
detected by western blot (Figure 5.15 upper panel). However, post GFP-Trap, only GFP-NS5A 
can be detected from the precipitates, so it cannot be concluded that NS5A dimerises in vivo.   
The explanation of this result might be that a minor proportion of cells were successfully 
transfected with both constructs for dimerization.  If it cannot be guaranteed that NS5A are 
expressed in the same cell, it is impossible for them to interact with its dimerizing partner- 
monomer NS5A with the other tag. This is also the major limitation of the research into NS5A 
dimerization in cells, which is urgent for construction of platform to investigate mechanism of 
dimerization.  
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Figure 5.15 Lack of NS5A dimerization in intact cells.  
A modified version of mSGR-Luc-JFH1 containing a GFP tag near the C-terminus of domain III 
of NS5A (termed mSGR-Luc-JFH1(GFP)) was a kind gift from John McLauchlan (Jones et al., 
2007b).  In vitro transcribed mSGR-Luc-JFH1(GFP) RNA was electroporated into Huh7.5 cells 
(lane 1), or Huh7.5 cells stably harbouring the SGR-Neo-JFH1 (Kelly et al., 2017) (lane 2) or SGR-
Neo-JFH1(NS5A- OST) (Goonawardane et al., 2017) (lane 3), or co-electroporated with either 
pCMV10-NS3-NS5B plasmid (lane 4) or mSGR-Luc-JFH1 RNA (lanes 5. 6) into Huh7.5 cells.  
Alternatively, DNA constructs of both pCMV10-NS3-NS5B (GFP) (GFP tagged NS5A) and 
pCMV10-NS3-NS5B were co-transfected into Huh7.5 cells (lane 7).  Cells were harvested into 
GLB at 72 hpe or 48 hpt and subjected to GFP pull down assay following the GFP-Trap® 
(ChromoTek) protocol. After GFP-Trap, protein bound on beads (lower panel) together with 
input samples (upper panel) were analysed by western blot using anti-NS5A antibody.   
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5.2.5 V67A and P145A increased binding affinity to HCV 3’UTR 
Implicit in the above scenario is the specific interaction of NS5A with genomic RNA.  In this 
context, domain I has been shown by us, and others (Foster et al., 2010, Huang et al., 2005, 
Hwang et al., 2010), to bind specifically to the HCV 3’UTR. RNA binding activity was supported 
by the “open” dimeric structure, as it provides an attractive groove for RNA-binding. The 
protein ‘arms’ extending out past this groove are more acidic, and might serve to prevent RNA 
from exiting the groove (Tellinghuisen et al., 2005). Hence, dimerization and RNA binding of 
domain I is potentially linked. 
I therefore asked whether the three mutations affected this binding capacity. To address this, 
I expressed domain I WT and mutants as a His-SUMO fusion protein in E.coli. The fusion 
proteins were purified and cleaved to release the untagged domain I (Figure 5.9). The RNA 
binding capacity of the WT and mutant domain I proteins was determined by RNA filter binding 
assay utilizing 32P-labelled HCV 3’UTR RNA (Figure 5.16). Intriguingly, it was found that V67A 
and P145A showed strong binding affinity to HCV 3’UTR RNA, exhibiting a 10-20 fold increase 
in Kd value compared to WT or P35A, despite with the similar Rmax values (Table 5.1).  For WT 
and P35A the Kd values were 246.3 ± 77.19 nM and 245.7 ± 70.09 nM respectively. However 
for V67A and P145A, the values were 12.89 ± 6.25 nM and 22.35 ± 9.58 nM respectively (Table 
5.1).   
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Figure 5.16 Residues at positions V67 and P145 of domain I are involved in NS5A RNA 
binding.  
A. Filter binding analysis of the interaction between NS5A domain I and the HCV 3’UTR RNA. 
The indicated proteins were incubated with  32P -radiolabelled RNA (1nM), either HCV 3’UTR 
(upper panels) or control FMDV 3D aptamer (lower panel) (Foster et al., 2010), before 
application to a slot blot apparatus, filtering through nitrocellulose and Hybond-N membranes. 
Representative slot blot analysis of RNA-protein complexes captured on nitrocellulose 
membrane in a filter binding assay was visualized by phosphorimaging.  From left to right, the 
slots contained 0, 17, 34, 67.5, 125, 250, 500, and 1000 nM domain I protein. B. % RNA bound 
is shown graphically, quantified by phosphoimaging analysis. The data were fitted to a 
hyperbolic equation. These data were representative of three independent experiments using 
different batches of purified domain I protein. 
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  Kd,nM (mean ±SE) Rmax, % (mean ±SE) 
WT 246.3 ±77.19 26.84 ±3.225 
P35A 245.7±70.09 25.67 ± 2.841 
V67A 12.89±6.253 23.13 ± 1.378 
P145A 22.35±9.582 19.72 ±1.416 
 
Table 5.1 Binding of 3’UTR to NS5A domain I proteins is evaluated by filter binding assay. 
Rmax is the maximal percentage of RNA competent for binding, and Kd is the apparent 
dissociation constant. These data were from three independent experiments. 
 
To validate this in vitro data, NS5A was immunoprecipitated using α-NS5A antibody (sheep) 
from Huh7.5 cells electroporated with either JFH-1 WT or the three mutants and the amount 
of viral RNA in the immunoprecipitates was assessed by qRT-PCR. Consistent with the in vitro 
RNA filter binding assay data, both V67A and P145A bound more viral RNA compared to WT 
and P35A (Figure 5.17).  In contrast, a similar analysis of Core immunoprecipitates revealed 
significant reductions in the amount of genomic RNA bound to Core or LDs for V67A and P145A 
(Figure 4. 13).  Therefore, NS5A of V67A and P145A in virus transfected cells exhibited higher 
affinity to genomic RNA; as a result, less RNA was delivered from NS5A to viral nucleocapsid 
protein-Core for virus assembly.  
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Figure 5.17 V67A and P145A binds more genomic RNA in cells transfected with mutant virus. 
Huh7.5 cells were electroporated with in vitro transcripts of mJFH1 WT or the indicated 
mutants.  Cells were lysed at 72 hpe and NS5A was immunoprecipitated from cell lysates.  After 
washing the beads were subjected to analysis by western blot and RNA extraction. qRT-PCR 
were performed to quantify the level of (+) genome RNA bound to NS5A. The graph on the 
right shows the ratio of RNA copies to NS5A (n=2). *indicates significant difference (P<0.05) 
from WT, and ns indicates that there is no significant difference from WT. 
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5.2.6 DAA sensitivity 
As P35, V67 and P145 were located on the exposed surface of domain I, it was considered that 
these non-lethal mutants might be further involved in sensitivity to NS5A targeting DAAs, such 
as Daclatasvir (DCV). To quantify changes in DCV sensitivity for  P35A, V67A and P145A and to 
interrogate the drug-protein interaction surface, wild type and  mutants SGR replicons were 
electroporated into Huh7.5 cells and then were treated with 10 fold serial concentrations of 
Daclatasvir (from 10-4 pM to 107pM) at 4 hpe. After 48-hour treatment of DCV, cells were 
collected and the replication of each mutant was measured.  The fitness curve and EC50 of each 
mutant were calculated by Prism7 (Figure 5.18). Here EC50 result showed us that all the 
mutants shared the similar sensitivity to DCV compared with WT. 
 
 
Figure 5.18 Sensitivity of domain I mutants to DCV treatment is not altered. 
Huh7.5 cells were electroporated with the denoted mSGR-Luc-JFH1 WT and NS5A domain I 
mutants. Cells were treated with serial 10-fold dilutions of daclatasvir in 0.2% DMSO solutions 
4 hpe. After treatment for 72 hrs, cells were harvested in PLB and then luciferase activity was 
determined. EC50 curves and EC50 of each replicon were calculated using Graphpad Prism7. 
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5.3 Discussion  
5.3.1 Dimerization of domain I might be related to the virus assembly pathway  
In this study, it was determined via SEC and SEC-MALLS that WT NS5A domain I can exist as a 
dimer in vitro. Consistently, SEC-MALLS analysis of the NS5A domain I (33-202) by Ascher also 
showed that domain I assembles almost exclusively as dimers in solution (Ascher et al., 2014). 
Considering the specificity of mutations in its structures, it is possible to suggest that 
dimerization of domain I might be affected by the mutants. To test this, I performed GST pull 
down assay by using GST tagged domain I as bait to prey His tagged domain I, and if His tagged 
domain I could be detected, this means that domain I can be dimerized. In two parallel GST 
pull down assay with His-Domain I (WT) or mutated His-Domain I (WT) as preys, P35A showed 
WT level of dimerization despite modest inhibition with His-P35A, which is expected as it is 
indistinguishable in both RNA replication and virus production. Additionally, V67A showed 
different phenotypes when incubated with His-Domain I (WT) and His-Domain I (V67A), and 
P145A cannot dimerize with or without His-Domain I (WT) (Table 5.2). For such differences, we 
should look back to the position of these three residues, both P35A and P145A are located at 
the interfaces of dimers but with different interaction faces.  
For P35, it is on the head of domain monomer and dimerizes into 1ZH1 form by interaction 
with another non-P35 residue - A92 in the other monomer (Figure 5.11). When incubated with 
His-WT, A92 in GST-P35A could interact with P35 in His-WT domain I normally (Figure 5.12), 
but A92 showed modest reduction in interaction with A35 (P to A) from His-P35A (Figure 5.13). 
However, P145 residues from both monomers of the dimer face each other and both 
participate in the interface, which suggested that both P145 residues would be essential for 
interaction of monomers.  Although His-WT was used as prey, P145 in His-WT and A145 in GST-
P145A still can interact with each other, hence dimerization could not be compensated.  That 
is why P145A still cannot dimerize in presence of wildtype domain I while P35A can dimerize. 
Whereas in terms of V67A, it is surface exposed on the head in all four domain I dimeric 
conformations and not involved in dimer interactions. The mechanism of how V67A takes part 
in dimerization needs to be further demonstrated and to be supported by the characterization 
in cell cultures. Additionally, the model of domain I for structural analysis and hypothesis is 
informed by the dimeric domain I structures from genotype 1 because the structure of domain 
I from JFH1 (genotype 2a) has not yet been determined. Despite that the phenotypes of NS5A 
mutants cannot directly be extrapolated to other genotypes, it is worthwhile to take them as 
the targets within other HCV genotype like genotype 3 for further research in the future. 
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GST-WT GST-P35A GST-V67A GST-P145A 
His-WT 
++       
His-P35A 
++ +     
His-V67A 
++   
‒ 
  
His-P145A 
‒ 
    
‒ 
 
Table 5.2 Summary of GST pull down assay.  
‘GST- ’represents GST tagged domain I, the bait of GST pull down; ‘His-’ represents His tagged 
domain I, the prey of GST pull down. ‘++’ and ‘+’ indicate the positive binding between GST 
tagged domain I and His tagged domain I, but ‘+’ showed modest reduction in dimerization. ‘–
’ means they could not dimerize. 
Growing evidence suggested that dimerization of NS5A is related to RNA binding and 
replication (Tellinghuisen et al., 2004, Tellinghuisen et al., 2005, Lim et al., 2012), however it is 
interesting to speculate about the role of dimerization in virus assembly.  Intriguingly, it was 
reported that a small-molecule inhibitor of NS5A relocalizes NS5A from the ER to LDs in cells 
expressing a genotype 1b replicon (Targett-Adams et al., 2011), suggesting that the interaction 
between NS5A and LDs may also be regulated by NS5A conformation. In Targett-Adams 
research, they suggested that binding of the inhibitor to NS5A serves to lock, or alter, the 
conformation of the protein, rendering NS5A incapable of replication complex (RC) 
incorporation, resulting in the redistribution to LD surface. This hypothesis suggested that the 
conformation of domain I is important in the incorporation of NS5A into RC and assembly sites. 
Nevertheless, replication of V67A and P145A retained at a high level with a modest reduction 
compared with WT but cannot produce virus. Therefore, I propose that disruption of 
dimerization for V67A and P145A does not affect the formation of RC (Figure 5.19A). 
Furthermore, I propose that the monomeric NS5A cannot be recruited to core associated LDs 
as the monomeric domain I is not able to fit the interface between core proteins, in comparison 
with well-structured dimeric NS5A (Figure 5.19B and C). 
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Figure 5.19 Model of NS5A in replication complex and assembly sites. 
A. Formation of replicases including NS3 to NS5B of HCV together with genomic RNA in 
preformed RCs. B. Dimeric NS5A was recruited to core positive LDs –viral assembly sites. Well-
structured dimer can interact with core protein and fit into the interfaces between core 
proteins. C. Monomeric NS5A randomly goes into LDs sites but cannot interact with core 
proteins. 
 
5.3.2 RNA binding of domain I is key for NS5A shuttling from replication complex to virus 
assembly sites 
As mentioned, there is a correlation between dimerization and RNA binding (Lim et al., 2012). 
V67A and P145A abrogating dimerization of NS5A are expected to  further affect RNA binding 
activity, as NS5A has been demonstrated to bind the initiation site of negative-strand RNA 
synthesis, namely, the HCV genomic (positive-strand) 3’ UTR (Foster et al., 2010). To address 
this, the binding affinity for HCV positive-strand 3’ UTR RNA of domain I of either P35A, V67A 
and P145A or WT were assayed. 
A B
 
 A 
C
 
 A 
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Unlike the abrogation of RNA binding seen in previous research for the NS5A mutants that did 
not dimerize (Lim et al., 2012), V67A and P145A exhibited an increased binding affinity to HCV 
3’UTR. To some extent, this can make sense because V67A and P145A retained the ability to 
replicate which indicates that they should retain RNA binding activity. For the increased RNA 
affinity, it might be that the monomeric domain I without dimer interfaces has more surface 
exposed, which can allow more regions of domain I with affinity for RNA to bind more RNA. In 
other words, monomeric NS5A is much more flexible to interact with 3’UTR.  To validate this 
in vitro data, NS5A was immunoprecipitated from Huh7.5 cells electroporated with either JFH1 
WT or the three mutants and the amount of viral RNA in the immunoprecipitates was assessed 
by qRT-PCR. Consistent with the in vitro RNA filter binding assay data, both V67A and P145A 
bound more viral RNA compared to WT and P35A (Figure 5.17).  In contrast, a similar analysis 
of core immunoprecipitates revealed significant reductions in the amount of genomic RNA 
bound to core  or LDs for V67A and P145A (Figure 4.13).   
Taken collectively, these data suggest that NS5A binds specifically to the nascent genomic RNA 
but that during the assembly process this must be released to core. By increasing the affinity 
of NS5A for the 3’UTR RNA, these mutations are preventing this transfer. These observations 
lead us to conclude a model in which domain I of NS5A binds to the 3’UTR of nascent genomes 
and transports them from sites of replication to LD.  Here, analogous to the handing on of a 
baton in a relay race, the RNA is transferred to core and then subsequently transported to 
assembly sites. The latter remain to be unambiguously defined but may be endosomal 
membrane compartments (Mankouri et al., 2016, Lai et al., 2010). The enhanced binding of 
V67A or P145A to the 3’UTR RNA may prevent the release of RNA for transfer to core.  The LD 
distribution in cells infected with V67A or P145A at 72 hpe resembles that in wildtype at 12/24 
hpe (Figure 4.7), suggesting that these mutations might block the transition from genome 
replication to virus assembly. Furthermore, the loss of dimerization by these two mutants 
implies that, in contrast to the accepted model of an open NS5A dimer revealing a basic RNA-
binding groove, monomeric NS5A is able to bind RNA.  It tempts me to speculate that 
monomeric NS5A might transport nascent RNA to LDs, then dimerizes and releases the RNA to 
core. 
For the assembly of HCV particles, it is well accepted that lipid droplets are the important 
organelles. Firstly following synthesis on the ER, the core protein homodimerizes and is 
trafficked to cytosolic lipid droplets (LDs). After then, NS5A bound with genomic RNA will be 
recruited to core positive areas via interaction between NS5A and core protein (Figure 5.20) 
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(Lindenbach and Rice, 2013, Miyanari et al., 2007). Previously it was believed that 
determinants of NS5A for virus assembly are in its C-terminal unfolded domain (Appel et al., 
2008, Kim et al., 2011, Tellinghuisen et al., 2008a). Nevertheless, here it is pointed out that the 
N-terminal domain of NS5A -domain I - is also involved in viral assembly, which might be 
related to its dimeric structures and RNA binding activity for the first time.  
 
Figure 5.20 Model of NS5A in HCV assembly pathway. 
Post trafficking of core dimers to cytosolic lipid droplets (cLDs).  NS5A and viral RNA is shifted 
out of replication and translation, and towards virus assembly. The interaction of p7–NS2 
(Jirasko et al., 2010, Popescu et al., 2011, Jones et al., 2007a, Gentzsch et al., 2013) with 
NS3‑4A (Phan et al., 2011, Ma et al., 2008) recruits viral core protein to the site of virus 
assembly (Lindenbach and Rice, 2013). Picture is adapted from (Lindenbach and Rice, 2013).  
 
5.3.3 Involvement of domain I in daclatasvir induced inhibition of HCV assembly 
Although it is known that daclatasvir (DCV) specifically targets NS5A, particularly its domain I, 
the mechanism of DCV‘s action is unclear. Initially chemical genetics strategy has identified 
that action of inhibition of DCV is the suppression of virus replication via the inhibition of the 
formation of double-membrane vesicles (DMVs) (Gao et al., 2010, Berger et al., 2014). 
Following that, a novel insight into its mechanism was proposed that DCV could rapidly inhibit 
intracellular assembly of HCV virions by blocking transfer of the viral genome to assembly sites 
(McGivern et al., 2014, Boson et al., 2017). From the perspective of DCV, the block of virus 
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assembly is correlational with domain I dimeric structures and RNA binding. DCV has been 
reported to target domain I, as judged by the location of DCV-resistance mutations (e.g. L31M 
and Y93H). Firstly, the structure of DCV is symmetrical and has the greatest chemical 
complementarity when docked across the dimer interface of domain I between and under the 
28-35 loops to change the conformation of dimer and disrupt the natural packing of the NS5A 
N termini (Sun et al., 2015).  Secondly, the binding of DCV to NS5A domain I inhibits RNA 
binding of NS5A domain I (Ascher et al., 2014). In combination of these observations, the 
mechanism of NS5A inhibitors in interrupting HCV assembly pathways can be shared with why 
V67A and P145A abrogate virus assembly. 
In this point, I suspect that binding of DCV of NS5A and mutations of NS5A domain I exhibit 
the same effect on function of NS5A-blocking assembly of virions. Hence, it is necessary to 
confirm the sensitivity of V67A and P145A to DCV to check whether V67 or P145 is also 
involved in the binding of DCV to NS5A so that mutation of these residues result in the defect 
of HCV assembly. If residues V67 and P145 is involved in the action of DCV to HCV, mutation of 
them might enable V67A and P145A resistant with DCV. Previous modelling viral kinetics of the 
therapeutic response to DCV revealed a dual mode of action involving both suppression of viral 
RNA synthesis (RNA replication) and inhibition of viral assembly (Guedj et al., 2013). 
Measurement of HCV genome replication post treatment with DCV showed that V67A and 
P145A exhibited wild type level of DCV sensitivity, which suggested that V67A and P145A did 
not affect DCV’s inhibition of RNA replication. It is hard to confirm whether V67A and P145A 
are further involved in the effect of DCV on virus assembly as V67A and P145A have already 
been shown to be deficient in virus assembly.  
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6.1 Introduction  
It is well accepted that the roles of NS5A in the virus life cycle are dependent on the interaction 
with other viral and cellular proteins. Firstly, the precise role of NS5A in genome replication 
remains obscure, despite NS5A mediating binding to viral RNA, other NS proteins and 
interactions with various cellular factors, including vesicle-associated membrane protein-
associated proteins A and B (VAP-A, VAP-B), cyclophilin A (CypA) and phosphatidylinositol-4-
kinase IIIα (PI4KIIIα), which are required for HCV replication (Evans et al., 2004, Gao et al., 
2004, Goonawardane et al., 2017, Ngure et al., 2016, Berger et al., 2009, Hamamoto et al., 
2005). Secondly, Apolipoprotein E (ApoE), diacylglycerol acyltransferase-1 (DGAT-1), Annexin 
A2, cell-death-inducing DFFA-like effector B (CIDEB) and Rab18 in host cells can interact with 
NS5A to promote assembly of HCV particles. Of the proteins that NS5A interacts with, most 
involve NS5A domain III or unclear (Section 1.3.3). To further identify protein-protein 
interactions, I will firstly check the known NS5A-cellular protein interactions through Strep-
tagged NS5A pull down assay or proximity ligation assay (PLA).  
The introduction of the isotope-coded affinity tag (ICAT) was one of the milestones to isotopic 
chemical labelling for relative quantification of peptides/proteins with mass spectrometry 
(MS). Tandem Mass Tagging (TMT) is a quantitative proteomic approach, which allows the 
comparison of protein levels in up to 10 different samples in a single experiment. With this 
approach, it is possible to identify and quantitate thousands of proteins in a single experiment. 
Samples for TMT analysis are labelled, fractionated and analysed by Nano-LC MS. Protein 
quantitation is based on the median values of multiple peptides identified from the same 
protein, resulting in highly accurate protein quantitation between samples. Measuring protein 
changes between mutants with significantly different phenotypes and wildtype is one of the 
important tasks of proteomics.  
To understand the molecular mechanism underpinning the phenotype of the mutants of 
domain I, it can be explained by the roles of domain I in regulating interactions between NS5A 
and cellular proteins. To address this, affinity purification of One-Strep-tagged NS5A was used 
in conjunction with TMT quantitative proteomics analysis to compare the interactome of wild 
type and mutants of domain I after pull down assays from virus transfected cells by nano-LC 
mass spectrometry and quantitative proteomic analysis. The abundance ratio of the peptide 
for each samples were taken as the parameters for comparing with untagged WT and Strep-
tagged WT as negative and positive controls. After quantification, proteins reduced in 
abundance by between 2- and 100-fold were further investigated in the protein network. 
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6.2 Results  
6.2.1 Purification of One-strep tagged (OST) NS5A from virus transfected cells 
NS5A is known to be involved in numerous interactions with host proteins and pathways. As I 
have revealed that mutations (V67A and P145A) in domain I of NS5A disrupted virus assembly 
and caused disruption of dimerization of domain I. These changes of phenotypes are likely 
involved with changes of certain interaction of proteins. To address this gap in our 
understanding, I took advantage of the fact that domain III of NS5A is able to tolerate in-frame 
insertions with no effect on the functions of protein in virus RNA replication or assembly. 
Specifically, JFH1 full-length virus construct -mJFH1 (NS5A-OST) was utilized, in which NS5A C-
terminal was tagged with the One-Strep affinity tag (OST). Insertion of this short tag was shown 
not to affect virus replication (Figure 6.1A) and to provide a highly efficient purification strategy 
(Amako et al., 2009, Ross-Thriepland and Harris, 2014b). 
Purification of OST-NS5A was performed using strep tag resins (Strep-Tactin® Sepharose®) from 
cytoplasmic lysates harvested at 72 hpe. Purification of OST-NS5A from JFH1-OST (WT) cell 
lysates was initially followed the Strep tag purification protocol (IBA Lifesciences) and improved 
for other virus samples (Figure 6.1B). After enough washes, protein bound resins were 
analysed by western blot using anti-NS5A antibody (Figure 6.1C) and stored at -80 °C  for 
further analysis. 
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Figure 6.1 Purification of Strep Tagged NS5A (OST-NS5A). 
A. Both untagged JFH1 (WT) and OST tagged viruses with corresponding mutations were 
electroporated into Huh7.5 cells and fixed 48 hpe for IncuCyte ZOOM. Replication of OST 
tagged JFH1 viruses were determined by counting NS5A positive cells. B. 72 hpe, supernatants 
of JFH1-OST (WT) cell lysates were harvested in GLB and incubated with Strep tag purification 
resins, washed 5 times using wash buffer and then eluted by wash buffer supplemented with 
2.5 mM desthiobiotin. Fractions collected from each step were analysed by western blot using 
anti-NS5A antibody.  Lane 1: Input of cell lysates; Lane 2: flow through after incubation with 
Strep tag purification resins; Lane 3-7:  Wash fractions of resins; Lane 8-12: Elution fractions 
from resins; Lane 13: Resins after wash and before elution.  C. Strep tag resins after purification 
of each OST-JFH1 virus were analysed by western blot. 
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6.2.2 V67 and P145 are not involved in interaction between NS5A and DGAT1, Rab18 and 
ApoE 
In regards to virus assembly and NS5A protein, Diacylglycerol acyltransferase-1 (DGAT1) is one 
of the targets worthy of investigation. During virus assembly, it was shown that the trafficking 
of NS5A to LDs depends on catalytical activity of DGAT1 (Camus et al., 2013) . DGAT1 could 
form a complex with NS5A and core and facilitates the interaction between both viral proteins. 
Our previous results exhibited that NS5A of V67A and P145A failed to interact with core protein 
and be recruited to LDs. Then I analysed the pooled NS5A protein complexes bound to Strep 
tag beads by western blot using both anti-NS5A and anti-DGAT1 antibodies to check whether 
NS5A of V67A and P145A could co-precipitate with DGAT1. Compared to untagged WT and 
tagged WT, all the mutants (P35A, V67A and P145A) still kept interaction with DGAT1 (Figure 
6.2A, upper panel), whereas P35A exhibited a lower interaction level.  
The other target is Rab18, which is also known to associate with LDs and promote physical 
interaction between LDs and ER membranes through a direct association between NS5A and 
the active, GTP-bound form of Rab18. Rab-18 promoted interaction between HCV 
membranous webs and LDs might enhance virion assembly by bringing sites of replication in 
close physical proximity to sites of virion assembly. In this case, here we also verified that it is 
not this pathway that V67A and P145A disrupted as both mutants showed WT level of 
interaction with Rab18 by check the NS5A co-precipitates (Figure 6.2A, lower panel). 
Very-low-density lipoprotein (VLDL) pathway has been shown to play a role in the assembly 
and maturation of infectious virus particles (Huang et al., 2007a, Gastaminza et al., 2008). 
Apolipoprotein B (ApoB), Apolipoprotein E (ApoE) and microsomal triglyceride transfer protein 
are required for the assembly of VLDV assembly (Huang et al., 2007a, Jiang and Luo, 2009). In 
this pathway, apoE can be recruitment by NS5A for the assembly and release of infectious viral 
particles. It was previously reported that mutants of NS5A domain I at 99-101 and 102-104 
disrupted the ApoE-NS5A interaction and showed a defect in viral assembly (Benga et al., 
2010a). Hence, PLA assay was conducted to check whether V67A and P145A of domain I failed 
to interact with ApoE. Here we can clearly notice that domain I mutants (P35A, V67A and 
P145A) and mJFH1 (WT) are indistinguishable in the level of interaction between ApoE and 
NS5A (Figure 6.2B). 
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Figure 6.2 V67A and P145A exhibited WT level of interaction with DGAT1, Rab18 and ApoE. 
A. JFH1-OST RNA constructs were electroporated into Huh7.5s. Cell lysates were harvested 72 
hpe and Strep tagged HCV NS5A from Huh7.5 cells was purified by using Strep tag pull down 
assay. Co-precipitated DGAT1 or Rab18 with NS5A were detected by western blot with 
respective antibodies. C is the JFH1 negative control without OST. B. Interaction of NS5A and 
ApoE in Huh7.5 cells studies with proximity ligation assay (PLA). Post electroporation of  mJFH1 
transcripts of either mutants or WT, cells were seeded onto coverslips and incubated for 72h 
prior to fixation, immunostaining for NS5A (mouse monoclonal antibody) and endogenous 
ApoE (Rabbit polyclonal antibody), followed by PLA probes minus and plus, ligation and rolling-
circle amplification (RCA). The hybridization probes were labelled with Alexa 555 (red), and the 
nuclei were counterstained with DAPI (blue). Scale bar represents 20μm. For each experiment, 
the PLA signals (counts per well) of each sample were counted using Imaris, from a minimum 
of 20 cells. 
A 
B 
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After pull down from each mutant virus transfected cells using Strep-Tactin® resin, strep tagged 
NS5A (OST-NS5A) bound with the Strep-Tactin® resin was then send for tandem mass tagged 
(TMT) mass spectrometry (TMT-MS) (University of Bristol) to analyse NS5A interacting 
partners. And the untagged JFH1-WT incubated resin was taken as the negative control. Here 
the TMT-MS result was consistent with what we observed above (Table 6.1), NS5A from either 
WT or mutants retained the interaction with DGAT1, Rab18 and ApoE. Intriguingly, P35A 
showed a reduction in the interaction with DGAT1, Rab18 and ApoE compared with V67A and 
P145A. 
Description 
Abundance Ratio 
OST-WT:WT 
OST-P35A:OST-
WT 
OST-V67A:OST-
WT 
OST-P145A:OST-
WT 
DGAT1 2.70 0.52 1.26 1.81 
ApoE 3.05 0.53 1.02 1.99 
Rab18  3.07 0.53 1.24 2.67 
 
Table 6.1 Characterization of interacting partners (DGAT1, ApoE and Rab18) of NS5A from 
tandem mass tagged (TMT) mass spectrometry (TMT-MS) (University of Bristol).  
Abundance ratio is the ratio of protein abundance between Strep tagged JFH1-WT (OST-WT) 
pull down to the untagged  JFH1-1 (WT) beads control, or the ratio of abundance of  Strep 
tagged JFH1 mutants (OST-P35A, OST-V67A and OST-P145A) to JFH1-WT (OST-WT). An 
abundance ratio of OST-WT: WT ≥1.5 were considered to have been specifically pulled down 
by NS5A. 
 
6.2.3 Potential mechanism of NS5A domain I involved  
To identify cellular candidates that are potentially involved in the P35A, V67A and P145A 
phenotypes, bound fractions following affinity purification from cytoplasmic lysates of Strep-
tagged wildtype (OST-WT), P35A (OST-P35A), and V67A (OST-V67A) and P145A (OST-P145A) 
NS5A together with untagged  wildtype were analysed by mass spectrometry. A great number 
of known NS5A interacting proteins were identified by this approach. These proteins had at 
least two high confidence peptide matches per protein (p <0.05). After a series of comparisons 
of abundance of interacting partners between WT and mutants or negative control (Untagged 
JFH1) (Figure 6.3), interaction networks that NS5A domain I mutant is involved in was 
determined. 
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Figure 6.3 Flow chart of comparative analysis of NS5A-interacting proteins involved by 
domain I mutants (P35A, V67A and P145A). 
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6.2.3.1 NS5A-interacting proteins potentially abrogated by P35A   
As described in the previous  chapters, P35A is partially involved in RNA replication (Figure 3.2), 
and showed modest reduction in virus production compared with wildtype (Figure 4.2, 4.3A 
and 4.5), which was most likely due to the reduction in RNA replication. 
After proteomic analysis and comparison of the protein expression levels between wildtype 
and P35A, two big groups of host proteins were identified. The first one is the GTPase 
associated proteins including Rab GTPase family (Rab1b, Rab8b and Rab34), Ras-related 
proteins (Rap1A, Rap1B and RalA), Rho family of GTPases (Rac1), and GTP-binding protein 
(GTPBP4), which are all involved in the  GTPase activating and downstream signalling pathways 
(Bourne et al., 1990). GTPase acts as a molecular switch whose 'on' and 'off' states are triggered 
by binding and hydrolysis of GTP, playing important roles in signal transduction, protein 
translation, cell division and transport of vesicles (Scheffzek and Ahmadian, 2005, Hippenstiel 
et al., 2002).  
The other group of proteins inhibited by P35A are mostly apolipoproteins (ApoA1, ApoC1, 
ApoC3 and ApoE) and DGAT1, which both participate in lipid metabolism (Figure 6.4 and Table 
6.1), which were supported by the immunochemistry analyses in the OST-NS5A pull down and 
PLA assays for interaction between NS5A and DGAT1 and ApoE (Figure 6.2). According to the 
density gradient analysis of P35A virus (Figure 4.5), the fraction with higher density (≥1.1005) 
contains more virus particles but with less infectivity. As previously reported that JFH1AAA99 
of NS5A domain I could only release non-infectious viral particles because of the abrogation of  
interaction of ApoE (Miyanari et al., 2007). Combination of this result, the decreased level of 
both ApoE and DGAT1 indicated that synthesis of LDs is critical for producing infectious viruses, 
whereas production of non-infectious viruses seems to follow a different pathway. Both P35A 
and JFH1AAA99 are likely to be at the determinant region of interaction between NS5A domain 
I and ApoE (Benga et al., 2010, Shavinskaya et al., 2007).  
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Figure 6.4 NS5A interacting protein network inhibited by P35A. 
Network illustration of the interactions analysed via STRING (https://string-db.org/) by input 
the proteins showed more than 2 -fold reduction in abundance ratio between P35A and WT. 
Two main groups of host proteins were identified as Lipid Metabolism and GTPases. 
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6.2.3.2 NS5A-interacting proteins potentially abrogated by V67A  
Post proteomic analysis of V67A, a large number of 40S ribosomal subunit were identified  at 
lower interaction level including RPS 3, 5,10, 19, and 24, together with one 28S ribosomal 
protein MRPS12 and eukaryotic translation initiation factor 2 subunit 3 (eIF2S3) (Figure 6.5), 
which are known to be tightly bound by the HCV IRES to facilitate initiation of translation of 
HCV polyproteins (Lytle et al., 2002, Fukushi et al., 2001, Otto and Puglisi, 2004). Additionally, 
a Tyrosyl-tRNA synthetase (YARS) and Histidyl-tRNA synthetase (HARS) catalyse the 
aminoacylation of transfer RNA (tRNA) by their cognate amino acid and plays an important role 
in RNA translation. 
Nucleosome assembly protein 1-like proteins 1 and 4 (NAP1L1 and NAP1L4) identified at the 
downstream of the ribosomal protein pathway (Figure 6.5),  are thought to act as histone 
chaperones, shuttling both nuclear core and linker histones from their site of synthesis in the 
cytoplasm to the nucleus (Rodriguez et al., 1997).   
 
Figure 6.5 NS5A interacting protein network inhibited by V67A. 
Network illustration of the interactions analysed via STRING (https://string-db.org/) by input 
the proteins showed more than 2 -fold reduction in abundance ratio between V67A and WT. A 
big group of host proteins related to HCV translation were identified. NAP1L1 and NAP1L4 are 
nucleosome assembly protein 1-like proteins 1 and 4. 
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6.2.3.3 NS5A-interacting proteins potentially abrogated by P145A  
Similar with V67A, P145A exhibited an series of reductions in interaction with ribosomal 
proteins (RPS 20, RPL 18, RPL 38, MRPL 4, MRPS 7, MRPS 27 and MRPS34) (Figure 6.6), whose 
functions are unknown in HCV life cycle.  
Sec61B belonging to Sec61 complex is the central component of the protein translocation 
apparatus of the endoplasmic reticulum (ER) membrane, trafficking proteins from ER to the 
nucleus and gene expression (Liao and Carpenter, 2007, Knight and High, 1998). SSR4, also 
called translocon-associated protein subunit delta (TRAPD), is another protein for 
translocation, which has ever been identified by proteomics analysis of crude replication 
complexes (MacPherson et al., 2011). The translocon is involved in protein translocation across 
the ER membrane and is formed by the association of the Sec61p complex, the translocation 
associated membrane protein (TRAM) and the translocon-associated protein (TRAP) 
complexes (Losfeld et al., 2014). Hence, direct or indirect Interaction between NS5A with 
Sec61B or SSR4 may regulate the genome replication and translation of viral proteins by 
association with the HCV replication complex (Figure 6.6). 
Sterol O-acyltransferase 1 (SOAT1), also called acyl-CoA: cholesterol acyltransferase 1 (ACAT1), 
is the enzyme responsible for cholesterol esterification, which also identified in the disrupted 
interaction network of P145A (Figure 6.6). As important organelles for HCV assembly,  LDs core 
is primarily  composed of triglycerides (TAGs), cholesterol esters (CEs), together with 
diacylglycerides (DAGs) (Fujimoto and Parton, 2011). Based on the phenotype of P145A in 
disruption of LDs formation (Figure 4.8 and 4.9), the impaired interaction between NS5A and 
SOAT1 is an interesting candidate to define the phenotype of this mutant in viral assembly.   
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Figure 6.6 NS5A interacting protein network inhibited by P145A. 
Network illustration of the interactions analysed via STRING (https://string-db.org/) by input 
the proteins showed more than 2 -fold reduction in abundance ratio between P145A and WT. 
A major group of host proteins mainly including ribosomal proteins was identified. SOAT1: 
Sterol O-acyltransferase 1.  
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6.3 Discussion  
6.3.1 Characterization of interaction of NS5A and known host proteins in virus assembly and 
lipid metabolism pathways 
It is well known that a common condition in HCV-infected individuals is steatosis, characterized 
by an accumulation of LDs. The mechanisms underlying development of steatosis include 
direct effects of the virus on lipid metabolism. LDs play a central role in generation of infectious 
virions as the target of viral proteins (Filipe and McLauchlan, 2015).  It has been demonstrated 
that mutations in domain I impaired the interaction between NS5A and core- associated LDs 
resulting in size reduction of LDs. In addition, the disrupted mechanisms of virus assembly 
were defined to the lipid metabolism pathways. Whether the increase in LD size is a direct 
consequence of recruitment of NS5A, or indirectly driven by NS5A-mediated effects on lipid 
metabolism, remains unclear. Nevertheless, both the recruitment of NS5A to LDs and the 
biogenesis of LDs should depend on protein - protein interactions to achieve virus assembly. 
Considering the recruitment of NS5A to LDs and lipid metabolism, DGAT-1 could be the 
foremost target as both core and NS5A  were previously shown to  be trafficked to LDs by 
DGAT1, functioning as a molecular bridge between the two proteins to ensure that they are 
targeted to the same LD (Herker et al., 2010, Camus et al., 2013). Moreover,  synthesis of 
triglycerides stored in LDs also require DGAT enzymes (Herker et al., 2010). The second factor 
identified with a role in LD targeting of NS5A is Ras-related protein 18 (Rab18), which can 
promote the physical association of NS5A and other components of the viral replicase 
machinery with LDs (Salloum et al., 2013). HCV particle production is tightly linked to 
apolipoproteins E (ApoE), ApoA1, ApoC1, and ApoB (Bartenschlager et al., 2011). ApoE 
exhibited an interaction with NS5A and viral envelope glycoprotein to facilitate assembly of 
viral particles. Following that, mature HCV particles containing ApoB, ApoE and eventually 
other apolipoproteins are then transported along the VLDL secretory pathway (Olofsson et al., 
2009).  However, the phenotype of V67A or P145A cannot be explained by a lack of binding to 
these proteins, both DGAT-1 and (to a lesser extent) Rab18 precipitated with both WT and the 
three mutant NS5As, difference in interaction with ApoE also was not detected for both V67A 
and P145A. To extend this analysis, a proteomic approach was used to determine the 
interactome of the three mutant NS5As in comparison to WT. 
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6.3.2 Proteomic analysis of NS5A interacting partners  
Utilising Strep-tagged NS5A based pull down assay and Tandem Mass Tagging quantitative 
proteomic, thousands of host proteins in various cellular pathways have been identified. To 
characterize the mechanism of NS5A mutants affected in RNA replication or even virus 
assembly, peptide binding abundance of the mutated NS5A that was dramatically decreased 
was filtered into the protein network.  
P35 that are assumed only involved in RNA replication seems participate in more pathways. It 
is noteworthy that P35A slightly impairs the interaction with ApoE and DGAT1, which can 
explain the reduction in infectious particles release by P35A. In general, most released HCV 
virus particles are infectious with low density via the LD assembly pathway requiring ApoE and 
DGAT1 (Miyanari et al., 2007). Compared to WT, a large proportion of P35A particles purified 
in the higher density fraction with low infectivity might assemble into viral particles via another 
pathway other than LD associated virus assembly. Beyond that, it was revealed that P35A was 
also involved in Rab protein signalling via cascade activation of a series of GTPase-activating 
proteins. The Rab family is part of the Ras superfamily of small GTPases. Rab GTPases recruit 
specific sets of effector proteins onto membranes via bound to GTP (Stenmark and Olkkonen, 
2001). It has been reported that Rab1 regulates ER-Golgi traffic and several Rabs including 
Rab8 modulate biosynthetic traffic from the trans-Golgi network (TGN) to the plasma 
membrane (Hutagalung and Novick, 2011). In HCV life cycle, Rab1 GTPase activity can be 
activated through interaction between TBC1D20 and Rab1. Furthermore, the Rab1 GTPase-
activating protein-TBC1D20 interacts with HCV NS5A, which is a prerequisite for LD 
homeostasis as well as for maintenance of viral replication complexes (Nevo-Yassaf et al., 2012, 
Sklan et al., 2007a). Combined with the function of other GTPases, it suggests that the 
impairment of replication for P35A might be due to the inhibition of GTPase activity. 
My study showed that both V67A and P145A inhibited the translation of proteins through 
abrogation of interaction with a series of ribosome proteins. There is only one study describing 
that HCV NS5A protein downregulates HCV IRES-dependent translation, whereas the 
molecular basis of the inhibitory effect of NS5A on HCV IRES has not been elucidated 
(Kalliampakou et al., 2005). It is still unclear what is the relationship between weak interaction 
with these translation factor and defects in RNA replication or viral assembly for V67A and 
P145.  
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The suppressed RNA replication of V67A might involve the nucleosome assembly pathway. 
NAP1L1 has been shown to interact with HCV core and NS5A (Germain et al., 2014, Pichlmair 
et al., 2012) as well as Kaposi’s sarcoma herpesvirus (KSHV) LANA and HIV-1 Tat (De Marco et 
al., 2010, Gupta et al., 2016). Although its roles in the nucleus associated with chromatin 
structure and gene expression are well defined, NAP1L1 and NAP1L4 are predominantly 
located in the cytoplasm, where its function(s) remains to be elucidated. Recently, 
Goonawardane et al reported that NAP1L1 could regulate genome replication of HCV via 
interaction with hyperphosphorylated NS5A (Goonawardane et al., 2017). Here domain I of 
NS5A is also likely to be involved in RNA replication through interaction with NAP1L1 or 
NAP1L4, which remains to be elucidated. 
Of note, the interruption of the interaction between NS5A and acyl-CoA: cholesterol 
acyltransferase 1 (ACAT1 or SOAT1) can explain why the LDs in P145A transfected cells were 
smaller. Acyl-CoA: cholesterol acyltransferase is the important component in the synthesis of 
LDs through catalysing cholesterol into cholesterol esters. Although how LDs contribute to 
virion production has not been clearly elucidated, I showed evidence for the participation of 
LDs in HCV assembly. SiRNAs or inhibitors that target host factors involved in LD biogenesis 
including DGAT1, ApoE, ApoB and ACAT can effectively inhibit infectious HCV production 
(Barter and Rye, 2016, Hu et al., 2017, Liefhebber et al., 2014). Hence, the impairment of the 
interaction with ACAT1 disrupted the functional LDs metabolism furthermore P145A failed to 
assemble into viral particles, whereas remains to be demonstrated.  
To summarize, my data provides a comprehensive identification of the HCV NS5A proteome, 
and insight into the change in proteome between HCV wildtype and domain I mutants, which 
will serve as useful resources.  These identified NS5A interacting partners disrupted by domain 
I mutations, such as ApoE and SOAT1, are of important value to be investigated in future 
research. 
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NS5A as an important target of direct acting antivirals (DAAs) plays essential roles throughout 
the HCV lifecycle, which demands for extensive research in order to find more effective DAAs 
targeting vital sites or regions in NS5A.  In this context, domain I of NS5A is both dimeric and 
highly conserved, providing more possibilities than the unstructured domains II and III.  
Previous efforts to investigate functions of NS5A in the HCV lifecycle have been focused on 
domain II and III together with phosphorylation of NS5A. Although much work has 
demonstrated that both domain II and III are required for both RNA replication and virus 
production, very little research about such functions of domain I has yet been defined. As 
domain I might present in a dimeric structure with RNA binding sites and with more conserved 
amino acids, this study attempts to reveal domain I by both functional and structural analyses. 
To investigate these functions, 12 residues of domain I conserved among all HCV genotypes 
and surface exposed were chosen for a mutagenic analysis. Taking advantage of sub-genomic 
replicons (SGR) and JFH1 full-length virus systems, this study identified nine of these residues 
in NS5A domain I for which alanine substitution absolutely disrupted HCV genome replication 
via modulation of the replication complex, whereas three residues (P35A, V67A and P145A) 
had a modest effect on genome replication, but significant defects in the production of 
infectious virus particles.  
The data of non-replicating mutants presented here shows the lethal replication phenotype is 
a direct result of a loss of NS5A function rather than the disruption of polyprotein processing. 
The observation that co-localisation between NS5A and NS3 in mutants (G45A, G51A and (153-
158)A) transfected cells is significantly disrupted points towards the important role of domain 
I in the formation of replication complex via interaction with other non-structural proteins, 
which is consistent with existing data about the important role of NS5A in the replication 
complex (Paul et al., 2014). The trans-complementation result demonstrates that all these 
negative mutants cannot be trans-complemented by helper RNA, which suggest that deficient 
NS5A within replication complex could not be replaced by functional NS5A from helper 
genome. These data are interesting as other trans-complementation studies have shown that 
both 1b and JFH-1 NS5A mutant replicons can be trans-complemented by an autonomously 
replicating stable cell line (Appel et al., 2005a, Tong and Malcolm, 2006). NS5A is predicted to 
be easily trans-complemented as it is only tethered to intracellular membranes via an 
amphipathic helix (Brass et al., 2002) and can therefore easily be replaced by a functional NS5A 
protein. Although the interpretation of these trans-complementation results in this study 
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remains inconclusive, I suspect it might be attributed to the unique structure and location of 
domain I in the replication factory. 
 In particular, my attention was focussed on V67A and P145A in this study. Both V67A and 
P145A mutants were shown to fail to produce intracellular infectious virus and consequently 
failed to release any virus particles, as judged by the lack of virus RNA or core protein in cell 
culture supernatants. In addition, this was not due to a lack of genome replication or core 
protein within the cells, as levels of both were similar to WT. Taken collectively, V67A and 
P145A were confirmed to completely abrogate virus assembly. Previously, domain I has been 
assumed only to function during genome replication, and to my knowledge, this is the first 
detailed analysis of a role for domain I in virus assembly. Moreover, high-resolution confocal 
microscopy clearly showed that in cells infected with V67A or P145A mutant viruses there were 
defects in LD production. Compared to WT, LD were smaller, closer to the nucleus and 
disruption of co-localisation of NS5A and LD or core tempt me to speculate that NS5A 
recruitment to LDs was impaired. Lastly, these two mutants enhanced binding of domain I to 
the HCV 3’UTR RNA and inhibited dimerization in vitro.  
Firstly, combination of these observations suggest that the dimeric and conserved domain I 
impart NS5A with multiple roles in virus assembly. Both the association of NS5A with LD and 
the increase in LD size and altered distribution are essential for the virus assembly during HCV 
infection. Taken together with the in vitro data, these support a model in which domain I of 
NS5A binds to the 3’UTR of nascent genomes and transports them from sites of replication to 
LD. Here, analogous to the handing on of a baton in a relay race, the RNA is transferred to core 
and then subsequently transported to assembly sites. The enhanced binding of V67A or P145A 
to the 3’UTR RNA may prevent the release of RNA for transfer to core post replication in the 
replicase factory.  Additionally and importantly, the LD distribution in cells infected with V67A 
or P145A at 72 hpe resembles that in wildtype at 12/24 hpe, suggesting that these mutations 
might block the transition from genome replication to virus assembly. Furthermore, the loss of 
dimerization by these two mutants implies that, in contrast to the accepted model of an open 
NS5A dimer revealing a basic RNA-binding groove, monomeric NS5A is able to bind RNA.  
However, we cannot rule out the possibility that in the intact protein, domains II and III 
influence both dimerization and RNA binding by domain I. In this regard, it is noted that the 
attempts to detect NS5A dimerization within intact cells have so far been unsuccessful, despite 
testing a variety of experimental protocols. Despite this, it is tempting to speculate that 
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monomeric NS5A might transport nascent RNA to LDs, then dimerizes and releases the RNA to 
core.  
Data in my study are consistent with previous studies into the role of NS5A during virus 
assembly, which support a model whereby NS5A orchestrates the processes of genome 
replication, and virus assembly. However, these studies have exclusively focused on the role of 
domain III (Appel et al., 2008, Pietschmann et al., 2009), and it has been widely accepted that 
the determinants of virus assembly within NS5A lie entirely within domain III. For example, a 
serine near the C-terminus of domain III is implicated in the interaction between NS5A and 
core, and it has been proposed that phosphorylation of this residue by casein kinase II is 
required for virus assembly (Tellinghuisen et al., 2008a).  More recently, mutations of a basic 
cluster at the N-terminus of domain III resulted in modest impairment of core-RNA and NS5A-
RNA interactions and virus particle envelopment, leading to a 100-fold reduction in released 
virus titres (Zayas et al., 2016). Data from my study extend these observations, providing 
evidence that domain I also makes a major contribution to virus assembly.  
Other implications of this study concern the modifications to LD morphology that occur during 
HCV infection.  Post transfection or infection of HCV, increases in LD size and total volume most 
likely reflect the coalescence of smaller LDs into larger structures. Our data indicate that 
domain I of NS5A plays a role in this process, as V67A and P145A do not exhibit this increase.  
NS5A is recruited to LDs, in most cases to discrete punctate locations on the surface, in contrast 
to the complete coating of LDs with core. Whether the increase in LD size is a direct 
consequence of recruitment of NS5A, or indirectly driven by NS5A-mediated effects on lipid 
metabolism, remains unclear. In this context, NS5A has previously been shown to interact with 
a number of LD-associated proteins, including DGAT-1 (Camus et al., 2013), Rab18 (Salloum et 
al., 2013) and ApoE (Benga et al., 2010). However, the phenotype of V67A or P145A cannot be 
explained by a lack of binding to these proteins as both DGAT-1 and Rab18 can be precipitated 
NS5A and ApoE exhibit WT level of interaction with NS5A in V67A and P145A transfected cells. 
Using a proteomic approach to determine the interactome of the three mutant NS5As in 
comparison to WT, it has been extended and confirmed that V67A and P145A are not involved 
in the either DGAT, Rab18 or ApoE related LDs biogenesis.  
In contrast to V67A and P145A, P35A exhibited a moderate virus assembly phenotype with 
only a small (less than 10-fold) reduction in virus titre. Nevertheless, some important 
observations can be made: firstly, in the density gradient analysis the peak of infectivity for 
P35A resolved at a lower buoyant density than WT (1.0475 g/ml compared with 1.064 g/ml). 
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In contrast, the second peak of infectivity with higher buoyant density for P35A was associated 
with more genome RNA and core than WT.  These data imply subtle differences in the 
association of virus particles with VLDL or other lipids.  Intriguingly, the proteomic analysis 
provides us with the evidence why more virus particles from P35A exhibited higher buoyant 
density but lower infectivity. P35A inhibits the VLDL assembly pathway associated with ApoE, 
DGAT1 and Rab18, whereas production of non-infectious viruses seems to follow a different 
pathway. This phenomenon was also observed by the other domain I mutant JFH1AAA99 
(Miyanari et al., 2007). In all other analyses (LD size and distribution, NS5A recruitment to LD, 
dimerization and 3’UTR binding), P35A was not statistically significantly different from WT.   In 
fact, purification of JFH1 WT particles also exhibits two main density peaks, but the majority 
of particles are of low density and high infectivity (Figure 4.5), which suggests the VLDL 
assembly pathway predominates in the production of WT JFH1 virus. These observations 
tempt me to put forward that assembly of HCV take place in different pathways, while LDs 
associated VLDL pathway is responsible for the infectious HCV particles.  
Lastly, it is important to consider our results in the context of the class of potent DAAs that are 
defined as NS5A inhibitors, exemplified by daclatasvir (DCV). Although initially developed as 
inhibitors of genome replication (Gao et al., 2010), it has become clear that DCV also has an 
independent effect on virus assembly.  Treatment of infected cells with DCV resulted in a rapid 
(2 h) block to virus assembly, preceding the inhibition of genome replication which was only 
apparent at later time points (24 h) (McGivern et al., 2014). More recently, it has been shown 
that DCV treatment prevented the transfer of genomic RNA to assembly sites (Boson et al., 
2017).  DCV has been reported to target domain I, as judged by the location of DCV-resistance 
mutations (e.g. L31M and Y93H). With similar phenotypes of domain I mutants (V67A and 
P145A) and DCV treatment in virus assembly, it is important to note that none of the three 
mutations analysed in this study exhibited any effect on the activity of DCV measured against 
HCV genome replication, which suggests that V67 and P145 are not the sites for DCV binding. 
However, our observation that domain I is directly implicated in virus assembly does provide a 
rationale for the rapid effect of DCV on this process, and may therefore help to explain the 
extraordinary potency of DCV and related compounds.    
In pursuit of a greater insight into how NS5A domain I regulate HCV assembly pathway, this 
study also set out to establish the NS5A-host protein interaction network using quantitative 
proteomic analysis. A number of partners involved in RNA translation and VLDL assembly 
pathway has been identified, which provides the supporting evidence for the phenotypes of 
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domain I mutants.  Impairment of interaction with LD-associated proteins (DGAT1, Rab18 and 
ApoE) confirm that P35A produces more less infectious HCV particles via a non- VLDL assembly 
pathway and not just due to the reduction of RNA replication. A novel host protein - SOAT1 
identified by P145A indicates a direction to investigate the role of domain I in virus assembly. 
This quantitative proteomic analysis serves as a versatile platform both to verify the currently 
known NS5A-interacting partners involved by NS5A domain I and to discriminate potential 
different pathways inhibited by domain I mutants. More importantly, more efforts need to be 
invested to corroborate it. 
A novel role of domain I of HCV NS5A protein in HCV assembly has been identified in this study 
and characterized to be related to lipid droplets of host cell and intrinsic activities of domain I 
including dimeric structures and RNA binding. In one word, NS5A is more likely to modulate 
processes from RNA replication to viral assembly. Nevertheless, there are a number of key 
unanswered questions. We need a clearer picture of how nucleocapsids are assembled, how 
NS5A protein contributes to this process and the relationship of virus particle assembly to lipid 
droplets during viral assembly. What are the clear roles that domain I participate in? Are there 
other NS5A domain I interacting host proteins involved in virus assembly pathway? Ultimately, 
to answer these questions, there is yet much work to be done.  
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Appendix Table 9.1 List of constructs generated and used throughout this study.
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Genotype Isolates Accession Number 
HCV-1a H77            JX472009 
HCV-1a HCV-RMT          AB520610 
HCV-1b M094AJK          AB010250 
HCV-1b IBJK             AB559564 
HCV-1b 1B-2             GQ259488 
HCV-1b NO.2            AB154177 
HCV-2a JCH-6            AB047645 
HCV-2a JFH1             AB047639 
HCV-2a JCH-2         AB047641 
HCV-2a JCH-1             AB047640  
HCV-2b patient NO.44     AB661373   
HCV-2b acute             AB559564   
HCV-2b 1-2b           AB600801 
HCV-2b HC10-0804        AB622121  
HCV-3a NR1               AF320804 
HCV-3a SR1               AF320787   
HCV-3a 1S_2            AM493508   
HCV-3b Tr                D49374 
HCV-3b SH37            JQ065709 
HCV-3h QC29             JF735121      
HCV-4a L835           DQ418789  
HCV-4b QC264           FJ462435   
HCV-5a SA13              AF064490    
HCV-5a EUH1480         Y13184                   
HCV-6a D9        EU246930 
HCV-6b Th580            D84262    
HCV-6c Th846         EF424629   
HCV-6h VN004           D84265    
HCV-7a QC69          EF108306   
BHV PDB-829      KC796074                 
BHV PDB-452        KC796090   
BHV PDB-112          KC796077  
GBV GBV-B                AF179612    
GHV-1 BWC04          KC551802    
GHV-1 BWC05         KC551801                
GHV-1 BWC08         KC551800  
NPHV EF369-11       JX948116    
RHV SAR-46-RSA-2008 KC411807   
RHV 339 KC815310  
Appendix Table 9.2 Isolates used for NS5A domain I sequence alignment. 
Sequences of NS5A amino acids from 29 virus isolates from 7 HCV genotypes and 10 related 
hepaciviruses were selected from NCBI database for alignment analysis of domain I region 
(Result was shown in Table 3.1). 15 virus isolates underlined were a subset of the viruses used 
for the conservation analysis of whole NS5A (Results was shown in Figure 3.1B). 
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Mutants   Quickchange Primer 
P35A 
Forward TGCCCGGCCTCGCCTTCATCTCTTGTCAAA 
Reverse TTTGACAAGAGATGAAGGCGAGGCCGGGCA 
Y43A 
Forward TTGTCAAAAGGGGGCCAAGGGTGTGTGGGC 
Reverse GCCCACACACCCTTGGCCCCCTTTTGACAA 
G45A 
Forward GGGGTACAAGGCTGTGTGGGCCGGCACTGG 
Reverse CCAGTGCCGGCCCACACAGCCTTGTACCCC 
W47A 
Forward GGGGTACAAGGGTGTGGCGGCCGGCACTGG 
Reverse CCAGTGCCGGCCGCCACACCCTTGTACCCC 
G51A 
Forward GGGCCGGCACTGCCATCATGACCACGCGCT 
Reverse AGCGCGTGGTCATGATGGCAGTGCCGGCCC 
C59A 
Forward CGCGCTGCCCTGCCGGCGCCAACATCTCTG 
Reverse CAGAGATGTTGGCGCCGGCAGGGCAGCGCG 
G60A 
Forward CGCGCTGCCCTTGCGCCGCCAACATCTCTG 
Reverse CAGAGATGTTGGCGGCGCAAGGGCAGCGCG 
V67A 
Forward AACATCTCTGGCAATGCCCGCCTGGGCTCT 
Reverse AGAGCCCAGGCGGGCATTGCCAGAGATGTT 
G96A 
Forward TTGCTACACGGAGGCCCAGTGCGCGCCGAA 
Reverse TTCGGCGCGCACTGGGCCTCCGTGTAGCAA 
T134A 
Forward CTCCTATGTAACAGGACTGGCCACTGACAATCTGAAAATT 
Reverse AATTTTCAGATTGTCAGTGGCCAGTCCTGTTACATAGGAG 
P145A 
Forward GAAAATTCCTTGCCAACTAGCTTCTCCAGAGTTTTTCTCC 
Reverse GGAGAAAAACTCTGGAGAAGCTAGTTGGCAAGGAATTTTC 
153-158A 
(Frag1) 
Forward TCCGGATCCTGGCTCCGCGACG 
Reverse GGCCGCCGCAGCGGCCGCCCAGGAGAAAAACTCTGGAGAAGGTAGTT
G 
153-158A 
(Frag2) 
Forward 
GCGGCCGCTGCGGCGGCCCATAGGTTTGCACCCACACCAAAGCCGTTT 
Reverse GGGAGTTATTAGCGCTCCGGTCCAGGAGTATGACATGGAGC 
Appendix Table 9.3 List of oligonucleotide primers used to generate mutations in NS5A 
domain I.  
Forward and Reverse indicate forward primer and reverse primer, respectively. 
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 Oligonucleotide Sequences 
Domain I-Forward  5'-ctgcccGGATCCCCCTTCATCTCTTGTCAAAAGGG-3' 
Domain I-Forward (P35A)  5'-ctgcccGGATCCGCCTTCATCTCTTGTCAAAAGGG-3' 
Domain I -249-Reverse  5'-cgtgccCTCGAGTTAGGTGTTGCTGTGGGTGGTGCAGG-3' 
Domain I -215-Reverse   5'-cgtgccCTCGAGTTACGCCGCAGTCTCCGCCGTG-3'  
 
Appendix Table 9.4 List of oligonucleotide primers used for the expression of recombinant 
domain I proteins.  
 
 
  Oligonucleotide Sequences 
qRT-PCR-Forward  5'-CTC CCG GGG CAC TCG CAA GC-3' 
qRT-PCR-Reverse 5'-GCCTAGCCATGGCGTTAGTA-3' 
Probe 5' - 6-FAM-GCT AGC ATT TGG GCG TGC CCC CGC AAG A-TAMRA-Sp -3'  
 
Appendix Table 9.5 List of oligonucleotide primers used for the qRT-PCR for the detection of 
positive HCV genome RNA.  
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Accession Description 
Abundance 
Ratio: 
(OST-WT) / 
(JFH1-WT) 
Abundance 
Ratio: 
(OST-35) / 
(OST-WT) 
Abundance 
Ratio: 
(OST-67) / 
(OST-WT) 
Abundance 
Ratio: 
(OST-145) 
/ (OST-WT) 
Q9UHD9 Ubiquilin-2  100 0.006 0.01 0.01 
B2RDG0 Proteasome subunit alpha type 100 0.786 1.131 0.823 
Q6PJF5 Inactive rhomboid protein 2  100 0.611 1.113 0.01 
T1ECW5 
Serine/threonine-protein 
phosphatase 6 regulatory subunit 
2  100 0.499 0.961 1.87 
A0A0A7C5E9 MHC class I antigen (Fragment)  100 1.943 0.739 0.626 
Q9Y3Z3 
Deoxynucleoside triphosphate 
triphosphohydrolas+C3:C7e 100 1.459 1.718 1.564 
P51589 Cytochrome P450 2J2  100 0.414 0.706 0.262 
C9JMV9 Protein ABHD14A-ACY1 100 0.349 0.614 0.97 
A0A0S2Z5U8 Dystrobrevin binding protein 1  100 0.413 3.748 0.01 
B4DR52 Histone H2B  100 0.006 0.01 0.01 
Q13535 
Serine/threonine-protein kinase 
ATR  100 0.204 0.313 0.365 
Q9UGR2 
Zinc finger CCCH domain-
containing protein 7B  7.785 1.690 0.478 0.159 
A0A0S2Z5X6 L(3)mbt-like 2 (Drosophila) 4.319 0.753 0.681 0.291 
D7RF68 AGTRAP-BRAF fusion protein  4.291 0.359 0.829 0.641 
Q6ZUJ8 
Phosphoinositide 3-kinase 
adapter protein 1  3.992 0.387 0.282 0.22 
A8K8N3 
 Sperm associated antigen 5 
(SPAG5), 3.925 0.558 1.162 0.868 
tr HCV_NS5A_TwinStrep 3.583 1.006 0.732 0.269 
Q15773 Myeloid leukemia factor 2  3.338 0.644 1.623 1.093 
F8W0W8 
Serine/threonine-protein 
phosphatase 3.271 0.706 0.94 0.903 
B4DVR4 Vinexin  2.814 0.973 1.064 0.368 
Q8IVH2 Forkhead box protein P4  2.783 0.449 0.838 0.722 
C9J1B4 Kalirin (Fragment)  2.77 0.632 1.281 0.709 
Q5VUA4 Zinc finger protein 318  2.679 0.680 0.749 0.464 
B0LPF3 
Growth factor receptor-bound 
protein 2  2.652 0.923 1.356 0.709 
P53582 Methionine aminopeptidase 1 2.51 0.669 0.994 0.762 
Q9GZP9 Derlin-2  2.494 0.622 0.765 0.522 
Q5JWE9 
Guanine nucleotide-binding 
protein G(s) subunit alpha  2.483 0.442 0.857 0.567 
J3KN36 Nodal modulator 3  2.464 0.490 0.849 0.529 
H7C0G1 Transmembrane protein 245  2.418 0.436 0.879 0.527 
P27449 V-type proton ATPase  2.418 0.471 0.874 0.647 
B4E171 Tetraspanin  2.396 0.169 0.951 0.255 
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O94876 
Transmembrane and coiled-coil 
domains protein 1 2.378 0.477 1.04 0.766 
Q9H3R5 Centromere protein H  2.356 0.494 1.197 0.752 
Q9UPP1 Histone lysine demethylase PHF8 2.319 0.628 1.409 1.053 
Q13625 
Apoptosis-stimulating of p53 
protein 2  2.294 1.053 1.253 1.496 
J3QRU1 Tyrosine-protein kinase  2.289 0.785 0.798 0.494 
Q8NC42 
E3 ubiquitin-protein ligase 
RNF149  2.288 0.821 1.374 0.361 
Q9GZR7 
ATP-dependent RNA helicase 
DDX24 2.281 0.429 0.805 0.483 
Q9UKZ1 
CCR4-NOT transcription complex 
subunit 11 2.274 0.545 0.933 0.615 
Q7Z434 
Mitochondrial antiviral-signaling 
protein  2.237 0.436 0.622 0.75 
P02647 Apolipoprotein A-I  2.228 0.479 0.741 0.486 
J3KQ66 Reelin OS 2.19 0.529 0.99 0.779 
B4DK31  Acetyl-CoA carboxylase 1 2.182 0.663 1.68 4.442 
A0A0A8K8C7 G protein-coupled receptor 49 2.173 0.975 2.35 0.484 
A0A024RBB7 
Nucleosome assembly protein 1-
like 1 2.155 1.213 0.397 0.27 
B2R932 CD99 antigen (CD99) 2.15 0.489 0.779 0.618 
Q96HP0 Dedicator of cytokinesis protein 6  2.142 0.915 1.291 0.917 
Q13344 Fus-like protein (Fragment)  2.139 0.436 0.734 0.374 
D9ZGG2 Vitronectin  2.138 0.524 0.869 0.716 
P11117 Lysosomal acid phosphatase  2.136 0.607 0.71 0.484 
A0A024R9Y7 Melanoma antigen family D, 2  2.099 0.722 0.733 0.577 
O60942 mRNA-capping enzyme  2.085 0.682 1.194 0.934 
O14929 
Histone acetyltransferase type B 
catalytic  2.053 0.407 0.873 0.56 
Q4LE69 PIK4CA variant protein  2.048 0.606 0.445 0.394 
Q9NR31 GTP-binding protein SAR1a 2.041 0.461 0.879 0.76 
Q96LJ7 
Dehydrogenase/reductase SDR 
family member 1 2.008 0.441 0.812 0.544 
Q92925 
SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin subfamily 
D member 2  2.007 0.708 0.739 0.753 
Q7L5N1 
COP9 signalosome complex 
subunit 6  1.998 0.640 0.947 0.67 
P13498 Cytochrome b-245 light chain  1.989 0.505 0.846 0.551 
Q9GZT9 
Egl nine homolog 1 OS=Homo 
sapiens GN=EGLN1 PE=1 SV=1 1.984 0.789 1.421 1.447 
A8KAQ3 Sortilin 1 (SORT1) 1.984 0.525 0.916 0.691 
Q15906 
Vacuolar protein sorting-
associated protein 72 homolog  1.97 0.569 0.963 0.595 
Q96J42 
Thioredoxin domain-containing 
protein 15  1.967 0.445 1.188 1.329 
O95551 Tyrosyl-DNA phosphodiesterase 2  1.956 0.353 1.262 1.153 
Chapter 9: Appendix 
221 
 
B2R9U2  FK506 binding protein 4 1.956 0.734 1.036 0.848 
Q9UEI6 
Polio virus related protein 2, 
alpha isoform (Fragment)  1.937 0.441 0.886 0.529 
O43306 Adenylate cyclase type 6 1.93 0.564 0.864 0.517 
Q9NUN5 
Probable lysosomal cobalamin 
transporter  1.929 0.494 0.791 0.478 
B5MD23 Tetraspanin  1.918 0.387 0.856 0.362 
A0A0D9SFM0 E3 ubiquitin-protein ligase SHPRH  1.917 0.611 0.883 0.855 
B4DG73 Golgi complex component 6  1.914 0.520 0.991 0.535 
V9GYM3 Apolipoprotein A-II  1.907 0.587 0.906 0.566 
Q9UNS2 
COP9 signalosome complex 
subunit 3 1.905 0.617 0.971 0.775 
K7ER74 Protein APOC4-APOC2  1.905 0.459 0.794 0.52 
B4DS05 
Nucleosome assembly protein 1-
like 4  1.901 1.932 0.368 0.286 
Q9BZQ6 
ER degradation-enhancing alpha-
mannosidase-like protein 3  1.899 0.691 0.897 0.803 
Q9H1C4 Protein unc-93 homolog B1  1.895 0.404 1.153 0.808 
Q6FGQ5 ASGR1 protein (Fragment)  1.891 0.477 1.04 0.633 
P09564 T-cell antigen CD7 1.88 0.524 0.98 0.582 
B4DNC0 Ras-related protein Rab-34  1.876 0.428 0.864 0.773 
Q9BWJ5 Splicing factor 3B subunit 5  1.875 0.558 0.883 0.679 
A0PJW6 Transmembrane protein 223  1.874 0.568 0.863 0.61 
B4DPG9 
 Growth hormone-inducible 
transmembrane protein  1.863 0.516 0.897 0.664 
I6QTG3 Glypican 3 isoform 2  1.857 0.529 0.929 0.82 
A0A0B4J1V9 
Helicase, lymphoid-specific, 
isoform CRA_b 1.848 0.486 0.745 0.687 
A0A0S2Z3H8 GNAS complex locus isoform 1 1.847 0.504 0.873 0.773 
Q96CQ1 
Solute carrier family 25 member 
36 1.845 0.460 0.731 0.791 
A4D1F3 
Similar to Six transmembrane 
epithelial antigen of prostate  1.829 0.521 0.92 0.587 
Q8N370 
Large neutral amino acids 
transporter small subunit 4  1.822 0.749 1.299 0.523 
Q9BYV1 
Alanine--glyoxylate 
aminotransferase 2, 
mitochondrial  1.819 0.808 1.466 1.925 
Q96EX1 
Small integral membrane protein 
12  1.819 0.436 0.789 0.472 
Q6NVY4 BNIP3 protein 1.815 0.552 1.245 1.07 
Q8WUM0 
Nuclear pore complex protein 
Nup133  1.81 0.539 0.807 0.754 
A0A0C4DFL7 Lanosterol 14-alpha demethylase  1.795 0.493 0.859 0.6 
Q12770 
Sterol regulatory element-binding 
protein cleavage-activating 
protein  1.795 0.567 1 0.522 
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Q9NP77 
RNA polymerase II subunit A C-
terminal domain phosphatase 
SSU7 1.795 0.188 1.026 1.042 
A8QI98 DIS3  1.789 0.516 0.458 0.51 
P62877 E3 ubiquitin-protein ligase RBX1  1.787 0.590 0.904 0.518 
B4E0K4 
 Pre-B-cell leukemia transcription 
factor interacting protein 1  1.786 0.547 0.909 0.83 
Q9BRK5 45 kDa calcium-binding protein  1.786 0.524 1.018 1.095 
Q8N8V2 Guanylate-binding protein 7  1.78 0.321 0.868 0.467 
Q14997 
Proteasome activator complex 
subunit 4  1.777 0.498 0.907 0.746 
A6NMH8 Tetraspanin  1.775 0.453 0.803 0.468 
Q13501 Sequestosome-1  1.773 0.648 1.236 0.898 
P63096 
Guanine nucleotide-binding 
protein G(i) subunit alpha-1  1.767 0.624 0.333 1.415 
B7Z5W1 Junctional adhesion molecule A 1.765 0.419 0.902 0.717 
B3KNC3 
Nucleolar complex protein 2 
homolog  1.763 0.477 0.659 0.639 
O14894 
Transmembrane 4 L6 family 
member 5  1.757 0.504 0.82 0.524 
B2RAL9 
Dual specificity protein 
phosphatase  1.752 0.454 0.931 0.65 
A0A024R5F9 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 6, 1.751 0.458 0.909 0.575 
P07307 Asialoglycoprotein receptor 2  1.75 0.489 1.007 0.655 
Q9BXF3 
Cat eye syndrome critical region 
protein 2  1.745 0.418 0.914 0.73 
A8K4H5 Chloride channel protein  1.74 0.489 0.956 0.561 
B2R674 
Solute carrier family 19, member 
3 (SLC19A3) 1.738 0.496 0.921 0.536 
P31151 Protein S100-A7  1.734 1.565 2.323 2.449 
I1VE18 SEC22 vesicle trafficking protein B 1.73 0.520 0.957 0.657 
B4E2A6  Sad1/unc-84-like protein 21 1.728 0.477 1.069 0.739 
Q93074 
Mediator of RNA polymerase II 
transcription subunit 12  1.728 0.473 0.855 0.542 
B7ZLZ8 FAM73A protein  1.724 0.463 0.956 0.461 
M0QZ12 
GRAM domain-containing protein 
1A  1.723 0.576 0.846 0.652 
A0A024R371 
ADP-ribosylation-like factor 6 
interacting protein 5 1.721 0.438 0.766 0.558 
P13056 
Nuclear receptor subfamily 2 
group C member 1 1.716 0.615 0.969 0.728 
H3BMF4 Protein spinster homolog 1  1.709 0.545 0.841 0.579 
A0A024QZN7 
Chromosome 10 open reading 
frame 701 1.708 0.481 0.814 0.533 
B2R7U4 Heme oxygenase (decycling) 1  1.705 0.613 0.792 0.51 
Q9Y333 
U6 snRNA-associated Sm-like 
protein LSm2  1.704 0.863 1.015 0.905 
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P60602 
Reactive oxygen species 
modulator 1  1.703 0.423 0.851 0.533 
A0A024R1S7 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin 1.701 0.484 0.9 0.518 
Q7Z509 IFNRC OS 1.688 0.441 0.823 0.416 
D2JYI1 TGF-beta receptor type-2  1.681 0.588 1.572 0.721 
Q9Y519 Transmembrane protein 184B  1.68 0.542 0.925 0.632 
Q541P7 EPH receptor B4 1.679 0.428 0.887 0.611 
A0A024R466 Integral membrane protein 2C 1.672 0.521 1.167 1.036 
Q15800 Methylsterol monooxygenase 1  1.667 0.487 0.936 0.553 
Q6ZUY8 Lipase  1.665 0.523 0.883 0.764 
Q86T03 
Type 1 phosphatidylinositol 4,5-
bisphosphate 4-phosphatase  1.664 0.618 0.833 0.736 
A0A024R491 
Chromosome 2 open reading 
frame 33 1.663 0.479 0.971 0.564 
A0A024RAF0 Bridging integrator 1 1.66 1.154 0.832 0.409 
O15162 Phospholipid scramblase 1  1.66 0.509 0.875 0.566 
P00167 Cytochrome b5  1.656 0.493 0.956 0.998 
Q96SK2 Transmembrane protein 209  1.655 0.453 0.917 0.682 
A0A024RB87 RAP1B 1.651 0.452 0.675 0.469 
Q8WW52 Protein FAM151A  1.65 0.510 0.818 0.552 
Q9H7Z6 Histone acetyltransferase KAT8  1.65 0.525 0.891 0.829 
Q9UNS1 Protein timeless homolog  1.648 0.785 0.656 0.367 
P02649 Apolipoprotein E  1.647 0.532 0.748 0.534 
Q5VV42 
Threonylcarbamoyladenosine 
tRNA methylthiotransferase  1.647 0.566 0.982 0.695 
Q8WU67 Phospholipase ABHD3  1.646 0.543 0.861 0.657 
Q9NVT9 
Armadillo repeat-containing 
protein 1  1.646 0.545 0.792 0.7 
P15907 
Beta-galactoside alpha-2,6-
sialyltransferase 1 1.645 0.504 0.929 0.635 
A4LAA3 
Alpha thalassemia/mental 
retardation syndrome X-linked  1.64 0.463 1.01 0.634 
Q9P227 Rho GTPase-activating protein 23 1.639 0.503 0.803 0.532 
G1UI16 
SCC-112 proteinGN=PDS5A PE=2 
SV=1 1.638 0.512 0.771 0.601 
O75054 
Immunoglobulin superfamily 
member 3 1.629 0.463 0.889 0.536 
Q6BDS2 UHRF1-binding protein 1  1.628 0.230 0.93 0.656 
P11234 Ras-related protein Ral-B  1.627 0.474 0.752 0.614 
Q9NV79 
Protein-L-isoaspartate O-
methyltransferase domain-
containing protein 2  1.625 0.454 1.031 0.88 
Q92621 
Nuclear pore complex protein 
Nup205 1.624 0.465 0.814 0.688 
Q8IVW6 
AT-rich interactive domain-
containing protein 3B  1.624 0.432 0.827 0.617 
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B2R6P3 
Matrix metallopeptidase 14 
(membrane-inserted) (MMP14) 1.623 0.516 0.974 0.728 
O00469 
Procollagen-lysine,2-oxoglutarate 
5-dioxygenase 2  1.621 0.491 0.922 1.109 
Q92575 UBX domain-containing protein 4  1.619 0.443 0.814 0.51 
Q53HE6 HSPC163 protein variant 1.615 0.415 1.069 0.725 
P34741 Syndecan-2  1.608 0.484 0.944 0.605 
P11233 Ras-related protein Ral-A  1.607 0.441 0.816 0.515 
O95864 Fatty acid desaturase 2  1.603 0.496 0.85 0.572 
H0YMD1 Low-density lipoprotein receptor  1.602 0.439 0.612 0.511 
A0A090N8Q3 
Chromosome 7 open reading 
frame 21 1.602 0.508 0.853 0.648 
P15291 Beta-1,4-galactosyltransferase 1  1.601 0.581 0.998 0.922 
A0A0S2Z4L3 Protein S isoform 2  1.599 0.569 1.08 1.197 
B4DLJ3 to ADP-ribosylation factor 5  1.596 0.501 0.884 0.919 
B2RAF3 Placental protein 6 (PL6) 1.593 0.438 0.91 0.578 
Q9HBH0 
Rho-related GTP-binding protein 
RhoF  1.593 0.595 0.942 0.975 
P36941 
Tumor necrosis factor receptor 
superfamily member 3  1.589 0.579 1.289 0.647 
B7ZMF2 
Fanconi anemia, 
complementation group I  1.584 0.561 0.958 0.778 
Q99426 Tubulin-folding cofactor B  1.581 0.548 1.337 1.172 
Q8TF05 
Serine/threonine-protein 
phosphatase 4 regulatory subunit 
1  1.578 0.623 0.797 0.692 
P33908 
Mannosyl-oligosaccharide 1,2-
alpha-mannosidase IA  1.577 0.484 0.93 0.66 
A0A024R438 
ATG9 autophagy related 9 
homolog A 1.575 0.485 0.965 0.627 
A0A024RE09 
Transmembrane and coiled-coil 
domains 3 1.573 0.516 0.909 0.487 
E9PGC5 
Receptor-type tyrosine-protein 
phosphatase kappa  1.572 0.568 1.08 0.838 
O75976 Carboxypeptidase D  1.566 0.523 0.9 0.706 
Q6ZNA5 Ferric-chelate reductase 1  1.566 0.498 0.839 0.641 
Q9BV40 
Vesicle-associated membrane 
protein 8  1.564 0.513 0.853 0.554 
B5BU16 
Mitogen-activated protein kinase 
kinase 6  1.563 0.546 1.127 1.123 
Q9Y570 
Protein phosphatase 
methylesterase 1  1.563 1.002 0.961 1.263 
Q9BSA9 
Endosomal/lysomomal potassium 
channel TMEM175  1.562 0.414 1.03 0.563 
Q4G0I0 Protein CCSMST1  1.561 0.538 0.863 0.633 
Q96EU7 C1GALT1-specific chaperone 1  1.561 0.616 0.981 1.126 
Q13740 CD166 antigen ALCAM  1.559 0.460 0.912 0.557 
B3KWN0 
Ankyrin repeat domain-
containing protein 52  1.558 0.591 1.147 0.595 
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D3DSM6 
Solute carrier family 19 (Folate 
transporter) 1.557 0.469 0.846 0.444 
Q14318 
Peptidyl-prolyl cis-trans 
isomerase FKBP8 1.556 0.524 0.905 0.707 
H7C5E2 
B-cell receptor-associated protein 
29  1.556 0.573 0.672 0.41 
Q9H3Z4 
DnaJ homolog subfamily C 
member 5  1.553 0.467 0.828 0.581 
O14521 Succinate dehydrogenase  1.553 0.486 0.908 0.592 
Q6FG93 VAMP5  1.552 0.503 0.818 0.494 
Q9NRY5 Protein FAM114A2  1.547 0.531 0.937 0.685 
B4DEH1 
Dolichyl-phosphate 
mannosyltransferase  1.546 0.489 0.8 0.5 
Q2VJ45 HOOK3-RET fusion protein  1.546 0.354 0.94 0.683 
A6NHR9 
Structural maintenance of 
chromosomes flexible hinge 
domain-containing protein 1  1.543 0.527 1.042 1.096 
Q9HCE6 
Rho guanine nucleotide exchange 
factor 10-like protein  1.541 0.503 0.853 0.811 
Q7Z4F1 
Low-density lipoprotein receptor-
related protein 10  1.537 0.542 1.376 0.718 
P13688 
Carcinoembryonic antigen-
related cell adhesion molecule 1  1.532 0.529 0.813 0.738 
B4DF33 
cDNA FLJ57960 OS=Homo 
sapiens PE=2 SV=1 1.527 0.477 0.829 0.454 
Q9NUV7 Serine palmitoyltransferase 3  1.522 0.592 0.962 0.757 
Q8NBP0 
Tetratricopeptide repeat protein 
13  1.522 0.593 0.929 0.584 
A0A090N8N0 Importin alpha-2 subunit  1.519 0.442 0.715 0.604 
H3BND4 
Pyridoxal-dependent 
decarboxylase domain-containing 
protein 1  1.518 0.588 0.974 0.865 
I3L2B0 
Clustered mitochondria protein 
homolog  1.518 0.592 0.907 0.759 
Q9UG56 
Phosphatidylserine 
decarboxylase proenzyme 1.516 0.519 1.008 0.823 
A0A024RAP2 
3-hydroxy-3-methylglutaryl 
coenzyme A reductase 1.512 0.506 0.955 0.565 
Q8NF37 
Lysophosphatidylcholine 
acyltransferase 1  1.512 0.552 0.775 0.619 
Q9H5K3 Protein O-mannose kinase 1.508 0.494 0.815 0.651 
Q9H490 
Phosphatidylinositol glycan 
anchor biosynthesis class U 
protein  1.504 0.487 0.934 0.572 
O43681 ATPase ASNA1  1.502 0.594 0.829 0.712 
Q4LE58 EIF4G1 variant protein 1.5 0.499 0.874 0.684 
Q8N353 TMEM106B protein  1.5 0.506 0.827 0.524 
Q96Q42 Alsin  1.499 0.538 0.93 0.638 
Q14151 Scaffold attachment factor B2  1.498 0.567 0.931 0.736 
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B2RCJ6 
Bromodomain and WD repeat 
domain containing 2 (BRWD2),  1.496 0.596 0.915 0.842 
O95219 Sorting nexin-4  1.492 0.525 0.93 0.759 
P18858 DNA ligase 1  1.492 0.564 0.96 0.61 
A0A0A0MRK6 Metaxin 1, isoform CRA_b  1.491 0.466 0.761 0.611 
A4D2P0 
Ras-related C3 botulinum toxin 
substrate 1 (Rho family, small GTP 
binding protein Rac1) 1.491 0.428 0.805 0.713 
A8K9X0 Protein YIPF  1.491 0.441 1.021 0.694 
B3KMN2 Homo sapiens SCC-112 protein 1.49 0.424 0.654 0.589 
Q8N335 
Glycerol-3-phosphate 
dehydrogenase 1-like protein  1.487 0.606 0.895 0.734 
A0A087WX97 Bcl-2-like protein 13 SV=1 1.486 0.470 0.84 0.497 
P02786 Transferrin receptor protein 1  1.485 0.476 0.914 0.575 
A0A087X1Z3 
Proteasome activator complex 
subunit 2  1.485 0.492 0.754 0.685 
B5BUD2 
Replication factor C 2 isoform 1 
(Fragment)  1.481 0.410 0.845 0.717 
Q15554 Telomeric repeat-binding factor 2  1.481 0.539 0.783 0.639 
A5Y5A3 PC1/MRPS28 fusion protein  1.479 0.566 0.873 0.75 
Q9BX93 
Group XIIB secretory 
phospholipase A2-like protein  1.478 0.622 0.818 0.512 
Q6NUQ4 Transmembrane protein 214  1.477 0.443 0.814 0.525 
D3DVC4 Nestin, isoform CRA_c 1.477 0.501 0.948 0.894 
Q92930 
Ras-related protein Rab-8B PE=1 
SV=2 1.475 0.458 0.736 0.547 
Q9HBM0 Vezatin OS 1.475 0.507 0.833 0.57 
A0A024R9G2 Ankyrin repeat domain 46 1.475 0.526 1.027 0.507 
X5DR09 
General transcription factor IIi 
isoform A 1.47 0.587 0.983 0.948 
Q9NV96 Cell cycle control protein 50A  1.47 0.535 1.096 0.634 
Q9P0B6 
Coiled-coil domain-containing 
protein 167 1.47 0.548 0.871 0.66 
A0A024R061 Synaptobrevin-like 1 1.468 0.514 0.995 0.636 
Q96BZ9 TBC1 domain family member 20  1.468 0.608 0.765 0.548 
Q07954 
Prolow-density lipoprotein 
receptor-related protein 1  1.467 0.496 1.003 0.763 
Q9HC07 Transmembrane protein 165  1.467 0.528 1.075 0.685 
Q9UBV7 Beta-1,4-galactosyltransferase 7 1.467 0.579 0.906 0.703 
Q7Z7M9 
Polypeptide N-
acetylgalactosaminyltransferase 5  1.466 0.537 1.086 0.865 
R4GN18 Membrane cofactor protein  1.466 0.471 0.892 0.509 
Q99943 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase alpha  1.466 0.483 0.923 0.664 
A0A087WT44 Heme oxygenase 2  1.465 0.405 0.842 0.609 
O00487 
26S proteasome non-ATPase 
regulatory subunit 14  1.464 0.550 0.941 0.785 
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Q5STZ8 
ATP-binding cassette sub-family F 
member 1 (Fragment)  1.464 0.638 0.906 0.882 
Q9H3S7 
Tyrosine-protein phosphatase 
non-receptor type 23  1.464 0.566 1.053 0.883 
O14874 
[3-methyl-2-oxobutanoate 
dehydrogenase [lipoamide]] 
kinase 1.463 0.535 1.427 1.884 
B2RDJ6 
Probable cytosolic iron-sulfur 
protein assembly protein CIAO1  1.462 0.542 0.867 0.713 
A0A024R324 
Ras homolog gene family, 
member A 1.461 0.553 0.806 0.74 
P19075 Tetraspanin-8  1.461 0.509 0.803 0.662 
C9JBG5 
SID1 transmembrane family 
member 2  1.46 0.698 0.556 1.604 
Q9Y232 Chromodomain Y-like protein  1.46 0.438 0.711 0.786 
Q3BDU4 
Rhabdomyosarcoma antigen MU-
RMS-40.10B 1.458 0.626 0.898 0.629 
P27037 Activin receptor type-2A 1.458 0.960 1.944 0.56 
A0A0U1RR27 
C-myc promoter-binding protein 
OS 1.457 0.421 0.767 0.584 
A0A0S4XQU8 MHC class I antigen  1.456 0.366 0.826 0.566 
P51148 Ras-related protein Rab-5C  1.455 0.499 0.87 0.735 
Q8IXI1 Mitochondrial Rho GTPase 2 1.455 0.506 0.962 0.847 
P30260 
Cell division cycle protein 27 
homolog  1.453 0.566 0.753 0.544 
Q6IAX1 FDFT1 protein  1.451 0.448 0.864 0.552 
Q59G70 
Mannosyl (Alpha-1,3-)-
glycoprotein beta-1,2-N-
acetylglucosaminyltransferase 
variant  1.451 0.453 0.885 0.618 
Q96A57 Transmembrane protein 230 1.449 0.486 0.859 0.495 
E5KLJ5 
Dynamin-like 120 kDa protein, 
mitochondrial  1.447 0.487 0.811 0.552 
A0A024R8U1 
Solute carrier family 16 
(Monocarboxylic acid 
transporters) 1.446 0.489 1.011 0.748 
A0A024R9E0 
Estrogen receptor binding site 
associated, antigen 1.446 0.437 0.625 0.527 
Q9UKV5 E3 ubiquitin-protein ligase AMFR  1.444 0.489 0.73 0.537 
H3BNX8 
Cytochrome c oxidase subunit 5A, 
mitochondrial  1.444 0.533 0.852 0.662 
P31689 
DnaJ homolog subfamily A 
member 1 1.443 0.654 0.938 0.844 
O95159 Zinc finger protein-like 1  1.443 0.534 0.869 0.641 
P05362 Intercellular adhesion molecule 1  1.442 0.432 0.759 0.533 
A8K3S3 Kinesin-like protein  1.441 0.639 0.996 0.949 
P10589 COUP transcription factor 1  1.44 0.521 0.844 1.065 
Q14643 
Inositol 1,4,5-trisphosphate 
receptor type 1  1.44 0.559 1.037 0.67 
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P09132 
Signal recognition particle 19 kDa 
protein  1.439 0.954 1.393 1.375 
P57740 
Nuclear pore complex protein 
Nup107 1.438 0.532 1.103 0.597 
Q96HR9 
Receptor expression-enhancing 
protein 6  1.436 0.458 0.804 0.712 
I3L0M9 
Transcription elongation factor B 
polypeptide 2  1.435 0.612 1.368 1.45 
Q96QK1 
Vacuolar protein sorting-
associated protein 35 1.434 0.678 1.03 0.535 
B5MDU6 
Lipid droplet-associated 
hydrolase 1.433 0.529 1.004 0.586 
Q12772 
Sterol regulatory element-binding 
protein 2  1.432 0.633 1.056 0.853 
Q6IBW4 Condensin-2 complex subunit H2  1.432 0.733 0.984 0.807 
A0A0S2Z5J4 
Adaptor-related protein complex 
3 beta 1 subunit isoform 1  1.431 0.564 0.844 0.578 
A0A0A0MRI2 Sorting nexin 6, isoform CRA_b 1.431 0.469 0.844 0.694 
B3KM57 
CCR4-NOT transcription complex 
subunit 7  1.429 0.516 0.906 0.611 
A0PK00 Transmembrane protein 120B  1.429 0.523 0.816 0.558 
Q9Y277 
Voltage-dependent anion-
selective channel protein 3  1.428 0.551 0.814 0.885 
Q8N6C5 
Immunoglobulin superfamily 
member 1  1.428 0.236 0.697 0.337 
P78382 CMP-sialic acid transporter  1.427 0.512 0.977 0.67 
P14543 Nidogen-1  1.426 0.649 0.72 0.632 
Q4KWH8 
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
eta-1  1.425 0.536 0.729 0.5 
Q96KA5 
Cleft lip and palate 
transmembrane protein 1-like 
protein  1.424 0.489 0.872 0.558 
Q13563 Polycystin-2  1.423 0.416 0.86 0.597 
O14949 
Cytochrome b-c1 complex 
subunit 8  1.421 0.480 0.783 0.731 
A8K2G0 
Secretory carrier membrane 
protein 1 (SCAMP1) 1.42 0.461 0.92 0.609 
A6NEM2 Host cell factor 1  1.419 0.501 1.069 0.822 
B7ZL91 Metalloendopeptidase  1.418 0.586 1.061 0.728 
P35613 Basigin  1.417 0.451 0.917 0.692 
B3KQL8 
 Probable dolichyl 
pyrophosphateGlc1Man9GlcNAc2 
alpha-1,3- glucosyltransferase 1.415 0.509 0.869 0.551 
Q9NQG1 Protein MANBAL  1.415 0.468 0.873 0.57 
A8KAF0 
 CCR6 chemokine receptor 
(CMKBR6)  1.412 0.516 0.847 0.447 
A0A0B5HR54 
Serine/threonine-protein kinase 
receptor  1.412 0.526 0.988 0.675 
Q504R6 RAB13 protein  1.411 0.519 0.887 0.825 
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Q9NS00 
Glycoprotein-N-
acetylgalactosamine 3-beta-
galactosyltransferase 1  1.41 0.469 0.88 0.624 
Q9NR09 
Baculoviral IAP repeat-containing 
protein 6  1.41 0.626 0.966 0.684 
B7Z3D4 Myosin-10  1.41 1.050 0.969 0.925 
Q92896 Golgi apparatus protein 1  1.407 0.532 0.911 0.793 
O60488 
Long-chain-fatty-acid--CoA ligase 
4  1.406 0.480 0.874 0.634 
O60664 Perilipin-3  1.406 0.499 0.829 0.622 
Q8NET6 Carbohydrate sulfotransferase 13  1.405 0.562 1.135 0.897 
A8K509 Yip1 interacting factor homolog A  1.405 0.501 1.056 0.733 
O43678 
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 2 1.405 0.517 1.061 0.956 
B7Z881 
 Ras GTPase-activating-like 
protein  1.404 0.592 0.874 0.675 
Q9NX62 Inositol monophosphatase 3  1.404 0.496 0.869 0.715 
Q9Y6D5 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 2  1.404 0.566 0.927 0.574 
P14625 Endoplasmin  1.402 0.504 0.796 0.52 
A0A024R9K7 
Chromosome 15 open reading 
frame 24 1.402 0.471 0.815 0.521 
Q6WKZ4 
Rab11 family-interacting protein 
1  1.402 0.423 0.906 0.834 
A0A024R201 
Proteasome (Prosome, 
macropain) 26S subunit, non-
ATPase, 13, isoform CRA_a  1.401 0.579 0.874 0.69 
P68431 Histone H3.1  1.401 0.606 0.853 0.695 
 
Appendix Table 9.6 Host proteins identified by proteomic analysis. 
Host proteins listed here are Strep-tagged NS5A samples from wildtype, P35A, V67A and 
P145A with more than 1.4- fold enrichment compared with untagged JFH1 wildtype beads. 
Abundance ratio (OST-WT /JFH1-WT) is the ratio protein abundance for the wildtype OST-N5SA 
(OST-WT) pull down to the untagged JFH1 wildtype negative control. Abundance ratio (OST-
P35A, V67A or P145A /OST-WT) is the ratio protein abundance for the mutated OST-N5SA pull 
down to the wildtype OST-NS5A positive control. 
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Appendix Table 9.7 Summary of phenotypes of domain I mutants in HCV (JFH1) lifecycle.  
 
 
 
